id,hla_adr_pubmed_link,hla_adr_drug_id,hla_adr_gene_id,hla_adr_gene_class_id,hla_adr_allele,hla_adr_cohort_ethnicity_id,hla_adr_pvalue_exposed,hla_adr_pvalue_population,hla_adr_patient_frequency,hla_adr_exposed_frequency,hla_adr_population_frequency,hla_adr_adr,hla_adr_stat_analysis,hla_adr_association,hla_adr_cal_performed_id,hla_adr_stat_correction_id,hla_adr_country_id,hla_adr_disease_id,hla_adr_notes,hla_adr_odds_exposed,hla_adr_odds_population,hla_adr_region_id,hla_adr_study
1,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*07:02,Caucasian,0.0114,,0 / 20,15 / 43,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,0.083 (0 - 0.646),,Europe,
2,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*44:02,Caucasian,0.3233,,2 / 20,6 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,0.377 (0.053 - 2.797),,Europe,
3,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Caucasian,0.9869,,3 / 20,6 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,1.013 (0.241 - 4.849),,Europe,
4,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Caucasian,0.1229,,6 / 20,2 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,4.714 (0.591 - 30.132),,Europe,
5,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Caucasian,0.4161,,4 / 20,4 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,2.264 (0.278 - 14.569),,Europe,
6,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Caucasian,0.7656,,3 / 20,6 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,0.768 (0.121 - 3.95),,Europe,
7,http://www.ncbi.nlm.nih.gov/pubmed/16981842,carbamazepine,HLA-B,MHC class I,HLA-B*27:05,Caucasian,0.6807,,3 / 20,6 / 43,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,epilepsy,,0.664 (0.086 - 4.318),,Europe,
8,http://www.ncbi.nlm.nih.gov/pubmed/18505179,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),0.0005,,11 / 11,2 / 9,4 / 8,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Australia,HIV,General Population is comprised of HIV patients who were abacavir naive,,,Oceania,
647,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-A,MHC class I,HLA-A*01,Caucasian,,,7 / 31,17 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
495,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*01:01,Japanese,,,0 / 61,6 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
564,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*01:01,Han Chinese,0.33,0.21,1 / 36,0 / 64,3 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.14 (0.24 - 155.12),5.65 (0.57 - 55.86),Asia,
12,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.0022,,3 / 6,1 / 87,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,1.09 (0.04 - 27.51),,North America,
13,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,1,,0 / 6,1 / 87,,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,1.09 (0.04 - 27.51),,North America,
14,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,1,,0 / 6,1 / 87,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,4.44 (0.16 - 120.08),,North America,
15,http://www.ncbi.nlm.nih.gov/pubmed/21071176,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.239,,1 / 3,1 / 21,6 / 71,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-square test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,10 (0.44 - 228.7),5.42 (0.43 - 68.8),Asia,
16,http://www.ncbi.nlm.nih.gov/pubmed/21071176,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,,2 / 22,1 / 21,6 / 71,maculopapular exanthema (MPE),"Fisher's exact test, chi-square test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,2 (0.17 - 23.9),1.08 (0.2 - 5.8),Asia,
17,http://www.ncbi.nlm.nih.gov/pubmed/22197535,abacavir,HLA-B,MHC class I,HLA-B*57:01,Diverse,0.0001,,18 / 18,2 / 470,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as < 0.0001,number of carriers (n),Null,Canada,HIV,,6934 (321 - 149735),,North America,
18,http://www.ncbi.nlm.nih.gov/pubmed/22909208,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.000000000824,2.1E-15,13 / 13,7 / 63,80 / 572,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,gout,,203.4 (10.93 - 3785.04),165.19 (9.72 - 2806.13),Asia,
19,http://www.ncbi.nlm.nih.gov/pubmed/22909208,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,9.21E-14,3.74E-24,22 / 22,7 / 63,80 / 572,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,China,gout,,339 (18.58 - 6186.39),275.31 (16.54 - 4583.53),Asia,
20,http://www.ncbi.nlm.nih.gov/pubmed/22909208,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.002,0.002,3 / 3,7 / 63,80 / 572,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,China,gout,,52.73 (2.47 - 1124.13),42.83 (2.19 - 836.89),Asia,
21,http://www.ncbi.nlm.nih.gov/pubmed/23362284,nevirapine,HLA-C,MHC class I,HLA-C*04:01,Black,0.001,,23 / 36,39 / 153,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,p-value was reported as < 0.001,number of carriers (n),Null,Malawi,HIV,,5.17 (2.39 - 11.18),,Africa,
22,http://www.ncbi.nlm.nih.gov/pubmed/21244392,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Malay,,0.00000787,12 / 16,,47 / 300,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,,16.15 (4.57 - 62.4),Asia,
23,http://www.ncbi.nlm.nih.gov/pubmed/21244392,carbamazepine,HLA-B,MHC class I,HLA-B*52:01,Malay,,,1 / 16,,15 / 300,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,,,Asia,
24,http://www.ncbi.nlm.nih.gov/pubmed/21244392,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Malay,,,1 / 16,,8 / 300,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,,,Asia,
585,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*01:01,Han Chinese,1,,1 / 24,0 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),3.13 (0.12 - 80.69),,Asia,
26,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-C,MHC class I,HLA-C*04:01,Thai,,,17 / 128,4 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),5.36 (1.83 - 15.6),,Asia,
27,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-C,MHC class I,HLA-C*07:02,Thai,,,14 / 128,34 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),0.4 (0.2 - 0.78),,Asia,
28,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-B,MHC class I,HLA-B*35:05,Thai,0.035,,15 / 152,1 / 152,,maculopapular exanthema (MPE),Fisher's exact test,,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),16.53 (2.74 - 98.98),,Asia,
29,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-B,MHC class I,HLA-B*38:02,Thai,,,3 / 152,13 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),0.22 (0.07 - 0.72),,Asia,
30,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Thai,,,41 / 160,19 / 160,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),2.56 (1.41 - 4.61),,Asia,
31,http://www.ncbi.nlm.nih.gov/pubmed/23692434,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,3.51E-18,,24 / 26,16 / 135,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,epilepsy,,89.25 (19.25 - 413.83),,Asia,
32,http://www.ncbi.nlm.nih.gov/pubmed/23692434,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.045,,7 / 15,15 / 75,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,epilepsy,,3.5 (1.1 - 11.18),,Asia,
33,http://www.ncbi.nlm.nih.gov/pubmed/23692434,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.256,,2 / 6,4 / 30,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,epilepsy,,3.25 (0.44 - 23.95),,Asia,
34,http://www.ncbi.nlm.nih.gov/pubmed/23692434,valproic acid,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,,1 / 3,4 / 15,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,epilepsy,,1.38 (0.1 - 19.64),,Asia,
35,http://www.ncbi.nlm.nih.gov/pubmed/23692434,phenobarbital,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,,0 / 2,2 / 10,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,epilepsy,,,,Asia,
36,http://www.ncbi.nlm.nih.gov/pubmed/22348415,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.0001,,19 / 20,4 / 30,,"drug-induced hypersensitivity syndrome (DIHS),Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced skin reaction (DISI)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Hong Kong,gout,,123.5 (12.8 - 1195.1),,Asia,
37,http://www.ncbi.nlm.nih.gov/pubmed/15007363,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Korean,,,3 / 76,8 / 73,12 / 91,aspirin-intolerant asthma (AIA),chi-square test,p-value was reported as not significant (after correction for multiple comparisons),number of carriers (n),Corrected for chi-square,South Korea,,,,0.3,Asia,
38,http://www.ncbi.nlm.nih.gov/pubmed/15007363,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Korean,,,9 / 76,2 / 73,4 / 91,aspirin-intolerant asthma (AIA),chi-square test,p-value was reported as not significant (after correction for multiple comparisons),number of carriers (n),Corrected for chi-square,South Korea,,,9.7,,Asia,
39,http://www.ncbi.nlm.nih.gov/pubmed/15007363,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Korean,,,28 / 76,14 / 73,19 / 91,aspirin-intolerant asthma (AIA),chi-square test,p-value was reported as not significant (after correction for multiple comparisons),number of carriers (n),Corrected for chi-square,South Korea,,,2.3,2.2,Asia,
40,http://www.ncbi.nlm.nih.gov/pubmed/15007363,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Korean,,,5 / 76,10 / 73,16 / 91,aspirin-intolerant asthma (AIA),chi-square test,p-value was reported as not significant (after correction for multiple comparisons),number of carriers (n),Corrected for chi-square,South Korea,,,,0.4,Asia,
41,http://www.ncbi.nlm.nih.gov/pubmed/15007363,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*03:01,Korean,0.04,0.001,21 / 76,6 / 73,4 / 91,aspirin-intolerant asthma (AIA),chi-square test,,number of carriers (n),Corrected for chi-square,South Korea,,,5.2 (1.8 - 14.7),8.3 (2.7 - 25.5),Asia,
42,http://www.ncbi.nlm.nih.gov/pubmed/15057820,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,3.13E-27,1.38E-21,44 / 44,3 / 101,8 / 93,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,2504 (126 - 49522),895 (50 - 15869),Asia,
671,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-A,MHC class I,HLA-A*01:01,Unknown,0.4008,,4 / 38,25 / 172,,maculopapular exanthema (MPE),chi-square test,the odds ratio for this entry represents the Hazard Ratio,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.446 (0.472 - 4.428),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
44,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-B,MHC class I,HLA-B*41:01,Caucasian,,0.12,1 / 10,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
45,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-B,MHC class I,HLA-B*58:01,Caucasian,,0.999,1 / 10,,6 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
46,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-C,MHC class I,HLA-C*03:02,Caucasian,,,0 / 10,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
47,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-C,MHC class I,HLA-C*08:01,Caucasian,,,0 / 10,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
48,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Caucasian,,0.575,1 / 10,,2 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
49,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Caucasian,,0.575,1 / 10,,2 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
50,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Caucasian,,0.366,1 / 10,,33 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
51,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Caucasian,,,0 / 10,,4 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
52,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-DQB1,MHC class II,HLA-DQB1*02:02,Caucasian,,0.672,6 / 10,,25 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
827,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-A,MHC class I,HLA-A*01:01,Han Chinese,0.308,,1 / 10,1 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,5.444 (0.311 - 95.21),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
54,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-B,MHC class I,HLA-B*41:01,Caucasian,,0.06,1 / 7,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
55,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Caucasian,,0.248,3 / 7,,6 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
56,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Caucasian,,,2 / 7,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
57,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-C,MHC class I,HLA-C*08:01,Caucasian,,,2 / 7,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
58,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Caucasian,,0.575,2 / 7,,2 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
59,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Caucasian,,0.575,1 / 7,,2 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
60,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Caucasian,,0.366,0 / 7,,33 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
61,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Caucasian,,,2 / 7,,4 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
62,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-DQB1,MHC class II,HLA-DQB1*02:02,Caucasian,,0.672,3 / 7,,25 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
63,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-B,MHC class I,HLA-B*57:01,Caucasian,8.97E-19,,43 / 51,4 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,80.6 (22.8 - 284.9),,Europe,
64,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian,0.000019,,36 / 51,16 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Bonferroni's correction,United Kingdom,bacterial infections,,7.2 (3.15 - 16.45),,Europe,
65,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*01,Caucasian,0.459,,7 / 51,13 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
66,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*03,Caucasian,0.557,,16 / 51,24 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
67,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*04,Caucasian,0.096,,10 / 51,22 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
68,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*08,Caucasian,0.086,,5 / 51,1 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
69,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*09,Caucasian,0.502,,0 / 51,2 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
70,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*10,Caucasian,1,,0 / 51,1 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
71,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*11,Caucasian,1,,4 / 51,4 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
72,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*13,Caucasian,0.643,,9 / 51,14 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
73,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*14,Caucasian,0.38,,1 / 51,4 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
74,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*15,Caucasian,0.21,,5 / 51,18 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Bonferroni's correction,United Kingdom,bacterial infections,,0.27 (0.09 - 0.81),,Europe,
75,http://www.ncbi.nlm.nih.gov/pubmed/19483685,flucloxacillin,HLA-DRB1,MHC class II,HLA-DRB1*16,Caucasian,1,,1 / 51,1 / 64,,drug induced liver injury (DILI),chi-square test,,number of carriers (n),Null,United Kingdom,bacterial infections,,,,Europe,
76,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Japanese,,,3 / 25,65 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.83,,Asia,
77,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Japanese,,,3 / 25,30 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.95,,Asia,
78,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*04:03,Japanese,,,1 / 25,9 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,2.09,,Asia,
79,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Japanese,,,10 / 25,236 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.63,,Asia,
80,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*04:06,Japanese,,,0 / 25,19 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.44,,Asia,
81,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*04:10,Japanese,,,2 / 25,20 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.91,,Asia,
82,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*08:02,Japanese,0.0000196,,7 / 25,7 / 460,,bucillamine-induced proteinuria,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,25.17 (7.98 - 79.38),,Asia,
83,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*08:03,Japanese,,,1 / 25,45 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.38,,Asia,
84,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Japanese,,,10 / 25,125 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.79,,Asia,
85,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Japanese,,,0 / 25,15 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.56,,Asia,
86,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Japanese,,,2 / 25,35 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.06,,Asia,
87,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Japanese,,,0 / 25,9 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.93,,Asia,
88,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Japanese,,,2 / 25,41 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.89,,Asia,
89,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*14:03,Japanese,,,1 / 25,7 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,2.7,,Asia,
90,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*14:06,Japanese,,,1 / 25,13 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.43,,Asia,
91,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*14:54,Japanese,,,0 / 25,28 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.3,,Asia,
92,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Japanese,,,1 / 25,51 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.33,,Asia,
93,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Japanese,,,2 / 25,80 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.41,,Asia,
94,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*03:01,Japanese,,,7 / 25,89 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.62,,Asia,
95,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*03:02,Japanese,,,2 / 25,40 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.91,,Asia,
96,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*03:03,Japanese,,,9 / 25,129 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.44,,Asia,
97,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*04:01,Japanese,,,10 / 25,243 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.6,,Asia,
98,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*04:02,Japanese,0.000269,,8 / 25,20 / 460,,bucillamine-induced proteinuria,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,10.35 (3.99 - 26.83),,Asia,
99,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Japanese,,,3 / 25,69 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.77,,Asia,
100,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*05:02,Japanese,,,1 / 25,25 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.73,,Asia,
101,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*05:03,Japanese,,,0 / 25,17 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.5,,Asia,
102,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*06:01,Japanese,,,3 / 25,124 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.37,,Asia,
103,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*06:02,Japanese,,,1 / 25,49 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.35,,Asia,
104,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DQB1,MHC class II,HLA-DQB1*06:04,Japanese,,,2 / 25,37 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.99,,Asia,
105,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*02:01,Japanese,,,13 / 25,209 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.3,,Asia,
106,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*02:02,Japanese,,,3 / 25,46 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.23,,Asia,
107,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*03:01,Japanese,,,3 / 25,32 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.82,,Asia,
108,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*04:01,Japanese,,,2 / 25,36 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,1.02,,Asia,
109,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*04:02,Japanese,,,9 / 25,100 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,2.03,,Asia,
110,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*05:01,Japanese,,,12 / 25,275 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.62,,Asia,
111,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*09:01,Japanese,,,2 / 25,62 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.56,,Asia,
112,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*13:01,Japanese,,,0 / 25,13 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.65,,Asia,
113,http://www.ncbi.nlm.nih.gov/pubmed/24899791,bucillamine,HLA-DPB1,MHC class II,HLA-DPB1*14:01,Japanese,,,0 / 25,17 / 460,,bucillamine-induced proteinuria,Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Japan,rheumatoid arthritis,,0.5,,Asia,
872,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*01:01,Caucasian (North West),,1,35 / 134,,37 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.76,Europe,Values have been provided based on data obtained directly from the study authors
115,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,European,,,0 / 20,0 / 257,4 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Null,Taiwan,epilepsy,,,,Asia,
986,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*01:01,Caucasian (North West),,1,3 / 134,,21 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.38,Europe,Values have been provided based on data obtained directly from the study authors
117,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,European,,,0 / 10,0 / 257,4 / 8862,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Null,Taiwan,epilepsy,,,,Asia,
1146,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*01:01,Unknown,,,5 / 34,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
119,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.001,0.001,41 / 53,4 / 72,60 / 710,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as < 0.001,number of carriers (n),Null,Taiwan,epilepsy,,58.1 (17.6 - 192),37 (18.5 - 74.2),Asia,
1220,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*01:01,Unknown,,,3 / 24,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
121,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,,0 / 10,4 / 72,60 / 710,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Null,Taiwan,epilepsy,,,,Asia,
122,http://www.ncbi.nlm.nih.gov/pubmed/23600531,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Caucasian,0.05,0.05,12 / 19,1 / 23,63 / 3200,drug-induced hypersensitivity syndrome (DIHS),chi-square test,p-value was not reported but the study declared this as significant (using P < 0.05 as the threshold),number of carriers (n),Null,Portugal,gout,,37.71 (4.13 - 343.87),85.36 (32.52 - 224.04),Europe,
123,http://www.ncbi.nlm.nih.gov/pubmed/23600531,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Caucasian,0.05,0.05,4 / 6,1 / 23,63 / 3200,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,p-value was not reported but the study declared this as significant (using P < 0.05 as the threshold),number of carriers (n),Null,Portugal,gout,,44 (3.18 - 608.19),99.59 (17.91 - 553.72),Europe,
124,http://www.ncbi.nlm.nih.gov/pubmed/23600531,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Caucasian,,,1 / 6,1 / 23,63 / 3200,maculopapular exanthema (MPE),chi-square test,p-value was not reported but the study declared this as not significant (using P < 0.05 as the threshold),,Null,Portugal,gout,,,,Europe,
125,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,0.32,0.001,4 / 28,4 / 70,11 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.75 (0.64 - 11.87),7.83 (2.32 - 26.41),Asia,
126,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,1,1,1 / 28,3 / 70,24 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.83 (0.08 - 8.31),0.78 (0.1 - 5.97),Asia,
127,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,0.699,1 / 28,1 / 70,39 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.23 (0.11 - 14.47),0.46 (0.06 - 3.51),Asia,
128,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:27,Han Chinese,0.08,0.007,2 / 28,0 / 70,1 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),13.3 (0.62 - 286.29),40.54 (3.56 - 461.64),Asia,
129,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*27:04,Han Chinese,0.08,0.071,2 / 28,0 / 70,7 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),13.3 (0.62 - 286.29),5.73 (1.13 - 28.93),Asia,
130,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.69,0.817,5 / 28,15 / 70,76 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.8 (0.26 - 2.45),1.29 (0.48 - 3.51),Asia,
131,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.51,0.94,4 / 28,14 / 70,63 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.67 (0.2 - 2.24),1.23 (0.41 - 3.66),Asia,
132,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,1,0.936,2 / 28,4 / 70,26 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.27 (0.22 - 7.36),1.49 (0.33 - 6.6),Asia,
133,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,0.29,0.519,1 / 28,0 / 70,13 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),1.47 (0.19 - 11.63),Asia,
134,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*56:04,Han Chinese,0.29,0.098,1 / 28,0 / 70,1 / 528,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),19.52 (1.19 - 320.54),Asia,
135,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:19,Han Chinese,0.29,0.024,1 / 28,0 / 70,0 / 1138,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),124.2 (4.94 - 3117.64),Asia,
136,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*27:09,Han Chinese,0.29,0.024,1 / 28,0 / 70,0 / 1138,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),124.2 (4.94 - 3117.64),Asia,
137,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*39:05,Han Chinese,0.29,0.093,1 / 28,0 / 70,3 / 1138,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),14.01 (1.41 - 139.08),Asia,
138,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*48:04,Han Chinese,0.29,0.024,1 / 28,0 / 70,0 / 1138,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),124.2 (4.94 - 3117.64),Asia,
139,http://www.ncbi.nlm.nih.gov/pubmed/22818943,oxcarbazepine,HLA-B,MHC class I,HLA-B*49:01,Han Chinese,0.29,0.22,1 / 28,0 / 70,1 / 212,maculopapular exanthema (MPE),Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),7.69 (0.3 - 194.59),7.82 (0.48 - 128.59),Asia,
1294,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*01:01,Unknown,,,2 / 20,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
141,http://www.ncbi.nlm.nih.gov/pubmed/17339877,ticlopidine,HLA-B,MHC class I,HLA-B*44:03,Japanese,0.000535,,10 / 14,13 / 85,,drug induced liver injury (DILI) - cholestatic,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,13.85 (3.77 - 50.87),,Asia,
142,http://www.ncbi.nlm.nih.gov/pubmed/17339877,ticlopidine,HLA-C,MHC class I,HLA-C*14:03,Japanese,0.000158,,10 / 14,12 / 85,,drug induced liver injury (DILI) - cholestatic,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,15.21 (4.1 - 56.39),,Asia,
143,http://www.ncbi.nlm.nih.gov/pubmed/17339877,ticlopidine,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Japanese,0.0000395,,10 / 14,10 / 85,,drug induced liver injury (DILI) - cholestatic,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,18.75 (4.94 - 71.19),,Asia,
144,http://www.ncbi.nlm.nih.gov/pubmed/17339877,ticlopidine,HLA-DQB1,MHC class II,HLA-DQB1*06:04,Japanese,0.00000905,,10 / 14,9 / 85,,drug induced liver injury (DILI) - cholestatic,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,21.11 (5.47 - 81.42),,Asia,
145,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,,,1 / 112,12 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.11 (0.01 - 0.8),,Asia,
146,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,5.8E-43,,99 / 112,11 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,97.62 (42 - 226.8),,Asia,
147,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*27:04,Han Chinese,,,2 / 112,4 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.67 (0.1 - 3.7),,Asia,
148,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.000083,,13 / 112,57 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.22 (0.1 - 0.4),,Asia,
149,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*48:01,Han Chinese,,,0 / 112,1 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.45 (0.02 - 11.1),,Asia,
150,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,,,3 / 112,10 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.39 (0.1 - 1.5),,Asia,
151,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,,,2 / 112,11 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.23 (0.05 - 1.1),,Asia,
152,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,,,1 / 112,9 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.14 (0.02 - 1.1),,Asia,
1412,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*01:01,Indian,1,,0 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.58 (0.02 - 13.05),,Asia,
1460,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*01:01,Caucasian,1,0.976,1 / 3,2 / 10,50 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2 (0.04 - 78.77),2.03 (0.07 - 29.33),Europe,
1509,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*01:01,Caucasian,1,1,1 / 3,2 / 10,50 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2 (0.04 - 78.77),2.03 (0.07 - 29.33),Europe,
1679,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*01:01,Diverse,,0.17,2 / 39,,20 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1789,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*01:01,European,,0.503,14 / 28,,2731 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,2.2 (1.1 - 4.7),Europe,
1802,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*01:01,European,,0.06,14 / 28,,124 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,3.3 (1.5 - 7),Europe,
873,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*01:02,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
1147,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*01:03,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1221,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*01:03,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1295,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*01:03,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
163,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,,,1 / 23,12 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,53 (0.07 - 4.3),,Asia,
164,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,,0 / 23,11 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.26 (0.01 - 4.6),,Asia,
165,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*27:04,Han Chinese,,,5 / 23,4 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,10.28 (2.5 - 41.8),,Asia,
166,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,,,2 / 23,57 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.16 (0.04 - 0.7),,Asia,
167,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*48:01,Han Chinese,,,2 / 23,1 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,14.38 (1.2 - 165.6),,Asia,
168,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,,,5 / 23,10 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,3.94 (1.2 - 12.8),,Asia,
169,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,,,3 / 23,11 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.92 (0.5 - 7.5),,Asia,
170,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,,,1 / 23,9 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.72 (0.1 - 6),,Asia,
648,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-A,MHC class I,HLA-A*02,Caucasian,,,13 / 31,40 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
153,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,,,36 / 112,55 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.84 (0.5 - 1.4),,Asia,
171,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,,,9 / 23,55 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.13 (46 - 2.8),,Asia,
189,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,,,19 / 51,55 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.04 (0.4 - 2.7),,Asia,
232,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,0.7662,,3 / 26,17 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.7 (0.2 - 2.7),,Asia,
329,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Korean,,,3 / 7,14 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.9 (0.4 - 9.7),,Asia,
342,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Korean,,,3 / 17,14 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.6 (0.1 - 2.2),,Asia,
355,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Korean,,,6 / 24,14 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.9 (0.3 - 2.6),,Asia,
375,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,0.033,0.094,11 / 40,5 / 52,10 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
400,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,0.166,0.993,6 / 43,2 / 44,10 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
181,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,,,4 / 51,12 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.99 (0.3 - 3.2),,Asia,
182,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,,4 / 51,11 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.8 (0.3 - 3.6),,Asia,
183,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*27:04,Han Chinese,,,2 / 51,4 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.51 (0.3 - 8.5),,Asia,
184,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,,,12 / 51,57 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.51 (0.2 - 1.1),,Asia,
185,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*48:01,Han Chinese,,,1 / 51,1 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,3.02 (0.2 - 49.2),,Asia,
186,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,0.02,,13 / 51,10 / 152,,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,4.86 (2 - 11.9),,Asia,
187,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,,,5 / 51,11 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.39 (0.5 - 4.2),,Asia,
188,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,,,4 / 51,9 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.35 (0.4 - 4.6),,Asia,
496,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Japanese,,,5 / 61,93 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
565,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,1,1,2 / 36,4 / 64,31 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1 (0.17 - 5.77),1.07 (0.24 - 4.68),Asia,
586,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,0.49,,2 / 24,0 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),5.44 (0.25 - 119.64),,Asia,
672,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-A,MHC class I,HLA-A*02:01,Unknown,0.0145,,14 / 38,31 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.377 (0.175 - 0.81),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
874,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:01,Caucasian (North West),,0.000006395,128 / 134,,51 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,4,Europe,Values have been provided based on data obtained directly from the study authors
987,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:01,Caucasian (North West),,1,34 / 134,,60 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.87,Europe,Values have been provided based on data obtained directly from the study authors
1148,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:01,Unknown,,,3 / 34,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1222,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:01,Unknown,,0.01,7 / 24,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1296,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:01,Unknown,,,3 / 20,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1413,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*02:01,Indian,1,,0 / 10,4 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.43 (0.02 - 9.34),,Asia,
199,http://www.ncbi.nlm.nih.gov/pubmed/21169036,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.294,0.011,4 / 9,1 / 9,6 / 72,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,6.4 (0.5471 - 74.891),8.8 (1.853 - 41.79),Asia,
200,http://www.ncbi.nlm.nih.gov/pubmed/15247625,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian,0.006,,6 / 13,5 / 51,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,England,HIV,,7.9 (1.5 - 41.4),,Europe,
1429,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Caucasian,0.123,0.136,7 / 2,15 / 28,133 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,6.93 (0.69 - 168.29),3.16 (0.59 - 22.46),Europe,
1461,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*02:01,Caucasian,0.874,0.929,1 / 3,6 / 10,133 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.33 (0.01 - 8.01),0.45 (0.02 - 6.44),Europe,
1474,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Caucasian,0.113,0.294,2 / 2,8 / 23,133 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,9.12 (0.37 - 62610000),4.51 (0.23 - 286.11),Europe,
204,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1.6E-41,,59 / 60,6 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1357 (193.4 - 8838.3),,Asia,
205,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.00026,,6 / 60,59 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.16 (0.1 - 0.4),,Asia,
206,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,0.0086,,8 / 60,54 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.26 (0.1 - 0.6),,Asia,
207,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,7.8E-27,,56 / 60,20 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,86.8 (29.3 - 254.6),,Asia,
208,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Han Chinese,0.03,,1 / 60,25 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.08 (0.01 - 0.5),,Asia,
209,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.000000000023,,41 / 60,23 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,11.4 (5.6 - 22.9),,Asia,
1484,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Caucasian,1,1,3 / 5,15 / 28,133 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.8 (0.08 - 8.82),1.35 (0.18 - 11.79),Europe,
1510,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*02:01,Caucasian,0.874,0.929,1 / 3,6 / 10,133 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.33 (0.01 - 8.01),0.45 (0.02 - 6.44),Europe,
1522,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,Caucasian,1,0.559,1 / 4,8 / 23,133 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.63 (0.02 - 9.16),0.3 (0.01 - 3.29),Europe,
213,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,,0 / 13,6 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.79 (0.1 - 8.8),,Asia,
214,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,,,3 / 13,59 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.43 (0.1 - 1.5),,Asia,
215,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,,,5 / 13,54 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.04 (0.3 - 3.2),,Asia,
216,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,,,0 / 13,20 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.23 (0 - 2.3),,Asia,
217,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Han Chinese,,,1 / 13,25 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.4 (0 - 2.5),,Asia,
218,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,,,3 / 13,23 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.58 (0.4 - 5.8),,Asia,
1590,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Thai,,,6 / 39,4 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,4.05 (1.06 - 15.08),,Asia,
1600,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Thai,,,3 / 21,4 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,3.67 (0.76 - 17.81),,Asia,
1635,http://www.ncbi.nlm.nih.gov/pubmed/28476759,phenytoin,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,0.042,,3 / 13,1 / 40,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,11.7 (1.1 - 124.84),,Asia,
222,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,,1 / 18,6 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.35 (0.2 - 9.3),,Asia,
223,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,,,7 / 18,59 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.92 (0.4 - 2.4),,Asia,
224,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,,,9 / 18,54 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.67 (0.6 - 4.3),,Asia,
225,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,,,2 / 18,20 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.78 (0.2 - 3.3),,Asia,
226,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Han Chinese,,,7 / 18,25 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,3.03 (1.1 - 8.4),,Asia,
227,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,,,2 / 18,23 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.66 (0.2 - 2.8),,Asia,
228,http://www.ncbi.nlm.nih.gov/pubmed/15743917,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,4.7E-24,8.1E-18,51 / 51,20 / 135,19 / 93,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,gout,,580.3 (34.4 - 9780.9),393.5 (23.2 - 6665.26),Asia,
229,http://www.ncbi.nlm.nih.gov/pubmed/15743917,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,1.4E-19,0.00000000000025,48 / 51,19 / 135,19 / 93,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,gout,,97.7,62.3,Asia,
1658,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,6.45,4.9,2 / 12,11 / 34,28 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,0.42 (0.08 - 2.24),1.82 (0.38 - 8.73),Asia,
231,http://www.ncbi.nlm.nih.gov/pubmed/15743917,allopurinol,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Han Chinese,0.0000028,0.00085,33 / 51,17 / 135,14 / 93,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,gout,,12.7,10.3,Asia,
1680,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:01,Diverse,,1,18 / 39,,61 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1790,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,European,,0.724,11 / 28,,5118 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,0.5 (0.2 - 1),Europe,
1803,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*02:01,European,,0.245,11 / 28,,274 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,0.6 (0.3 - 1.3),Europe,
1818,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*02:01,Han Chinese,,0.2,3 / 15,/ 118,28 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
875,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:02,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
1681,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:02,Diverse,,1,1 / 39,,5 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
154,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,,,10 / 112,22 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.58 (0.26 - 1.3),,Asia,
172,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,,,1 / 23,22 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.27 (0.03 - 2.1),,Asia,
240,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.0154,,9 / 26,14 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,3.7 (1.4 - 10),,Asia,
241,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.0041,,8 / 26,9 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,5.1 (1.8 - 15.1),,Asia,
242,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*15:25,Han Chinese,0.4654,,1 / 26,2 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.2 (0.2 - 25.5),,Asia,
243,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*35:01,Han Chinese,0.6753,,2 / 26,7 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.3 (0.2 - 6.5),,Asia,
244,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,0.315,,5 / 26,12 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2 (0.6 - 6.3),,Asia,
245,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.1907,,8 / 26,52 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.2 - 1.3),,Asia,
246,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*40:06,Han Chinese,0.0898,,2 / 26,1 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,9.3 (0.8 - 107.2),,Asia,
247,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.4091,,3 / 26,24 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.1 - 1.7),,Asia,
248,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*46:02,Han Chinese,0.1871,,1 / 26,0 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,9 (0.3 - 277),,Asia,
249,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,0.1698,,3 / 26,5 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.8 (0.6 - 12.6),,Asia,
250,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*51:02,Han Chinese,1,,1 / 26,4 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.1 (0.1 - 10.2),,Asia,
251,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*52:01,Han Chinese,0.4654,,1 / 26,2 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.2 (0.2 - 25.5),,Asia,
252,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,1,,2 / 26,9 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1 (0.2 - 4.7),,Asia,
253,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*56:01,Han Chinese,0.4654,,1 / 26,2 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.2 (0.2 - 25.5),,Asia,
254,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.1963,,1 / 26,16 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.2 (0 - 1.9),,Asia,
255,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-B,MHC class I,HLA-B*67:01,Han Chinese,0.1871,,1 / 26,0 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,9 (0.3 - 277),,Asia,
256,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,0.1103,,5 / 26,41 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.4 (0.1 - 1.2),,Asia,
257,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,0.5254,,2 / 26,16 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.1 - 2.3),,Asia,
258,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*03:03,Han Chinese,0.5254,,2 / 26,16 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.1 - 2.3),,Asia,
259,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,0.4261,,7 / 26,22 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.5 (0.6 - 4.1),,Asia,
260,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*04:01,Han Chinese,0.1951,,1 / 26,17 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.2 (0 - 1.8),,Asia,
261,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*04:03,Han Chinese,0.4654,,1 / 26,2 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.2 (0.2 - 25.5),,Asia,
262,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*07:02,Han Chinese,1,,11 / 26,48 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1 (0.4 - 2.4),,Asia,
263,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,0.0281,,9 / 26,17 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,3 (1.1 - 7.8),,Asia,
264,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*12:02,Han Chinese,0.6433,,2 / 26,6 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.5 (0.3 - 7.8),,Asia,
265,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-C,MHC class I,HLA-C*14:02,Han Chinese,0.063,,4 / 26,5 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,3.9 (1 - 15.8),,Asia,
266,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Han Chinese,0.4618,,1 / 26,12 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.3 (0 - 2.7),,Asia,
267,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*03:17,Han Chinese,0.1871,,1 / 26,0 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,9 (0.3 - 277),,Asia,
268,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*04:03,Han Chinese,1,,2 / 26,11 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.8 (0.2 - 3.7),,Asia,
269,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Han Chinese,0.5343,,5 / 26,15 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.6 (0.5 - 4.8),,Asia,
270,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*04:06,Han Chinese,1,,1 / 26,4 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.1 (0.1 - 10.2),,Asia,
271,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*08:03,Han Chinese,0.7368,,2 / 26,13 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.6 (0.1 - 3),,Asia,
272,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Han Chinese,1,,7 / 26,33 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.9 (0.3 - 2.3),,Asia,
273,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Han Chinese,0.7864,,6 / 26,22 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.2 (0.4 - 3.4),,Asia,
274,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Han Chinese,1,,1 / 26,6 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.7 (0.1 - 6.2),,Asia,
275,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.4428,,8 / 26,25 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.6 (0.6 - 4),,Asia,
276,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Han Chinese,1,,1 / 26,4 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.1 (0.1 - 10.1),,Asia,
277,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*13:12,Han Chinese,0.4654,,1 / 26,2 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,2.2 (0.2 - 25.5),,Asia,
278,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Han Chinese,1,,2 / 26,9 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1 (0.2 - 4.7),,Asia,
279,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:43,Han Chinese,0.3402,,1 / 26,1 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,4.5 (0.3 - 74.1),,Asia,
280,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Han Chinese,0.5974,,4 / 26,24 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.7 (0.2 - 2.1),,Asia,
281,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Han Chinese,0.2345,,2 / 26,3 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,3.1 (0.5 - 19.3),,Asia,
282,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*16:02,Han Chinese,0.0128,,7 / 26,9 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,4.3 (1.4 - 12.8),,Asia,
283,http://www.ncbi.nlm.nih.gov/pubmed/20235791,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.03,,2 / 6,6 / 67,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,7.62 (1.4 - 42.4),,Asia,
284,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Korean,0.0000000000245,2.47E-16,23 / 25,6 / 57,59 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,97.8 (18.3 - 521.5),83 (19 - 361.3),Asia,
285,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Korean,0.0000000000939,0.00000000000558,23 / 25,7 / 57,99 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,82.1 (15.8 - 426.5),44.8 (10.4 - 193.4),Asia,
190,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,,,4 / 51,22 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.5 (0.2 - 1.53),,Asia,
287,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Korean,0.000000000145,2.83E-14,19 / 20,6 / 57,59 / 485,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,161.5 (18.2 - 1430.9),137.5 (18.1 - 1046.2),Asia,
288,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Korean,0.000000000504,0.000000000124,19 / 20,7 / 57,99 / 485,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,135.7 (15.6 - 1177.8),74.3 (9.8 - 561.6),Asia,
233,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,0.3312,,5 / 26,13 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.8 (0.6 - 5.7),,Asia,
290,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Korean,0.016,0.01,4 / 5,6 / 57,59 / 485,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,34 (3.2 - 356.1),28.9 (3.2 - 263.4),Asia,
291,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Korean,0.018,0.04,4 / 5,7 / 57,99 / 485,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,28.3 (2.8 - 293.6),15.6 (1.7 - 141.1),Asia,
403,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,0.441,0.731,4 / 43,2 / 44,5 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
293,http://www.ncbi.nlm.nih.gov/pubmed/19018717,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Japanese,,0.0001,4 / 20,,6 / 986,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as < 0.0001,,Null,Japan,gout,,,40.83 (10.5 - 158.9),Asia,
566,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,1,0.57,2 / 36,4 / 64,59 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1 (0.17 - 5.77),0.53 (0.12 - 2.27),Asia,
295,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-B,MHC class I,HLA-B*58:01,Caucasian (predominantly),,,3 / 44,0 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),14.59 (0.74 - 289),,North America,
296,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),,,2 / 44,3 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.98 (0.09 - 7.13),,North America,
297,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-C,MHC class I,HLA-C*07:18,Caucasian (predominantly),,,3 / 44,0 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),14.59 (0.74 - 289),,North America,
298,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-DQB1,MHC class II,HLA-DQB1*06:09,Caucasian (predominantly),,,3 / 44,0 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),14.59 (0.74 - 289),,North America,
299,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Caucasian (predominantly),,,4 / 44,1 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),8.5 (0.79 - 423),,North America,
300,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Korean,,,7 / 188,,25 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
301,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Korean,,,17 / 188,,29 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
302,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Korean,,,13 / 188,,28 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
303,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*08:03,Korean,,,14 / 188,,29 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
304,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Korean,,,15 / 188,,38 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
305,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Korean,,,14 / 188,,19 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
306,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Korean,,,7 / 188,,16 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
307,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Korean,,,7 / 188,,18 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
308,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Korean,,0.0005,34 / 188,,30 / 370,aspirin-induced urticaria (AIU),chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,2.5,Asia,
309,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Korean,,,7 / 188,,26 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
310,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Korean,,,10 / 188,,30 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
311,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*05:03,Korean,,,9 / 188,,15 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
312,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*06:01,Korean,,,16 / 188,,34 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
313,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*06:04,Korean,,,15 / 188,,18 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
314,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*06:09,Korean,,0.0008,19 / 188,,12 / 370,aspirin-induced urticaria (AIU),chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,3.4,Asia,
315,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*03:01,Korean,,,31 / 188,,56 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
316,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*03:02,Korean,,,14 / 188,,44 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
317,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*03:03,Korean,,,19 / 188,,45 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
318,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DQB1,MHC class II,HLA-DQB1*04:01,Korean,,,16 / 188,,28 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
319,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*02:01,Korean,,,54 / 188,,93 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
320,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*02:02,Korean,,,11 / 188,,16 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
321,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*03:01,Korean,,,11 / 188,,11 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
322,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*04:01,Korean,,,18 / 188,,26 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
323,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*04:02,Korean,,,18 / 188,,29 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
324,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*05:01,Korean,,0.028,54 / 188,,141 / 370,aspirin-induced urticaria (AIU),chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,0.7,Asia,
325,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*09:01,Korean,,,3 / 188,,8 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
326,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*13:01,Korean,,0.0324,6 / 188,,29 / 370,aspirin-induced urticaria (AIU),chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,0.4,Asia,
327,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*14:01,Korean,,,4 / 188,,3 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
328,http://www.ncbi.nlm.nih.gov/pubmed/15784113,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*17:01,Korean,,,6 / 188,,5 / 370,aspirin-induced urticaria (AIU),chi-square test,p-value was reported as not significant,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
587,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:03,Han Chinese,1,,1 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1 (0.06 - 16.97),,Asia,
876,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:05,Caucasian (North West),,1,6 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.59,Europe,Values have been provided based on data obtained directly from the study authors
988,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:05,Caucasian (North West),,1,0 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1149,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:05,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
333,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Korean,,,1 / 7,7 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1 (0.1 - 9.8),,Asia,
334,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Korean,,,1 / 7,0 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,23.3 (0.9 - 634),,Asia,
335,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Korean,,,3 / 7,2 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,18 (2.3 - 141.2),,Asia,
336,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Korean,,,3 / 7,10 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,3 (0.6 - 15.6),,Asia,
337,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Korean,,,3 / 7,13 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,2.1 (0.4 - 10.8),,Asia,
338,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:03,Korean,,,3 / 7,12 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,2.4 (0.5 - 12.1),,Asia,
339,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:04,Korean,,,0 / 7,6 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.5 (0 - 9),,Asia,
340,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*06:02,Korean,,,0 / 7,5 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.6 (0 - 11),,Asia,
341,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*14:02,Korean,,,3 / 7,8 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,3.9 (0.7 - 21.1),,Asia,
1223,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:05,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1297,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:05,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1682,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:05,Diverse,,0.131,3 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
155,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,,,9 / 112,11 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.12 (0.45 - 2.8),,Asia,
346,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Korean,,,4 / 17,7 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.9 (0.5 - 7.5),,Asia,
347,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Korean,,,0 / 17,0 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,,,Asia,
348,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Korean,,,0 / 17,2 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.5 (0 - 12.1),,Asia,
349,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Korean,,,4 / 17,10 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.2 (0.3 - 4.6),,Asia,
350,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Korean,,,3 / 17,13 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.6 (0.2 - 2.5),,Asia,
351,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:03,Korean,,,4 / 17,12 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1 (0.3 - 3.6),,Asia,
352,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:04,Korean,,,4 / 17,6 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,2.3 (0.6 - 9.2),,Asia,
353,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*06:02,Korean,,,4 / 17,5 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,2.8 (0.6 - 11.8),,Asia,
354,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*14:02,Korean,,,3 / 17,8 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.1 (0.3 - 4.8),,Asia,
173,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,,,0 / 23,11 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.28 (0.02 - 4.9),,Asia,
191,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,,,2 / 51,11 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.52 (0.1 - 2.4),,Asia,
234,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,1,,2 / 26,8 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.1 (0.2 - 5.5),,Asia,
497,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Japanese,0.000246,,1 / 61,68 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value stated here is the uncorrected value.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
359,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Korean,,,5 / 24,7 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.6 (0.5 - 5.7),,Asia,
360,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Korean,,,1 / 24,0 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,6.4 (0.3 - 164.3),,Asia,
361,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Korean,,,3 / 24,2 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,3.4 (0.5 - 22.1),,Asia,
362,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Korean,,,7 / 24,10 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.6 (0.5 - 5),,Asia,
363,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*01:02,Korean,,,6 / 24,13 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.3 (0.4 - 4.2),,Asia,
364,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:03,Korean,,,7 / 24,12 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.3 (0.4 - 3.9),,Asia,
365,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*03:04,Korean,,,4 / 24,6 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.5 (0.4 - 5.8),,Asia,
366,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*06:02,Korean,,,4 / 24,5 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.8 (0.4 - 7.4),,Asia,
367,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-C,MHC class I,HLA-C*14:02,Korean,,,6 / 24,8 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.8 (0.5 - 5.8),,Asia,
368,http://www.ncbi.nlm.nih.gov/pubmed/23153709,antituberculosis drugs,HLA-C,MHC class I,HLA-C*04:01,Korean,0.0204,0.0132,7 / 14,21 / 166,62 / 485,drug-induced hypersensitivity syndrome (DIHS),chi-square test,,number of carriers (n),Bonferroni's correction,South Korea,tuberculosis,,6.9 (2.2 - 21.66),6.82 (2.31 - 20.11),Asia,
369,http://www.ncbi.nlm.nih.gov/pubmed/21676164,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Thai,0.001,,32 / 34,7 / 40,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, Chi-squared test",p-value was reported as < 0.001,number of carriers (n),Null,Thailand,epilepsy,,75.4 (13 - 718.9),,Asia,
370,http://www.ncbi.nlm.nih.gov/pubmed/19392989,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*03:01,Korean,0.00001,,43 / 184,11 / 207,,aspirin-intolerant asthma (AIA),"Fisher's exact test, Chi-squared test",p-value was reported as < 0.00001,number of carriers (n),Null,South Korea,,,5.4 (2.6 - 12.1),,Asia,
371,http://www.ncbi.nlm.nih.gov/pubmed/19392989,aspirin,HLA-DPB1,MHC class II,HLA-DPB1*03:01,Korean,0.00001,,25 / 364,11 / 207,,aspirin-induced urticaria (AIU),"Fisher's exact test, Chi-squared test",p-value was reported as < 0.00001,number of carriers (n),Null,South Korea,,,4.1 (2.4 - 7.3),,Asia,
567,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,1,0.82,2 / 36,3 / 64,20 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.36 (0.22 - 8.55),1.69 (0.38 - 7.59),Asia,
588,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,1,,2 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.09 (0.18 - 24.73),,Asia,
698,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,0.449,,2 / 20,7 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,1.873 (0.36 - 9.732),,Asia,
756,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Indian,,0.938,1 / 20,,3 / 55,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,India,,,,0.91 (0.09 - 9.31),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
758,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Diverse,,,0 / 39,,0 / 134,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,Brazil,,,,,South America,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
760,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Korean,,0.0362,11 / 31,,14 / 90,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,South Korea,,,,3 (1.18 - 7.57),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
378,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.545,0.694,15 / 40,16 / 52,24 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
379,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.795,0.479,7 / 40,8 / 52,17 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
380,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.877,0.356,6 / 40,10 / 52,6 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
381,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,0.087,0.528,5 / 40,1 / 52,6 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
382,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,0.748,4 / 40,5 / 52,6 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
383,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,0.47,0.775,4 / 40,3 / 52,10 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
384,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,0.729,0.461,4 / 40,4 / 52,4 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
385,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.037,0.189,3 / 40,13 / 52,12 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
386,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,0.117,1,2 / 40,9 / 52,3 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
387,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,0.58,0.291,2 / 40,1 / 52,1 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
388,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-B,MHC class I,HLA-B*07:02,Han Chinese,1,0.127,2 / 40,2 / 52,0 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
389,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Han Chinese,0.545,0.709,15 / 40,16 / 52,30 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
390,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Han Chinese,0.276,0.039,10 / 40,8 / 52,7 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
391,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*14:05,Han Chinese,0.003,0.058,7 / 40,0 / 52,4 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
392,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.475,0.309,6 / 40,11 / 52,17 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
393,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*08:03,Han Chinese,0.475,0.576,6 / 40,11 / 52,14 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
394,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Han Chinese,0.169,0.056,4 / 40,1 / 52,1 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
395,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Han Chinese,0.024,0.75,3 / 40,14 / 52,8 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
396,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*16:02,Han Chinese,0.07,0.554,0 / 40,5 / 52,3 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
762,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Indian,,0.939,1 / 40,,3 / 110,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,India,,patient and control sample sizes represent the number of alleles (not the number of individuals),,0.91 (0.09 - 9.06),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
764,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Diverse,,,0 / 78,,0 / 268,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,Brazil,,patient and control sample sizes represent the number of alleles (not the number of individuals),,,South America,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
766,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Korean,,0.0526,12 / 62,,16 / 180,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,2.46 (1.09 - 5.54),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
799,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Japanese,4.75E-15,,62 / 131,57 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,5.71 (3.666 - 8.881),,Asia,
813,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*02:06,Japanese,0.0056,,9 / 20,30 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,5.18 (1.98 - 13.56),,Asia,
851,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,0.352,,1 / 6,19 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,2.78 (0.31 - 25),,Asia,
877,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*02:06,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
1150,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:06,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
405,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.633,0.552,17 / 43,20 / 44,24 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
406,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,0.547,0.187,8 / 43,6 / 44,7 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
407,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.608,0.238,6 / 43,8 / 44,17 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
408,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,0.013,0.082,6 / 43,0 / 44,3 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
409,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.275,0.751,5 / 43,2 / 44,6 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
410,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,1,0.288,4 / 43,4 / 44,12 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
411,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,0.441,0.482,4 / 43,2 / 44,10 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
412,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,0.058,0.429,4 / 43,0 / 44,3 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
413,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.682,0.713,2 / 43,4 / 44,6 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
414,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,0.243,0.558,2 / 43,0 / 44,1 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
415,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-B,MHC class I,HLA-B*07:02,Han Chinese,0.368,0.374,1 / 43,4 / 44,0 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
416,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Han Chinese,0.502,0.683,16 / 43,20 / 44,30 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
417,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Han Chinese,0.138,0.169,9 / 43,4 / 44,8 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
418,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.547,0.555,8 / 43,6 / 44,17 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
419,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Han Chinese,0.823,0.314,7 / 43,8 / 44,7 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
420,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Han Chinese,0.166,0.663,6 / 43,2 / 44,8 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
421,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*08:03,Han Chinese,0.745,0.298,5 / 43,4 / 44,14 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
422,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*16:02,Han Chinese,0.082,0.154,5 / 43,12 / 44,3 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
423,http://www.ncbi.nlm.nih.gov/pubmed/18637831,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,0.005,,4 / 4,0 / 7,,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Null,Thailand,epilepsy,,18.5 (1.82 - 188.4),,Asia,
424,http://www.ncbi.nlm.nih.gov/pubmed/18637831,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Thai,0.0005,,6 / 6,0 / 4,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,epilepsy,,25.5 (2.68 - 242.61),,Asia,
425,http://www.ncbi.nlm.nih.gov/pubmed/18192896,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Diverse,,0.000001,15 / 27,,28 / 1822,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,France,gout,,,80 (34 - 187),Europe,
426,http://www.ncbi.nlm.nih.gov/pubmed/18192896,sulfamethoxazole,HLA-B,MHC class I,HLA-B*38:01,Diverse,,0.59,4 / 25,,78 / 1822,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,France,bacterial infections,,,4.3 (1.4 - 12.7),Europe,
427,http://www.ncbi.nlm.nih.gov/pubmed/18192896,sulfamethoxazole,HLA-B,MHC class I,HLA-B*38:02,Diverse,,0.73,1 / 25,,1 / 1822,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,France,bacterial infections,,,76 (4.6 - 1250),Europe,
428,http://www.ncbi.nlm.nih.gov/pubmed/18192896,lamotrigine,HLA-B,MHC class I,HLA-B*38:01,Diverse,,1,4 / 17,,78 / 1822,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,France,epilepsy,,,4.7 (1.3 - 16),Europe,
429,http://www.ncbi.nlm.nih.gov/pubmed/18192896,oxicam NSAIDs,HLA-B,MHC class I,HLA-B*73:01,Diverse,,0.73,2 / 14,,2 / 1822,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,France,inflammation,,,152 (20 - 1167),Europe,
430,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*07:05,Han Chinese,1,1,0 / 14,1 / 28,4 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),4.81 (0.25 - 91.38),Asia,
431,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.86,0.62,2 / 14,2 / 28,44 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.08 (0.28 - 15.58),2.08 (0.48 - 9.06),Asia,
432,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,1,0.46,3 / 14,5 / 28,69 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.22 (0.27 - 5.54),2.03 (0.6 - 6.89),Asia,
433,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,0.18,0.26,4 / 14,2 / 28,86 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),4.5 (0.77 - 26.27),2.23 (0.76 - 6.57),Asia,
434,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.65,0.49,1 / 14,5 / 28,29 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.38 (0.04 - 3.4),1.54 (0.2 - 11.73),Asia,
435,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,0.55,1,0 / 14,2 / 28,21 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.38 (0.02 - 8.24),0.99 (0.06 - 16.78),Asia,
436,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:13,Han Chinese,1,1,0 / 14,1 / 28,1 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),14.45 (0.58 - 362.44),Asia,
437,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:27,Han Chinese,0.33,0.07,1 / 14,0 / 28,2 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),22.85 (2.01 - 259.72),Asia,
438,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:58,Han Chinese,0.33,0.07,1 / 14,0 / 28,2 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),22.85 (2.01 - 259.72),Asia,
439,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*27:05,Han Chinese,1,1,0 / 14,1 / 28,6 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),3.32 (0.18 - 60.38),Asia,
440,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*35:08,Han Chinese,1,1,0 / 14,1 / 28,1 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),14.45 (0.58 - 362.44),Asia,
441,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*38:01,Han Chinese,1,1,0 / 14,1 / 28,8 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),2.54 (0.14 - 45),Asia,
442,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,0.42,0.018,3 / 14,2 / 28,23 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),3.24 (0.51 - 20.63),6.329 (1.783 - 22.46),Asia,
443,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*39:01,Han Chinese,1,1,0 / 14,1 / 28,23 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),0.91 (0.05 - 15.29),Asia,
444,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.89,0.88,3 / 14,4 / 28,100 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.56 (0.32 - 7.51),1.36 (0.41 - 4.59),Asia,
445,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*40:06,Han Chinese,1,1,0 / 14,1 / 28,39 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),0.53 (0.03 - 8.87),Asia,
446,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*44:02,Han Chinese,0.33,0.24,1 / 14,0 / 28,11 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),4.13 (0.51 - 33.09),Asia,
447,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*44:03,Han Chinese,1,0.17,2 / 14,5 / 28,32 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.79 (0.14 - 4.32),2.89 (0.66 - 12.72),Asia,
448,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,1,0.46,1 / 14,3 / 28,118 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.07 - 6.59),0.35 (0.05 - 2.61),Asia,
449,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*48:01,Han Chinese,0.25,1,0 / 14,5 / 28,24 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.16 (0.01 - 3.08),0.87 (0.05 - 14.63),Asia,
450,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,1,1,1 / 14,1 / 28,66 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.04 (0.12 - 33.83),0.66 (0.09 - 4.91),Asia,
451,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*51:02,Han Chinese,1,1,0 / 14,1 / 28,6 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),3.32 (0.18 - 60.38),Asia,
452,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*52:01,Han Chinese,0.33,0.39,1 / 14,0 / 28,21 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),2.14 (0.28 - 16.51),Asia,
453,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*55:01,Han Chinese,1,1,0 / 14,1 / 28,7 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),2.88 (0.16 - 51.58),Asia,
454,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,1,0.56,1 / 14,1 / 28,35 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.04 (0.12 - 33.83),1.27 (0.17 - 9.62),Asia,
455,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*56:01,Han Chinese,0.33,0.07,1 / 14,0 / 28,2 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),22.85 (2.01 - 259.72),Asia,
456,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*56:04,Han Chinese,1,1,0 / 14,1 / 28,1 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),14.45 (0.58 - 362.44),Asia,
457,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.55,0.35,0 / 14,3 / 28,74 / 1236,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.27 (0.01 - 5.38),0.27 (0.02 - 4.53),Asia,
458,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:42,Han Chinese,0.33,0.12,1 / 14,0 / 28,0 / 210,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),22.96 (0.91 - 577.76),Asia,
459,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*35:31,Han Chinese,0.55,,0 / 14,2 / 28,0 / 210,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.38 (0.02 - 8.24),,Asia,
460,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*47:01,Han Chinese,1,,0 / 14,1 / 28,0 / 210,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),,Asia,
461,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*48:04,Han Chinese,1,,0 / 14,1 / 28,0 / 210,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),,Asia,
462,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*53:01,Han Chinese,0.33,0.12,1 / 14,0 / 28,0 / 210,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.16 (0.24 - 156.27),22.96 (0.91 - 577.76),Asia,
463,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*13:15,Han Chinese,1,,0 / 14,1 / 28,,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),,Asia,
464,http://www.ncbi.nlm.nih.gov/pubmed/23829937,oxcarbazepine,HLA-B,MHC class I,HLA-B*37:10,Han Chinese,1,,0 / 14,1 / 28,,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,,continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.45),,Asia,
465,http://www.ncbi.nlm.nih.gov/pubmed/11888582,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),0.0001,,14 / 18,4 / 167,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as < 0.0001,number of carriers (n),Bonferroni's correction,Australia,HIV,All hypersensitive patients were reported to be Caucasian whilst exposed controls were diverse (mostly Caucasian),117 (29 - 481),,Oceania,
466,http://www.ncbi.nlm.nih.gov/pubmed/15024131,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),0.0001,,17 / 18,4 / 230,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as < 0.0001,number of carriers (n),Bonferroni's correction,Australia,HIV,All hypersensitive patients were reported to be Caucasian whilst exposed controls were diverse (mostly Caucasian),960,,Oceania,
1224,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:06,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
468,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*07:02,Japanese,1,,1 / 15,4 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",Allele designation not as reported in study (as 07020),number of carriers (n),Null,Japan,epilepsy,,0.518 (0.053 - 5.074),,Asia,
469,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
470,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*13:02,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
471,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*13:10,Japanese,0.313,,1 / 15,0 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,6.931 (0.266 - 180.436),,Asia,
472,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Japanese,1,,0 / 15,4 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.518 (0.053 - 5.074),,Asia,
473,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*15:07,Japanese,0.313,,1 / 15,0 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,6.931 (0.266 - 180.436),,Asia,
474,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Japanese,0.532,,1 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,2.286 (0.133 - 39.203),,Asia,
475,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*15:18,Japanese,1,,0 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.467 (0.021 - 10.386),,Asia,
476,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*27:04,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
477,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*35:01,Japanese,0.082,,0 / 15,7 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.114 (0.006 - 2.136),,Asia,
478,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*37:01,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
479,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*39:04,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
480,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Japanese,1,,2 / 15,4 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,1.115 (0.181 - 6.878),,Asia,
481,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*40:02,Japanese,0.236,,3 / 15,4 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,2.636 (0.56 - 12.421),,Asia,
482,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*40:06,Japanese,1,,0 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.103 (0.004 - 2.418),,Asia,
483,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*44:03,Japanese,0.227,,2 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,4.923 (0.41 - 59.112),,Asia,
484,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Japanese,1,,1 / 15,3 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.714 (0.068 - 7.493),,Asia,
485,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*48:01,Japanese,1,,0 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.103 (0.004 - 2.418),,Asia,
486,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Japanese,0.031,,6 / 15,5 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,4.9 (1.219 - 19.689),,Asia,
487,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*52:01,Japanese,1,,3 / 15,8 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.781 (0.175 - 3.483),,Asia,
488,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Japanese,0.65,,0 / 15,5 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.4 (0.043 - 3.76),,Asia,
489,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Japanese,0.579,,2 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,2.385 (0.303 - 18.788),,Asia,
490,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*56:01,Japanese,0.532,,1 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,2.286 (0.133 - 39.203),,Asia,
491,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Japanese,1,,0 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.103 (0.004 - 2.418),,Asia,
492,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*59:01,Japanese,1,,0 / 15,1 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,0.699 (0.027 - 18.157),,Asia,
493,http://www.ncbi.nlm.nih.gov/pubmed/22211527,carbamazepine,HLA-B,MHC class I,HLA-B*67:01,Japanese,1,,1 / 15,2 / 33,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Japan,epilepsy,,1.107 (0.093 - 13.248),,Asia,
494,http://www.ncbi.nlm.nih.gov/pubmed/11034591,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Caucasian,0.0000025,,14 / 20,27 / 134,,jaundice,"Fisher's exact test, chi-squared test","Study reports the use of correction but not declared method, The p-value stated here is the uncorrected value.",number of carriers (n),unknown,Scotland,bacterial infections,,9.25,,Europe,
1298,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:06,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1659,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,8.32,2.9,2 / 12,3 / 34,19 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,2.07 (0.3 - 14.18),2.78 (0.57 - 13.6),Asia,
1819,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*02:06,Han Chinese,,0.14,4 / 15,/ 118,19 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,,5.05 (1.47 - 17.38),Asia,
235,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.4428,,8 / 26,25 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.6 (0.6 - 4),,Asia,
374,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.596,0.206,13 / 40,14 / 52,15 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
398,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.943,0.079,16 / 43,16 / 44,15 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
498,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*02:07,Japanese,,,3 / 61,23 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
568,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.6,1,3 / 36,10 / 64,42 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.56 (0.14 - 2.19),1.2 (0.35 - 4.09),Asia,
589,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.66,,2 / 24,4 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.46 (0.08 - 2.76),,Asia,
828,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.128,,5 / 10,12 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,3.167 (0.782 - 12.831),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
852,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,1,,1 / 6,44 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,1.09 (0.12 - 9.52),,Asia,
1660,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,0.0011,0.0017,7 / 12,2 / 34,44 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,22.4 (3.58 - 139.98),7.61 (2.31 - 25.04),Asia,
1820,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*02:07,Han Chinese,,0.14,6 / 15,/ 118,44 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,,3.62 (1.23 - 10.68),Asia,
1151,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:08,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1225,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:08,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1299,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:08,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
499,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*02:10,Japanese,,,2 / 61,2 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
1152,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:11,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1226,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:11,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1300,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:11,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
515,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*07:05,Diverse,0.01,,3 / 53,1 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
516,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*15:10,Diverse,0.042,,4 / 53,20 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
517,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*18:01,Diverse,0.096,,4 / 53,2 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
518,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*35:01,Diverse,0.47,,1 / 53,4 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
519,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*35:05,Diverse,0.81,,1 / 53,1 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
520,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*41:01,Diverse,0.072,,0 / 53,4 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
521,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*58:01,Diverse,0.018,,12 / 53,9 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
522,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-B,MHC class I,HLA-B*58:02,Diverse,0.057,,6 / 53,25 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
523,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-C,MHC class I,HLA-C*02:10,Diverse,0.0012,,2 / 55,19 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
524,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-C,MHC class I,HLA-C*03:02,Diverse,0.041,,6 / 55,3 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
525,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-C,MHC class I,HLA-C*03:04,Diverse,0.047,,4 / 55,19 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
526,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-C,MHC class I,HLA-C*06:02,Diverse,0.042,,12 / 55,39 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
527,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-C,MHC class I,HLA-C*12:03,Diverse,0.017,,8 / 55,4 / 106,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
528,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Diverse,0.14,,0 / 54,3 / 103,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
529,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*01:02,Diverse,0.022,,8 / 54,4 / 103,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
530,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Diverse,0.086,,4 / 54,15 / 103,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
531,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Diverse,0.072,,0 / 54,4 / 103,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
532,http://www.ncbi.nlm.nih.gov/pubmed/19195327,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),0.001,,21 / 27,17 / 1728,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,"p-value reported as <0.001, Study only reported incidence rate as percentages - therefore the number of patients and controls with the allele has been infered from this.",number of carriers (n),Null,Switzerland,HIV,,,,Europe,
533,http://www.ncbi.nlm.nih.gov/pubmed/19195327,abacavir,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian (predominantly),0.01,,6 / 27,138 / 1728,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,Allele reported as ''HLA-DR*0701''. This has been assumed to be HLA-DRB1*07:01 Study only reported incidence rate as percentages - therefore the number of patients and controls with the allele has been infered from this.,number of carriers (n),Null,Switzerland,HIV,,,,Europe,
534,http://www.ncbi.nlm.nih.gov/pubmed/18184080,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian,0.01,,11 / 26,1 / 27,,drug-induced hypersensitivity syndrome (DIHS),unknown,p-value reported as <0.01,number of carriers (n),unknown,Spain,HIV,,,,Europe,
535,http://www.ncbi.nlm.nih.gov/pubmed/24687830,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,0.00000000000024,,29 / 37,218 / 1071,,drug induced liver injury (DILI),Fisher's exact test,,number of carriers (n),Null,United States,breast cancer,,14.12 (6.36 - 31.32),,North America,
536,http://www.ncbi.nlm.nih.gov/pubmed/24687830,lapatinib,HLA-DQA1,MHC class II,HLA-DQA1*02:01,Diverse,0.00000000000026,,29 / 37,218 / 1071,,drug induced liver injury (DILI),Fisher's exact test,,number of carriers (n),Null,United States,breast cancer,,14.08 (6.35 - 31.24),,North America,
537,http://www.ncbi.nlm.nih.gov/pubmed/24687830,lapatinib,HLA-DQB1,MHC class II,HLA-DQB1*02:02,Diverse,0.00000000079,,23 / 37,170 / 1071,,drug induced liver injury (DILI),Fisher's exact test,,number of carriers (n),Null,United States,breast cancer,,8.64 (4.36 - 17.13),,North America,
538,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*07:05,Han Chinese,1,0.39,0 / 56,1 / 22,9 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.23 (0.11 - 14.09),2.26 (0.28 - 18.42),Asia,
539,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.32,1,1 / 56,9 / 22,36 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.25 (0.03 - 2.091),0.65 (0.09 - 4.98),Asia,
540,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,0.67,0.09,2 / 56,2 / 22,11 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.7 (0.36 - 20.48),4.7 (0.98 - 22.62),Asia,
541,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,0.93,1 / 56,4 / 22,39 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.62 (0.07 - 5.87),0.6 (0.08 - 4.56),Asia,
542,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*15:03,Han Chinese,1,0.13,0 / 56,2 / 22,1 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.8 (0.08 - 8.07),11.48 (1 - 131.23),Asia,
543,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*15:27,Han Chinese,1,0.13,0 / 56,2 / 22,1 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.8 (0.08 - 8.07),11.48 (1 - 131.23),Asia,
544,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*39:01,Han Chinese,0.49,0.28,1 / 56,1 / 22,7 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.62 (0.16 - 43.81),3.54 (0.42 - 30.13),Asia,
545,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.54,0.18,6 / 56,10 / 22,76 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.73 (0.54 - 5.51),2.23 (0.85 - 5.88),Asia,
546,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*44:03,Han Chinese,1,0.39,0 / 56,1 / 22,9 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.22 (0.11 - 14.09),2.26 (0.28 - 18.42),Asia,
547,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,1,0.24,5 / 56,12 / 22,63 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.08 (0.33 - 3.52),2.17 (0.77 - 6.09),Asia,
548,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*48:01,Han Chinese,0.49,0.39,1 / 56,1 / 22,11 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.62 (0.16 - 43.81),2.24 (0.28 - 18.15),Asia,
549,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,0.49,0.44,1 / 56,1 / 22,13 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.62 (0.16 - 43.81),1.89 (0.24 - 15.1),Asia,
550,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*54:17,Han Chinese,1,,0 / 56,1 / 22,/ 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.22 (0.11 - 14.09),,Asia,
551,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.92,1,2 / 56,3 / 22,47 / 528,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.77 (0.28 - 11.37),1.02 (0.23 - 4.51),Asia,
552,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*15:19,Han Chinese,1,0.08,0 / 56,1 / 22,0 / 569,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.22 (0.11 - 14.09),24.78 (1.5 - 408.76),Asia,
553,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*44:08,Han Chinese,1,0.08,0 / 56,1 / 22,0 / 569,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.22 (0.11 - 14.09),24.78 (1.5 - 408.76),Asia,
554,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*55:01,Han Chinese,0.81,0.08,0 / 56,4 / 22,0 / 569,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.46 (0.05 - 4.17),24.78 (1.5 - 408.76),Asia,
555,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*55:02,Han Chinese,0.2,0.39,1 / 56,0 / 22,12 / 569,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),5.18 (0.45 - 60.07),2.21 (0.27 - 17.8),Asia,
556,http://www.ncbi.nlm.nih.gov/pubmed/21306565,lamotrigine,HLA-B,MHC class I,HLA-B*81:01,Han Chinese,0.2,0.07,1 / 56,0 / 22,1 / 569,"Stevens-Johnson syndrome (SJS),maculopapular exanthema (MPE)","Fisher's exact test, chi-squared test",,number of carriers (n),continuity correction,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),5.18 (0.45 - 60.07),27.05 (1.64 - 447.38),Asia,
557,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,,0.55,1 / 36,,36 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,0.39 (0.05 - 2.93),Asia,
558,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,0.0000000000975,15 / 36,,39 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,8.96 (4.28 - 18.74),Asia,
559,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,,0.01,2 / 36,,1 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,31 (2.74 - 350.5),Asia,
560,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,,0.53,1 / 36,,37 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,0.38 (0.05 - 2.85),Asia,
561,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,,0.2,8 / 36,,76 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,1.7 (0.75 - 3.87),Asia,
562,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,,0.57,6 / 36,,63 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,1.48 (0.59 - 3.69),Asia,
563,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Han Chinese,,0.25,2 / 36,,13 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,2.33 (0.51 - 10.75),Asia,
1153,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:12,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1227,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:12,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1301,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:12,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1154,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*02:81,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1228,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:81,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1302,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*02:81,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
649,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-A,MHC class I,HLA-A*03,Caucasian,,,6 / 31,17 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
500,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*03:01,Japanese,,,0 / 61,2 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
673,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-A,MHC class I,HLA-A*03:01,Unknown,0.2811,,9 / 38,21 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.448 (0.187 - 1.076),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
800,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*03:01,Japanese,0.412,,5 / 131,4 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,4.12 (1.089 - 15.564),,Asia,
814,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*03:01,Japanese,,,0 / 20,19 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
853,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-A,MHC class I,HLA-A*03:01,Han Chinese,0.192,,1 / 6,9 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,6.09 (0.64 - 57.62),,Asia,
878,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*03:01,Caucasian (North West),,1,27 / 134,,24 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.98,Europe,Values have been provided based on data obtained directly from the study authors
577,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.32,,1 / 13,3 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.25 (0.02 - 2.82),,Asia,
578,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,1,,2 / 13,2 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.91 (0.11 - 7.72),,Asia,
579,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*15:03,Han Chinese,0.48,,0 / 13,1 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.28 (0.01 - 7.67),,Asia,
580,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*15:25,Han Chinese,0.48,,0 / 13,1 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.28 (0.01 - 7.67),,Asia,
581,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.16,,5 / 13,1 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.88 (0.67 - 70.82),,Asia,
582,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.65,,4 / 13,2 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.22 (0.33 - 15.18),,Asia,
583,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*56:01,Han Chinese,0.48,,0 / 13,1 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.28 (0.01 - 7.67),,Asia,
584,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-B,MHC class I,HLA-B*56:10,Han Chinese,1,,1 / 13,1 / 12,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,Allele count for patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.92 (0.05 - 16.49),,Asia,
989,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*03:01,Caucasian (North West),,1,15 / 134,,23 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.51,Europe,Values have been provided based on data obtained directly from the study authors
1155,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*03:01,Unknown,,,1 / 34,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1229,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*03:01,Unknown,,,0 / 24,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1303,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*03:01,Unknown,,,2 / 20,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1380,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-A,MHC class I,HLA-A*03:01,Indian,1,,2 / 62,14 / 200,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1383,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-A,MHC class I,HLA-A*03:01,Indian,0.08,,3 / 14,14 / 200,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1386,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-A,MHC class I,HLA-A*03:01,Indian,0.11,,3 / 16,14 / 200,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1389,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-A,MHC class I,HLA-A*03:01,Indian,0.005,,4 / 10,14 / 200,,fixed drug eruption,Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1462,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*03:01,Caucasian,1,0.93,1 / 3,3 / 10,47 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.17 (0.05 - 34.03),2.19 (0.08 - 31.72),Europe,
1485,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*03:01,Caucasian,0.896,0.483,2 / 5,6 / 28,47 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.89 (0.17 - 20.5),2.92 (0.33 - 22.3),Europe,
1523,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*03:01,Caucasian,0.991,1,1 / 4,3 / 23,47 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.22 (0.07 - 46.47),1.46 (0.06 - 16.28),Europe,
596,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DQA1,MHC class II,HLA-DQA1*02:01,Diverse,0.00008,,17 / 24,33 / 155,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the confrmatory study,9 (3.2 - 27.4),,North America,
597,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DQB1,MHC class II,HLA-DQB1*02:02,Diverse,0.0003,,15 / 24,30 / 155,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the confrmatory study,6.9 (2.5 - 19.6),,North America,
598,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,0.0004,,16 / 24,35 / 155,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the confrmatory study,6.9 (2.5 - 19.9),,North America,
599,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DQA1,MHC class II,HLA-DQA1*02:01,Diverse,0.03,,14 / 35,58 / 283,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the exploratory study,2.6 (1.1 - 5.7),,North America,
600,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DQB1,MHC class II,HLA-DQB1*02:02,Diverse,0.007,,13 / 35,47 / 283,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the exploratory study,2.9 (1.3 - 6.6),,North America,
601,http://www.ncbi.nlm.nih.gov/pubmed/21245432,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,0.04,,14 / 35,59 / 283,,drug induced liver injury (DILI),unknown,,number of carriers (n),Bonferroni's correction,United States,breast cancer,two sub-studies were performed. This data refers to the exploratory study,2.5 (1.1 - 5.6),,North America,
602,http://www.ncbi.nlm.nih.gov/pubmed/16816555,abacavir,HLA-B,MHC class I,HLA-B*57:01,Caucasian (predominantly),0.03,,2 / 9,0 / 41,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,United States,HIV,,6.9 (3.5 - 13.6),,North America,
1683,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*03:01,Diverse,,0.193,8 / 39,,16 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
604,http://www.ncbi.nlm.nih.gov/pubmed/23874514,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*18:01,Caucasian,,0.22,11 / 28,,163 / 855,drug induced liver injury (DILI) - hepatocellular type of damage,chi-square test,,number of carriers (n),Bonferroni's correction,Spain,bacterial infections,The study reports that amoxicillin-clavulanate is commonly used in Spain and therefore assumed that a large proportion of the population controls were exposed to the drug at some stage of their lives.,,2.9 (1.3 - 6.2),Europe,
605,http://www.ncbi.nlm.nih.gov/pubmed/23874514,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Caucasian,,0.06,17 / 47,,158 / 855,drug induced liver injury (DILI) - cholestatic/mixed type of damage,chi-square test,confidence intervals for the odds ratios were not provided for this association,number of carriers (n),Bonferroni's correction,Spain,bacterial infections,The study reports  that amoxicillin-clavulanate is commonly used in Spain and therefore assumed that a large proportion of the population controls were exposed to the drug at some stage of their lives.,,2.6,Europe,
606,http://www.ncbi.nlm.nih.gov/pubmed/23874514,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:02,Caucasian,,0.03,17 / 47,,150 / 855,drug induced liver injury (DILI) - cholestatic/mixed type of damage,chi-square test,confidence intervals for the odds ratios were not provided for this association,number of carriers (n),Bonferroni's correction,Spain,bacterial infections,The study reports  that amoxicillin-clavulanate is commonly used in Spain and therefore assumed that a large proportion of the population controls were exposed to the drug at some stage of their lives.,,2.8,Europe,
607,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.000000000000161,,27 / 27,7 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,348.3 (19.2 - 6336.9),,Asia,
608,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.68,,4 / 27,10 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.8 (0.2 - 2.7),,Asia,
609,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.18,,2 / 27,10 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.4 (0.1 - 1.7),,Asia,
610,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*18:02,Thai,0.19,,3 / 27,2 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,3.3 (0.5 - 20.7),,Asia,
611,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*38:02,Thai,0.37,,1 / 27,5 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.4 (0.04 - 3.4),,Asia,
612,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.19,,1 / 27,7 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.3 (0.03 - 2.2),,Asia,
613,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.06,,3 / 27,16 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.3 (0.08 - 1.1),,Asia,
614,http://www.ncbi.nlm.nih.gov/pubmed/19696695,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.13,,1 / 27,8 / 54,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.2 (0.03 - 1.9),,Asia,
615,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Thai,0.00000000000289,,37 / 42,5 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,54.76 (14.62 - 205.13),,Asia,
616,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*15:21,Thai,0.2398,,2 / 42,0 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,5.25 (0.24 - 112.66),,Asia,
617,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*15:35,Thai,0.1245,,3 / 42,0 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,7.53 (0.38 - 150.47),,Asia,
618,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Thai,0.4572,,3 / 42,5 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.57 (0.13 - 2.55),,Asia,
619,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*18:01,Thai,0.2363,,2 / 42,5 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.37 (0.07 - 2.02),,Asia,
620,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*18:02,Thai,0.1665,,1 / 42,4 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.23 (0.02 - 2.17),,Asia,
621,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*27:06,Thai,0.3968,,2 / 42,4 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.48 (0.08 - 2.75),,Asia,
622,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*35:05,Thai,0.1245,,0 / 42,3 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.13 (0.0066 - 2.65),,Asia,
623,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*38:02,Thai,1,,2 / 42,2 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,1 (0.13 - 7.45),,Asia,
624,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*39:09,Thai,0.6447,,3 / 42,2 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,1.54 (0.24 - 9.71),,Asia,
625,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Thai,0.2899,,3 / 42,6 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.46 (0.11 - 1.98),,Asia,
626,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Thai,0.6084,,9 / 42,11 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.77 (0.28 - 2.11),,Asia,
627,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Thai,0.0343,,0 / 42,5 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.08 (0.0043 - 1.4995),,Asia,
628,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*51:02,Thai,0.2398,,0 / 42,2 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.19 (0.0089 - 4.09),,Asia,
629,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Thai,0.6086,,1 / 42,2 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.59 (0.07 - 4.64),,Asia,
630,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*56:01,Thai,0.3055,,3 / 42,1 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,3.15 (0.31 - 31.62),,Asia,
631,http://www.ncbi.nlm.nih.gov/pubmed/20345939,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Thai,0.1058,,3 / 42,8 / 42,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.33 (0.08 - 1.33),,Asia,
632,http://www.ncbi.nlm.nih.gov/pubmed/24394201,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.000000069,,13 / 13,3 / 26,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Singapore,epilepsy,,181 (8.7 - 3785),,Asia,
633,http://www.ncbi.nlm.nih.gov/pubmed/21397523,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.001,0.001,9 / 9,11 / 80,11 / 62,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,epilepsy,,114.826 (6.25 - 2111.03),85.087 (4.61 - 1569.48),Asia,
634,http://www.ncbi.nlm.nih.gov/pubmed/21397523,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.11,0.341,10 / 39,11 / 80,11 / 62,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,epilepsy,,2.163 (0.828 - 5.649),1.599 (0.606 - 4.218),Asia,
635,http://www.ncbi.nlm.nih.gov/pubmed/20833111,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.05,0.05,8 / 8,4 / 50,6 / 71,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, Chi-squared test","p-values for this association were not provided, although they were reported as statistically significant, which the study considered <0.05",number of carriers (n),Unknown,China,epilepsy,,184 (33.2 - 1021),173.3 (36 - 834.5),Asia,
636,http://www.ncbi.nlm.nih.gov/pubmed/20833111,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.697,0.724,3 / 28,4 / 50,6 / 71,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Unknown,China,epilepsy,,1.4 (0.3 - 6.7),1.3 (0.3 - 5.6),Asia,
637,http://www.ncbi.nlm.nih.gov/pubmed/21424386,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.0001,0.0001,16 / 17,2 / 21,17 / 185,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",p-values reported as <0.0001,number of carriers (n),Null,China,epilepsy,,152 (12 - 1835),158 (19 - 1266),Asia,
638,http://www.ncbi.nlm.nih.gov/pubmed/19915237,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Indian,0.0014,,6 / 8,0 / 10,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,India,epilepsy,,71.4 (3 - 1698),,Asia,
639,http://www.ncbi.nlm.nih.gov/pubmed/24225276,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.004,,5 / 5,1 / 10,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",unknown,the 95% confidence intervals for the odds ratio were reported as (2.67 to infinity),number of carriers (n),Unknown,Singapore,epilepsy,"patient and control ethnicities are diverse (Chinese, Malay and Indian)",27.2 (2.67 - ∞),,Asia,
640,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DQB1,MHC class II,HLA-DQB1*02:01,Caucasian,0.07,,13 / 30,20 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,2.22 (0.92 - 5.36),,Europe,
641,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DQB1,MHC class II,HLA-DQB1*03,Caucasian,,,16 / 30,43 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,0.93 (0.4 - 2.17),,Europe,
642,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DQB1,MHC class II,HLA-DQB1*03:02,Caucasian,,,5 / 30,12 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,1.1 (0.35 - 3.44),,Europe,
643,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DQB1,MHC class II,HLA-DQB1*05:02,Caucasian,0.006,,5 / 30,1 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,15.4 (1.72 - 138),,Europe,
644,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DRB1,MHC class II,HLA-DRB1*04:02,Caucasian,,,3 / 30,2 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,4.22 (0.67 - 26.6),,Europe,
645,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DRB1,MHC class II,HLA-DRB1*16:01,Caucasian,,,3 / 30,3 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,2.78 (0.53 - 14.6),,Europe,
646,http://www.ncbi.nlm.nih.gov/pubmed/11146763,clozapine,HLA-DRB5,MHC class II,HLA-DRB5*02,Caucasian,0.02,,3 / 30,0 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Germany,schizophrenia,,,,Europe,
575,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*03:02,Han Chinese,1,,0 / 36,1 / 64,0 / 1138,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.44),,Asia,
990,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*03:02,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1156,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*03:02,Unknown,,,1 / 34,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
650,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-B,MHC class I,HLA-B*07,Caucasian,,,7 / 31,19 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
651,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-B,MHC class I,HLA-B*44,Caucasian,,,7 / 31,17 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
652,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-C,MHC class I,HLA-C*07,Caucasian,0.02,,20 / 31,30 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
653,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-C,MHC class I,HLA-C*12,Caucasian,,,10 / 31,16 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
654,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-C,MHC class I,HLA-C*16,Caucasian,,,4 / 31,21 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
655,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DPB,MHC class II,HLA-DPB*02:01,Caucasian,,,9 / 31,21 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
656,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DPB,MHC class II,HLA-DPB*03:01,Caucasian,,,6 / 31,16 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
657,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DPB,MHC class II,HLA-DPB*04:01,Caucasian,0.034,,23 / 31,40 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
658,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DPB,MHC class II,HLA-DPB*04:02,Caucasian,,,8 / 31,19 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
659,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DQB,MHC class II,HLA-DQB*02:01,Caucasian,,,13 / 31,20 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
660,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DQB,MHC class II,HLA-DQB*05:02,Caucasian,0.007,,5 / 31,1 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
661,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DQB,MHC class II,HLA-DQB*05:03,Caucasian,,,3 / 31,5 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
662,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DQB,MHC class II,HLA-DQB*06:03,Caucasian,,,6 / 31,8 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
663,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DQB,MHC class II,HLA-DQB*06:04,Caucasian,,,3 / 31,3 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
664,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Caucasian,0.06,,3 / 31,20 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
665,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Caucasian,,,10 / 31,14 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
666,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian,,,6 / 31,16 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
667,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB3,MHC class II,HLA-DRB3*01:01,Caucasian,,,10 / 31,19 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
668,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB3,MHC class II,HLA-DRB3*02:02,Caucasian,0.07,,14 / 31,21 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
669,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB4,MHC class II,HLA-DRB4*01:01,Caucasian,,,12 / 31,35 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
670,http://www.ncbi.nlm.nih.gov/pubmed/11266078,clozapine,HLA-DRB5,MHC class II,HLA-DRB5*01:01,Caucasian,,,4 / 31,17 / 77,,agranulocytosis,"Fisher's exact test, chi-squared test",p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Germany,schizophrenia,,,,Europe,
1230,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*03:02,Unknown,,,1 / 24,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1304,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*03:02,Unknown,,,0 / 20,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1834,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*11,Han Chinese,,0.12,3 / 15,/ 118,143 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,,0.24 (0.07 - 0.89),Asia,
879,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*11:01,Caucasian (North West),,0.26396,8 / 134,,19 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.33,Europe,Values have been provided based on data obtained directly from the study authors
991,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*11:01,Caucasian (Spanish),,1,4 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.97,Europe,Values have been provided based on data obtained directly from the study authors
676,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*07:02,Unknown,0.6896,,4 / 38,19 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.056 (0.337 - 3.302),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
677,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*08:01,Unknown,0.3929,,4 / 38,12 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.638 (0.194 - 2.097),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
678,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*18:01,Unknown,0.3199,,5 / 38,12 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.495 (0.163 - 1.5),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
679,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*35:01,Unknown,0.7212,,1 / 38,12 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,2.775 (0.35 - 22.015),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
680,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*44:02,Unknown,0.9244,,3 / 38,16 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.197 (0.331 - 4.332),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
681,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*51:01,Unknown,0.4205,,5 / 38,11 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.451 (0.147 - 1.384),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
682,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-B,MHC class I,HLA-B*57:01,Unknown,0.8351,,2 / 38,9 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.994 (0.206 - 4.797),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
683,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*02:02,Unknown,0.4797,,2 / 38,17 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.974 (0.436 - 8.931),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
684,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*03:04,Unknown,0.5604,,1 / 38,12 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,2.775 (0.35 - 22.015),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
685,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*04:01,Unknown,0.4586,,3 / 38,19 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.449 (0.406 - 5.168),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
686,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*05:01,Unknown,0.5116,,2 / 38,16 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.846 (0.406 - 8.39),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
687,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*06:02,Unknown,0.5326,,3 / 38,18 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.364 (0.381 - 4.886),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
688,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*07:01,Unknown,0.1241,,9 / 38,20 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.424 (0.176 - 1.023),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
689,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*07:02,Unknown,0.8245,,4 / 38,24 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.378 (0.449 - 4.234),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
690,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-C,MHC class I,HLA-C*12:03,Unknown,0.4155,,4 / 38,11 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.581 (0.174 - 1.933),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
691,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Unknown,0.5782,,4 / 38,15 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.812 (0.254 - 2.6),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
692,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Unknown,0.304,,3 / 38,21 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.623 (0.458 - 5.745),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
693,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Unknown,0.1625,,2 / 38,20 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,2.368 (0.529 - 10.596),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
694,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Unknown,0.1442,,3 / 38,8 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.569 (0.144 - 2.253),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
695,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Unknown,0.0838,,5 / 38,9 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,0.364 (0.115 - 1.157),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
696,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Unknown,0.6382,,4 / 38,27 / 173,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,1.583 (0.519 - 4.824),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
697,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.001,,8 / 35,2 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as 0.000. This is likley a rounding issue.,number of carriers (n),Null,China,epilepsy,,18.222 (3.662 - 90.662),,Asia,
1231,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*11:01,Unknown,,0.02,0 / 24,,16 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1305,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*11:01,Unknown,,,1 / 20,,16 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
700,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.013,,4 / 20,6 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,4.958 (1.262 - 19.485),,Asia,
701,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,0.013,,4 / 20,6 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,4.958 (1.262 - 19.485),,Asia,
702,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-C,MHC class I,HLA-C*06:02,Han Chinese,0.215,,4 / 20,13 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.154 (0.625 - 7.421),,Asia,
703,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-DQB1,MHC class II,HLA-DQB1*03:01,Han Chinese,0.16,,7 / 20,26 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.05 (0.743 - 5.659),,Asia,
704,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-DQB1,MHC class II,HLA-DQB1*03:03,Han Chinese,0.022,,8 / 20,22 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,3.121 (1.141 - 8.536),,Asia,
705,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Han Chinese,0.003,,7 / 20,13 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,4.639 (1.57 - 13.709),,Asia,
706,http://www.ncbi.nlm.nih.gov/pubmed/21204807,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Japanese,,0.0263,2 / 22,,5 / 493,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,Japan,epilepsy,patient sample sizes represent the number of alleles (not the number of individuals),,9.75 (2.01 - 47.5),Asia,
707,http://www.ncbi.nlm.nih.gov/pubmed/21204807,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Japanese,,0.0004,4 / 28,,5 / 493,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,Japan,epilepsy,patient sample sizes represent the number of alleles (not the number of individuals),,16.3 (4.76 - 55.6),Asia,
708,http://www.ncbi.nlm.nih.gov/pubmed/19017052,carbamazepine,HLA-B,MHC class I,HLA-B*39:02,Japanese,,0.04,2 / 22,,4 / 371,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Null,Japan,epilepsy,,,,Asia,
1157,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*11:01,Unknown,,0.003,0 / 34,,16 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
710,http://www.ncbi.nlm.nih.gov/pubmed/16868443,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Caucasian,,,0 / 26,3 / 72,7 / 164,"drug-induced skin reaction (DISI),drug induced liver injury (DILI)",Fisher's exact test,p-value was reported as not significant,,Yates' continuity correction,Italy,HIV,All individuals in this study were reported as Sardinian. The general population group are HIV positive individuals who had not received nevirapine at the time of the study. Patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,
711,http://www.ncbi.nlm.nih.gov/pubmed/16868443,nevirapine,HLA-DRB1,MHC class II,HLA-DRB1*01:02,Caucasian,,,4 / 26,2 / 72,10 / 164,"drug-induced skin reaction (DISI),drug induced liver injury (DILI)",Fisher's exact test,p-value was reported as not significant,,Yates' continuity correction,Italy,HIV,All individuals in this study were reported as Sardinian. The general population group are HIV positive individuals who had not received nevirapine at the time of the study. Patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,
712,http://www.ncbi.nlm.nih.gov/pubmed/17509004,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.000148,,6 / 6,7 / 48,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Hong Kong,epilepsy,,71.9 (3.7 - 1415.8),,Asia,"study looked at several antiepileptic drugs (carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate)."
713,http://www.ncbi.nlm.nih.gov/pubmed/17509004,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.32,,2 / 16,7 / 48,,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Hong Kong,epilepsy,,0.84 (0.15 - 4.51),,Asia,"study looked at several antiepileptic drugs (carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate)."
714,http://www.ncbi.nlm.nih.gov/pubmed/23551241,phenobarbital,HLA-B,MHC class I,HLA-B*15:02,Thai,0.18,,5 / 20,2 / 20,,"Stevens-Johnson syndrome (SJS),drug-induced hypersensitivity syndrome (DIHS)",chi-square test,,number of carriers (n),Null,Thailand,epilepsy,,3.734 (0.5 - 25.7),,Asia,
715,http://www.ncbi.nlm.nih.gov/pubmed/23551241,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,0.35,,1 / 17,3 / 17,,"Stevens-Johnson syndrome (SJS),drug-induced hypersensitivity syndrome (DIHS)",chi-square test,,number of carriers (n),Null,Thailand,epilepsy,,0.35 (0.03 - 3.9),,Asia,
716,http://www.ncbi.nlm.nih.gov/pubmed/23669020,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Japanese,0.0009733,,4 / 7,0 / 25,,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Null,Japan,gout,,65.6 (2.9 - 1497),,Asia,
717,http://www.ncbi.nlm.nih.gov/pubmed/20639878,lumiracoxib,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Diverse,6.8E-25,,97 / 274,121 / 1154,,drug induced liver injury (DILI),Cochran-Mantel-Haenszel test,,,Null,Worldwide,osteoarthritis,patient sample sizes represent the number of alleles (not the number of individuals),7.5 (5 - 11.3),,,
718,http://www.ncbi.nlm.nih.gov/pubmed/20639878,lumiracoxib,HLA-DQB1,MHC class II,HLA-DQB1*06:02,Diverse,1.1E-22,,94 / 274,121 / 1154,,drug induced liver injury (DILI),Cochran-Mantel-Haenszel test,,,Null,Worldwide,osteoarthritis,patient sample sizes represent the number of alleles (not the number of individuals),6.9 (4.6 - 10.3),,,
719,http://www.ncbi.nlm.nih.gov/pubmed/20639878,lumiracoxib,HLA-DRB5,MHC class II,HLA-DRB5*01:01,Diverse,1.6E-20,,88 / 274,115 / 1154,,drug induced liver injury (DILI),Cochran-Mantel-Haenszel test,,,Null,Worldwide,osteoarthritis,patient sample sizes represent the number of alleles (not the number of individuals),7.2 (4.8 - 10.8),,,
720,http://www.ncbi.nlm.nih.gov/pubmed/20639878,lumiracoxib,HLA-DQA1,MHC class II,HLA-DQA1*01:02,Diverse,1.2E-18,,117 / 274,201 / 1154,,drug induced liver injury (DILI),Cochran-Mantel-Haenszel test,,,Null,Worldwide,osteoarthritis,patient sample sizes represent the number of alleles (not the number of individuals),6.3 (4.1 - 9.6),,,
721,http://www.ncbi.nlm.nih.gov/pubmed/22053601,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.0003,,6 / 6,0 / 8,,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Null,Malaysia,epilepsy,patient and control ethnicities are diverse (Malay and Chinese),,,Asia,
722,http://www.ncbi.nlm.nih.gov/pubmed/22053601,carbamazepine,HLA-B,MHC class I,HLA-B*15:03,Diverse,0.1032,,4 / 11,0 / 8,,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,Malaysia,epilepsy,patient and control ethnicities are diverse (Malay and Chinese),,,Asia,
723,http://www.ncbi.nlm.nih.gov/pubmed/24152261,dapsone,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,,0.000000000474,17 / 37,,32 / 201,drug-induced hypersensitivity syndrome (DIHS),Cochran's Q statistic and quantified by calculating the I2 statistic.,The number of patients and controls carrying this allele has been imputed from the paper (represented as a frequency),number of carriers (n),Null,China,leprosy,,,23.54 (8.71 - 63.62),Asia,"Only the results from the ""replication analysis"" is included here as this involved direct sequencing of the HLA genes (the larger discovery sample imputed HLA alleles via SNPs is not included)"
724,http://www.ncbi.nlm.nih.gov/pubmed/24152261,dapsone,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,,0.000000915,16 / 37,,32 / 201,drug-induced hypersensitivity syndrome (DIHS),Cochran's Q statistic and quantified by calculating the I2 statistic.,The number of patients and controls carrying this allele has been imputed from the paper (represented as a frequency),number of carriers (n),Null,China,leprosy,,,5.9 (2.9 - 11.97),Asia,"Only the results from the ""replication analysis"" is included here as this involved direct sequencing of the HLA genes (the larger discovery sample imputed HLA alleles via SNPs is not included)"
725,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Caucasian (predominantly),,,11 / 53,12 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
726,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*01:02,Caucasian (predominantly),,,3 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
727,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*01:03,Caucasian (predominantly),,,1 / 53,5 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
728,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Caucasian (predominantly),,,13 / 53,17 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
729,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*04,Caucasian (predominantly),,,5 / 53,9 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
730,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Caucasian (predominantly),,,12 / 53,16 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
731,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*04:02,Caucasian (predominantly),,,2 / 53,0 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
732,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*04:04,Caucasian (predominantly),,,0 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
733,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Caucasian (predominantly),,,0 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
734,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian (predominantly),,,12 / 53,23 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
735,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*08,Caucasian (predominantly),,,2 / 53,10 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
736,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*08:01,Caucasian (predominantly),,,1 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
737,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Caucasian (predominantly),,,2 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
738,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*10:01,Caucasian (predominantly),,,0 / 53,3 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
739,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*11,Caucasian (predominantly),,,8 / 53,8 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
740,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*11:02,Caucasian (predominantly),,,1 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
741,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*11:03,Caucasian (predominantly),,,1 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
742,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*12,Caucasian (predominantly),,,4 / 53,3 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
743,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*13,Caucasian (predominantly),,,7 / 53,16 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
744,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*13:03,Caucasian (predominantly),,,2 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
745,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*13:05,Caucasian (predominantly),,,1 / 53,0 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
746,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*14,Caucasian (predominantly),,,1 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
747,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Caucasian (predominantly),,,0 / 53,2 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
748,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*14:09,Caucasian (predominantly),,,2 / 53,0 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
749,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*15,Caucasian (predominantly),,,14 / 53,26 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
750,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Caucasian (predominantly),,,1 / 53,0 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
751,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*16:01,Caucasian (predominantly),,,0 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
752,http://www.ncbi.nlm.nih.gov/pubmed/19374512,co-trimoxazole,HLA-DRB1,MHC class II,HLA-DRB1*16:02,Caucasian (predominantly),,,0 / 53,1 / 83,,"maculopapular exanthema (MPE),Stevens-Johnson syndrome (SJS)",chi-square test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,United Kingdom,HIV,,,,Europe,
753,http://www.ncbi.nlm.nih.gov/pubmed/17505501,ximelagatran,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian,0.00004,,35 / 74,22 / 130,,elevated levels of serum alanine aminotransferase (ALAT),Fisher's exact test,,number of carriers (n),Null,Sweden,,,,,Europe,
754,http://www.ncbi.nlm.nih.gov/pubmed/22422616,statins,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Black,0.0000031,,7 / 7,29 / 263,,"Autoimmune-mediated necrotizing myositis,anti-HMGCR-myopathy",Fisher's exact test,,number of carriers (n),Bonferroni's correction,United States,,,,,North America,"some patients in the study were evaluated at the Chicoutimi Hospital Lipid Clinic and the Ecogene-21 Clinical Research Center (Chicoutimi, Quebec, Canada). Most patients and all controls reported to be from Johns Hopkins Myositis Center (United States of America)"
755,http://www.ncbi.nlm.nih.gov/pubmed/22422616,statins,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Caucasian,0.00000000032,,13 / 14,38 / 539,,"Autoimmune-mediated necrotizing myositis,anti-HMGCR-myopathy",Fisher's exact test,,number of carriers (n),Bonferroni's correction,United States,,,,,North America,"some patients in the study were evaluated at the Chicoutimi Hospital Lipid Clinic and the Ecogene-21 Clinical Research Center (Chicoutimi, Quebec, Canada). Most patients and all controls reported to be from Johns Hopkins Myositis Center (United States of America)"
156,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,13 / 112,83 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.1 (0.05 - 0.2),,Asia,
757,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Indian,,0.0000214,12 / 20,,6 / 55,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,India,,,,12.25 (3.57 - 42.01),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
174,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,16 / 23,83 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.9 (0.7 - 4.9),,Asia,
759,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Diverse,,0.0478,10 / 39,,15 / 134,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,Brazil,,,,2.74 (1.12 - 6.71),South America,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
192,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,24 / 51,83 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.74 (0.4 - 1.4),,Asia,
761,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Korean,,0.938,6 / 31,,18 / 90,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,South Korea,,,,0.96 (0.34 - 2.69),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
201,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,42 / 60,67 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,2.68 (1.4 - 5.1),,Asia,
763,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Indian,,0.000000187,17 / 40,,7 / 110,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,India,,patient and control sample sizes represent the number of alleles (not the number of individuals),,10.88 (4.04 - 29.3),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
210,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,6 / 13,67 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.99 (0.3 - 3),,Asia,
765,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Diverse,,0.0242,11 / 78,,15 / 268,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,Brazil,,patient and control sample sizes represent the number of alleles (not the number of individuals),,2.77 (1.22 - 6.31),South America,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
219,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,,6 / 18,67 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.58 (0.2 - 1.6),,Asia,
767,http://www.ncbi.nlm.nih.gov/pubmed/25099678,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Korean,,0.872,7 / 62,,19 / 180,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,,Bonferroni's correction,South Korea,,patient and control sample sizes represent the number of alleles (not the number of individuals),,1.07 (0.43 - 2.7),Asia,"There were 20 drugs or drug combinations reported to have been used by the patients in this study. The full list as provided by the study is: Acetaminophen, Analgin, Aspirin, Brufen, Diclofenac, Diclofenac & paracetamol, Dipyrone, Dipyrone & diclofenac, Fenton (cold medicine), Ibuprofen, Mefenamic acid, Nimesimide, Nimesulide, Paracetamol, Piroxicam, Tylenol (cold medicine), Cold remedies (unknown), Medicine for cold (NSAID), Medicine for cold (detail unknown) and NSAIDs (drug name unknown)."
768,http://www.ncbi.nlm.nih.gov/pubmed/26086150,sulfamethoxazole,HLA-B,MHC class I,HLA-B*15:02,Thai,0.0037,0.0202,14 / 43,10 / 91,67 / 400,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,,,3.91 (1.42 - 10.92),2.4 (1.11 - 4.98),Asia,
769,http://www.ncbi.nlm.nih.gov/pubmed/26086150,sulfamethoxazole,HLA-C,MHC class I,HLA-C*06:02,Thai,0.0131,0.2079,5 / 43,1 / 91,26 / 400,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,,,11.84 (1.24 - 566.04),1.89 (0.54 - 5.41),Asia,
770,http://www.ncbi.nlm.nih.gov/pubmed/26086150,sulfamethoxazole,HLA-C,MHC class I,HLA-C*08:01,Thai,0.0108,0.0536,12 / 43,9 / 91,63 / 400,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,,,3.53 (1.21 - 10.4),2.07 (0.92 - 4.41),Asia,
771,http://www.ncbi.nlm.nih.gov/pubmed/25266342,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Indian,0.0349,,2 / 5,2 / 52,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Malaysia,epilepsy,,16.67 (1.7 - 162.96),,Asia,
772,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Vietnamese,1,,4 / 38,3 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.86 (0.18 - 4.23),,Asia,
773,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*15:12,Vietnamese,0.38,,2 / 38,3 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.41 (0.06 - 2.63),,Asia,
774,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*15:13,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
775,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*15:18,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
776,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*15:25,Vietnamese,1,,2 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,1.33 (0.11 - 15.53),,Asia,
777,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*35:03,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
778,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*35:05,Vietnamese,,,2 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
779,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*38:01,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
780,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*38:02,Vietnamese,1,,2 / 38,2 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.64 (0.08 - 4.86),,Asia,
781,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*39:01,Vietnamese,1,,1 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.65 (0.04 - 10.87),,Asia,
782,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Vietnamese,1,,2 / 38,2 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.64 (0.08 - 4.86),,Asia,
783,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*40:02,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
784,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*46:01,Vietnamese,0.03,,5 / 38,9 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.27 (0.08 - 0.94),,Asia,
785,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Vietnamese,0.29,,1 / 38,3 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.2 (0.02 - 2.03),,Asia,
786,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*51:02,Vietnamese,,,2 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
787,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*54:01,Vietnamese,1,,2 / 38,2 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.64 (0.08 - 4.86),,Asia,
788,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*55:02,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
789,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*56:04,Vietnamese,,,1 / 38,0 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
790,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Vietnamese,1,,2 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,1.33 (0.11 - 15.53),,Asia,
791,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*07:05,Vietnamese,0.32,,5 / 38,6 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,0.48 (0.13 - 1.79),,Asia,
792,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Vietnamese,,,0 / 38,4 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
793,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*27:04,Vietnamese,,,0 / 38,2 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
794,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*08:01,Vietnamese,,,0 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
795,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*27:06,Vietnamese,,,0 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
796,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*39:05,Vietnamese,,,0 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
797,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*44:03,Vietnamese,,,0 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
798,http://www.ncbi.nlm.nih.gov/pubmed/25938071,carbamazepine,HLA-B,MHC class I,HLA-B*15:01,Vietnamese,,,0 / 38,1 / 25,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",unknown,,number of carriers (n),unknown,Vietnam,epilepsy,,,,Asia,
372,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.931,0.769,22 / 40,28 / 52,37 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
501,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Japanese,,,7 / 61,68 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
569,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.54,0.86,9 / 36,22 / 64,141 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.75 (0.3 - 1.89),1.07 (0.49 - 2.38),Asia,
590,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.38,,9 / 24,12 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.6 (0.19 - 1.9),,Asia,
803,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*13:01,Japanese,0.807,,10 / 131,13 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,2.58 (1.104 - 6.032),,Asia,
804,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*15:01,Japanese,0.755,,11 / 131,69 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.465 (0.238 - 0.908),,Asia,
805,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:02,Japanese,1.69,,5 / 131,5 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,3.29 (0.936 - 11.532),,Asia,
806,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Japanese,1.29,,31 / 131,66 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,1.66 (1.024 - 2.682),,Asia,
807,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*46:01,Japanese,0.453,,22 / 131,38 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,2.02 (1.148 - 3.566),,Asia,
808,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*52:01,Japanese,0.311,,12 / 131,79 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.434 (0.228 - 0.825),,Asia,
809,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*54:01,Japanese,1.33,,10 / 131,61 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.485 (0.241 - 0.976),,Asia,
810,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*03:04,Japanese,0.841,,42 / 131,98 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,1.55 (1 - 2.38),,Asia,
811,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*05:01,Japanese,0.897,,5 / 131,5 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,3.29 (0.936 - 11.532),,Asia,
812,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*12:02,Japanese,0.262,,13 / 131,80 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.467 (0.251 - 0.87),,Asia,
1475,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*11:01,Caucasian,0.002,0.007,2 / 2,4 / 23,38 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,63.89 (2.46 - 45610000),28.29 (1.42 - 180.77),Europe,
1661,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.38,7.22,7 / 12,8 / 34,138 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,4.55 (1.13 - 18.35),1.47 (0.46 - 4.75),Asia,
397,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.52,0.538,19 / 43,16 / 44,37 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
1463,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*11:01,Caucasian,0.395,0.784,1 / 3,0 / 10,38 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.5 (0.12 - 11530000),2.83 (0.1 - 41.29),Europe,
817,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*13:01,Japanese,,,2 / 20,6 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
818,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*15:01,Japanese,,,2 / 20,39 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
819,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:02,Japanese,,,0 / 20,4 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
820,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Japanese,0.0406,,8 / 20,30 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,4.22 (1.59 - 11.19),,Asia,
821,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*46:01,Japanese,,,2 / 20,18 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
822,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*52:01,Japanese,,,1 / 20,48 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
823,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*54:01,Japanese,,,5 / 20,33 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
824,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*03:04,Japanese,,,6 / 20,43 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
825,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*05:01,Japanese,,,0 / 20,4 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
826,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*12:02,Japanese,,,1 / 20,47 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
1405,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*11:01,Indian,0.33,,1 / 10,13 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.23 (0.02 - 2.36),,Asia,
801,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*11:01,Japanese,0.147,,10 / 131,71 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.405 (0.202 - 0.811),,Asia,
815,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*11:01,Japanese,,,2 / 20,39 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
1684,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*11:01,Diverse,,0.00791,0 / 39,,19 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,0.0743 (0.00438 - 1.26),South America,
236,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.3856,,14 / 26,49 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,1.5 (0.6 - 3.6),,Asia,
832,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*07:02,Han Chinese,0.427,,1 / 10,2 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.667 (0.218 - 32.611),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
833,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*07:05,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
834,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,0.069,,2 / 10,1 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,12.25 (0.991 - 151.357),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
835,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.668,,2 / 10,8 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,1.313 (0.234 - 7.36),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
836,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:25,Han Chinese,0.427,,1 / 10,2 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.667 (0.218 - 32.611),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
837,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*27:05,Han Chinese,0.308,,1 / 10,1 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,5.444 (0.311 - 95.21),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
838,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*37:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
839,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.278,,5 / 10,15 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.333 (0.587 - 9.268),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
840,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,0.33,,2 / 10,5 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,2.25 (0.37 - 13.667),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
841,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*52:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
842,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.671,,1 / 10,10 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,0.444 (0.05 - 3.928),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
843,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
844,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
845,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*08:02,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
846,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*10:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
847,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Han Chinese,0.308,,1 / 10,1 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,5.444 (0.311 - 95.21),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
848,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
849,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.188,,0 / 10,10 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,0.339 (0.039 - 2.916),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
850,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Han Chinese,0.188,,0 / 10,10 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,0.339 (0.039 - 2.916),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
1430,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*11:01,Caucasian,1,1,1 / 2,3 / 28,38 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.04 (0.04 - 14.68),0.71 (0.03 - 5.85),Europe,
854,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,0.385,,4 / 6,138 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,2.1 (0.38 - 11.66),,Asia,
1823,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*11:01,Han Chinese,,0.21,3 / 15,/ 118,138 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,,0.26 (0.07 - 0.95),Asia,
502,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*11:10,Japanese,,,0 / 61,1 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
591,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*11:53,Han Chinese,1,,1 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1 (0.06 - 16.97),,Asia,
856,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*07:02,Han Chinese,0.119,,1 / 6,5 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,11.12 (1.09 - 113.38),,Asia,
857,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,0.007,,4 / 6,43 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,11.16 (1.98 - 62.85),,Asia,
858,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.095,,1 / 6,40 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,0.21 (0.03 - 1.58),,Asia,
859,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*15:05,Han Chinese,0.041,,1 / 6,1 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,56.4 (3.07 - 1034.74),,Asia,
860,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*39:01,Han Chinese,0.025,,2 / 6,1 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,20.14 (1.77 - 229.18),,Asia,
861,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,0.531,,1 / 6,80 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,0.51 (0.06 - 4.41),,Asia,
862,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,0.448,,1 / 6,26 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,1.98 (0.22 - 17.57),,Asia,
863,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,0.967,,1 / 6,49 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,0.96 (0.11 - 8.36),,Asia,
864,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,0.985,,1 / 6,48 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,0.98 (0.11 - 8.57),,Asia,
865,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,0.122,,3 / 6,65 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,3.35 (0.66 - 17.02),,Asia,
866,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*04:01,Han Chinese,0.087,,2 / 6,23 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,5.65 (0.98 - 32.53),,Asia,
867,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*07:02,Han Chinese,0.555,,3 / 6,108 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,1.62 (0.32 - 8.17),,Asia,
868,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,0.662,,1 / 6,69 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,0.62 (0.07 - 5.4),,Asia,
869,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-C,MHC class I,HLA-C*14:02,Han Chinese,0.367,,1 / 6,20 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,2.63 (0.29 - 23.61),,Asia,
870,http://www.ncbi.nlm.nih.gov/pubmed/25918017,methazolamide,HLA-B,MHC class I,HLA-B*59:01,Han Chinese,0.00000063,0.000000000002,7 / 8,0 / 30,1 / 283,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,305 (11.3 - 8259.9),1974 (111.8 - 34868.4),Asia,
871,http://www.ncbi.nlm.nih.gov/pubmed/25918017,methazolamide,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,0.016,0.002,7 / 8,11 / 30,88 / 283,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,12.1 (1.3 - 111.7),15.5 (1.9 - 128),Asia,
1831,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*2,Han Chinese,0.024,0.024,13 / 15,58 / 118,137 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,6.72 (1.45 - 31.11),6.93 (1.54 - 31.26),Asia,
1158,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*21:02,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1232,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*21:02,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1306,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*21:02,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
880,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*23:01,Caucasian (North West),,1,3 / 134,,8 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.31,Europe,Values have been provided based on data obtained directly from the study authors
992,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*23:01,Caucasian (Spanish),,1,1 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.3,Europe,Values have been provided based on data obtained directly from the study authors
1159,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*23:01,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1233,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*23:01,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1307,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*23:01,Unknown,,,1 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1486,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*23:01,Caucasian,0.661,0.668,1 / 5,1 / 28,19 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,5.5 (0.12 - 269.64),3.08 (0.13 - 32.05),Europe,
1685,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*23:01,Diverse,,1,4 / 39,,13 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1832,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*24,Han Chinese,,0.78,4 / 15,/ 118,95 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1408,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*24:01,Indian,0.53,,1 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.83 (0.15 - 22.36),,Asia,
157,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,,18 / 112,43 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.45 (0.02 - 11.1),,Asia,
175,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,,2 / 23,43 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.24 (0.05 - 1.1),,Asia,
193,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,,13 / 51,43 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.86 (0.4 - 1.8),,Asia,
202,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.026,,5 / 60,41 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.23 (0.1 - 0.6),,Asia,
211,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,,3 / 13,41 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.75 (0.2 - 2.7),,Asia,
220,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,,6 / 18,41 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.26 (0.5 - 3.5),,Asia,
237,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.2377,,5 / 26,37 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.2 - 1.4),,Asia,
330,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Korean,,,2 / 7,21 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.5 (0.1 - 3.1),,Asia,
343,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Korean,,,3 / 17,21 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.3 (0.1 - 1.2),,Asia,
356,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Korean,,,5 / 24,21 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.4 (0.1 - 1.1),,Asia,
895,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*07:02,Caucasian (North West),,0.80751,58 / 134,,32 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.95,Europe,Values have been provided based on data obtained directly from the study authors
896,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*07:05,Caucasian (North West),,1,2 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,4.06,Europe,Values have been provided based on data obtained directly from the study authors
897,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*08:01,Caucasian (North West),,1,28 / 134,,31 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
898,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*13:02,Caucasian (North West),,1,3 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,5.72,Europe,Values have been provided based on data obtained directly from the study authors
899,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*14:01,Caucasian (North West),,0.28284,0 / 134,,7 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.06,Europe,Values have been provided based on data obtained directly from the study authors
900,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*14:02,Caucasian (North West),,1,7 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.35,Europe,Values have been provided based on data obtained directly from the study authors
901,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:01,Caucasian (North West),,1,11 / 134,,16 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.52,Europe,Values have been provided based on data obtained directly from the study authors
902,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:17,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
903,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:18,Caucasian (North West),,1,5 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.02,Europe,Values have been provided based on data obtained directly from the study authors
904,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:24,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
905,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:39,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
906,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*18:01,Caucasian (North West),,1,14 / 134,,9 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.25,Europe,Values have been provided based on data obtained directly from the study authors
907,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*27:05,Caucasian (North West),,1,10 / 134,,12 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.64,Europe,Values have been provided based on data obtained directly from the study authors
908,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:01,Caucasian (North West),,1,7 / 134,,7 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.79,Europe,Values have been provided based on data obtained directly from the study authors
909,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:02,Caucasian (North West),,1,3 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,5.72,Europe,Values have been provided based on data obtained directly from the study authors
910,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:03,Caucasian (North West),,1,2 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.34,Europe,Values have been provided based on data obtained directly from the study authors
911,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:08,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
912,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*37:01,Caucasian (North West),,1,3 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.61,Europe,Values have been provided based on data obtained directly from the study authors
913,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*38:01,Caucasian (North West),,1,0 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.16,Europe,Values have been provided based on data obtained directly from the study authors
914,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:01,Caucasian (North West),,1,2 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.43,Europe,Values have been provided based on data obtained directly from the study authors
915,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:06,Caucasian (North West),,1,1 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.8,Europe,Values have been provided based on data obtained directly from the study authors
916,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:24,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
917,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*40:01,Caucasian (North West),,1,22 / 134,,13 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.53,Europe,Values have been provided based on data obtained directly from the study authors
918,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*40:02,Caucasian (North West),,1,5 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.27,Europe,Values have been provided based on data obtained directly from the study authors
919,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*41:01,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
920,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*44:02,Caucasian (North West),,1,31 / 134,,17 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.45,Europe,Values have been provided based on data obtained directly from the study authors
921,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*44:03,Caucasian (North West),,1,10 / 134,,11 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.64,Europe,Values have been provided based on data obtained directly from the study authors
922,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*47:01,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
923,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*49:01,Caucasian (North West),,1,2 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.34,Europe,Values have been provided based on data obtained directly from the study authors
924,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*50:01,Caucasian (North West),,1,2 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.56,Europe,Values have been provided based on data obtained directly from the study authors
925,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*51:01,Caucasian (North West),,1,8 / 134,,10 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.55,Europe,Values have been provided based on data obtained directly from the study authors
926,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*51:08,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
927,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*52:01,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
928,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*53:01,Caucasian (North West),,1,1 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.47,Europe,Values have been provided based on data obtained directly from the study authors
929,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*55:01,Caucasian (North West),,0.12156,0 / 134,,7 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.05,Europe,Values have been provided based on data obtained directly from the study authors
930,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*56:01,Caucasian (North West),,1,6 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.59,Europe,Values have been provided based on data obtained directly from the study authors
931,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*57:01,Caucasian (North West),,1,8 / 134,,10 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.62,Europe,Values have been provided based on data obtained directly from the study authors
932,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*58:01,Caucasian (North West),,1,4 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,7.41,Europe,Values have been provided based on data obtained directly from the study authors
933,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*73:01,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
934,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Caucasian (North West),,1,18 / 134,,23 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
935,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:02,Caucasian (North West),,1,2 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.34,Europe,Values have been provided based on data obtained directly from the study authors
936,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:03,Caucasian (North West),,1,1 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
937,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Caucasian (North West),,1,30 / 134,,31 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.71,Europe,Values have been provided based on data obtained directly from the study authors
938,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Caucasian (North West),,1,20 / 134,,22 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
939,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:02,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
940,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:03,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
941,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:04,Caucasian (North West),,1,8 / 134,,15 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.4,Europe,Values have been provided based on data obtained directly from the study authors
942,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Caucasian (North West),,1,4 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.03,Europe,Values have been provided based on data obtained directly from the study authors
943,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:06,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
944,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:07,Caucasian (North West),,1,2 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.43,Europe,Values have been provided based on data obtained directly from the study authors
945,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:08,Caucasian (North West),,1,1 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.34,Europe,Values have been provided based on data obtained directly from the study authors
946,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian (North West),,1,20 / 134,,26 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.47,Europe,Values have been provided based on data obtained directly from the study authors
947,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*08:01,Caucasian (North West),,1,11 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.56,Europe,Values have been provided based on data obtained directly from the study authors
948,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*08:02,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
949,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*08:06,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
950,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*09:01,Caucasian (North West),,1,3 / 134,,5 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.5,Europe,Values have been provided based on data obtained directly from the study authors
951,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*10:01,Caucasian (North West),,1,3 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.12,Europe,Values have been provided based on data obtained directly from the study authors
952,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Caucasian (North West),,1,8 / 134,,11 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.56,Europe,Values have been provided based on data obtained directly from the study authors
953,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:03,Caucasian (North West),,1,4 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.03,Europe,Values have been provided based on data obtained directly from the study authors
954,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:04,Caucasian (North West),,1,3 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.79,Europe,Values have been provided based on data obtained directly from the study authors
955,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:12,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
956,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Caucasian (North West),,1,5 / 134,,3 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.27,Europe,Values have been provided based on data obtained directly from the study authors
957,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Caucasian (North West),,1,12 / 134,,12 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.06,Europe,Values have been provided based on data obtained directly from the study authors
958,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Caucasian (North West),,1,16 / 134,,8 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.63,Europe,Values have been provided based on data obtained directly from the study authors
959,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:03,Caucasian (North West),,1,2 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.34,Europe,Values have been provided based on data obtained directly from the study authors
960,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Caucasian (North West),,1,3 / 134,,5 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.5,Europe,Values have been provided based on data obtained directly from the study authors
961,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Caucasian (North West),,0.00002108,80 / 134,,25 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,4.03,Europe,Values have been provided based on data obtained directly from the study authors
962,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*16:01,Caucasian (North West),,1,4 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,5.72,Europe,Values have been provided based on data obtained directly from the study authors
963,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:01,Caucasian (North West),,1,27 / 134,,35 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.62,Europe,Values have been provided based on data obtained directly from the study authors
964,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:02,Caucasian (North West),,0.000000168,103 / 134,,33 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,4.6,Europe,Values have been provided based on data obtained directly from the study authors
965,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:03,Caucasian (North West),,1,12 / 134,,12 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.06,Europe,Values have been provided based on data obtained directly from the study authors
966,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*02:01,Caucasian (North West),,0.32818,20 / 134,,26 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.47,Europe,Values have been provided based on data obtained directly from the study authors
967,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*03:01,Caucasian (North West),,0.03245,37 / 134,,53 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.44,Europe,Values have been provided based on data obtained directly from the study authors
968,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*03:03,Caucasian (North West),,1,3 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,5.72,Europe,Values have been provided based on data obtained directly from the study authors
969,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*04:01,Caucasian (North West),,0.3798,11 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.93,Europe,Values have been provided based on data obtained directly from the study authors
970,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*05:01,Caucasian (North West),,1,51 / 134,,53 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.73,Europe,Values have been provided based on data obtained directly from the study authors
971,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*02:01,Caucasian (North West),,0.4724,42 / 134,,49 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.55,Europe,Values have been provided based on data obtained directly from the study authors
972,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:01,Caucasian (North West),,1,41 / 134,,42 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.78,Europe,Values have been provided based on data obtained directly from the study authors
973,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:02,Caucasian (North West),,0.63523,17 / 134,,27 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.48,Europe,Values have been provided based on data obtained directly from the study authors
974,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:03,Caucasian (North West),,1,11 / 134,,14 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.6,Europe,Values have been provided based on data obtained directly from the study authors
975,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*04:02,Caucasian (North West),,0.6752,11 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.93,Europe,Values have been provided based on data obtained directly from the study authors
976,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Caucasian (North West),,1,23 / 134,,30 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.65,Europe,Values have been provided based on data obtained directly from the study authors
977,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:02,Caucasian (North West),,1,4 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,5.72,Europe,Values have been provided based on data obtained directly from the study authors
978,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:03,Caucasian (North West),,1,3 / 134,,5 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.5,Europe,Values have been provided based on data obtained directly from the study authors
979,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:02,Caucasian (North West),,0.000009601,81 / 134,,25 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,4.15,Europe,Values have been provided based on data obtained directly from the study authors
980,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:03,Caucasian (North West),,1,12 / 134,,12 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.06,Europe,Values have been provided based on data obtained directly from the study authors
981,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:04,Caucasian (North West),,1,10 / 134,,7 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.13,Europe,Values have been provided based on data obtained directly from the study authors
982,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:09,Caucasian (North West),,1,6 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,3.59,Europe,Values have been provided based on data obtained directly from the study authors
983,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:20,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
984,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*50:10,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
985,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*60:20,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
373,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.234,0.82,16 / 40,14 / 52,27 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
399,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.477,0.636,14 / 43,18 / 44,27 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
503,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Japanese,,,37 / 61,211 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
570,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.03,0.03,10 / 36,8 / 64,86 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),3.18 (1.11 - 9.11),2.34 (1.07 - 5.11),Asia,
592,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.25,,6 / 24,2 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),3.67 (0.66 - 20.42),,Asia,
674,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-A,MHC class I,HLA-A*24:02,Unknown,0.1306,,2 / 38,27 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,3.352 (0.761 - 14.753),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
802,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*24:02,Japanese,0.0066,,57 / 131,256 / 419,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,0.49 (0.33 - 0.73),,Asia,
816,http://www.ncbi.nlm.nih.gov/pubmed/24781922,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*24:02,Japanese,,,14 / 20,132 / 220,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe ocular surface complications",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,,,Asia,
829,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.04,,1 / 10,23 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,0.13 (0.015 - 1.108),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
855,http://www.ncbi.nlm.nih.gov/pubmed/25303297,sulfasalazine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.334,,3 / 6,89 / 283,,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,China,,,2.18 (0.43 - 11.01),,Asia,
881,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*24:02,Caucasian (North West),,1,15 / 134,,17 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.67,Europe,Values have been provided based on data obtained directly from the study authors
993,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*24:02,Caucasian (Spanish),,1,8 / 48,,29 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.69,Europe,Values have been provided based on data obtained directly from the study authors
1160,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Unknown,,,5 / 34,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1234,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:02,Unknown,,0.017,7 / 24,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1308,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:02,Unknown,,,3 / 20,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1409,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*24:02,Indian,1,,1 / 10,5 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1 (0.09 - 11.02),,Asia,
1487,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*24:02,Caucasian,0.58,0.087,3 / 5,8 / 28,44 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.81 (0.29 - 31.65),7.13 (0.93 - 63.11),Europe,
1511,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*24:02,Caucasian,0.015,0.002,3 / 3,1 / 10,44 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,49 (1.25 - 46130000),34.53 (2.03 - 209.71),Europe,
1521,http://www.ncbi.nlm.nih.gov/pubmed/27888155,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Caucasian,0.003,0.001,6 / 8,9 / 38,44 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,22.56 (2.19 - 559.39),33.25 (3.95 - 737.61),Europe,
1614,http://www.ncbi.nlm.nih.gov/pubmed/29242946,sulfasalazine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,0.044,7 / 11,,89 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",,number of carriers (n),Null,China,,,,3.8 (1.1 - 13.4),Asia,
1630,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.015,,17 / 56,28 / 178,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,2.33 (1.16 - 4.69),,Asia,
1633,http://www.ncbi.nlm.nih.gov/pubmed/28476759,lamotrigine,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.04,,10 / 22,16 / 102,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,China,epilepsy,,4.48 (1.66 - 12.11),,Asia,
1634,http://www.ncbi.nlm.nih.gov/pubmed/28476759,phenytoin,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.027,,6 / 13,5 / 40,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,6 (1.42 - 25.27),,Asia,
1639,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.000143,,33 / 91,49 / 320,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,China,epilepsy,,3.15 (1.86 - 5.32),,Asia,
1642,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.056,,32 / 131,28 / 178,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,1.73 (0.98 - 3.05),,Asia,
1644,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.221,,13 / 55,16 / 102,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,0.221 (0.73 - 3.78),,Asia,
1012,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*07:02,Caucasian (Spanish),,1,15 / 48,,18 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.35,Europe,Values have been provided based on data obtained directly from the study authors
1013,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*07:05,Caucasian (Spanish),,1,1 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.82,Europe,Values have been provided based on data obtained directly from the study authors
1014,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*08:01,Caucasian (Spanish),,1,3 / 48,,16 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1015,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*13:02,Caucasian (Spanish),,1,1 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.82,Europe,Values have been provided based on data obtained directly from the study authors
1016,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*14:01,Caucasian (Spanish),,1,1 / 48,,7 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.48,Europe,Values have been provided based on data obtained directly from the study authors
1017,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*14:02,Caucasian (Spanish),,1,4 / 48,,19 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.53,Europe,Values have been provided based on data obtained directly from the study authors
1018,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:01,Caucasian (Spanish),,1,2 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.96,Europe,Values have been provided based on data obtained directly from the study authors
1019,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:03,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1020,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:10,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1021,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:17,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1022,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*15:18,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1023,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*18:01,Caucasian (Spanish),,0.51331,13 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,3.29,Europe,Values have been provided based on data obtained directly from the study authors
1024,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*18:04,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1025,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*27:02,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1026,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*27:05,Caucasian (Spanish),,1,0 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.22,Europe,Values have been provided based on data obtained directly from the study authors
1027,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:01,Caucasian (Spanish),,1,6 / 48,,13 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.47,Europe,Values have been provided based on data obtained directly from the study authors
1028,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:02,Caucasian (Spanish),,1,2 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.14,Europe,Values have been provided based on data obtained directly from the study authors
1029,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:03,Caucasian (Spanish),,1,1 / 48,,8 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.42,Europe,Values have been provided based on data obtained directly from the study authors
1030,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*35:08,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1031,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*37:01,Caucasian (Spanish),,1,0 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.27,Europe,Values have been provided based on data obtained directly from the study authors
1032,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*38:01,Caucasian (Spanish),,1,2 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.82,Europe,Values have been provided based on data obtained directly from the study authors
1033,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:01,Caucasian (Spanish),,1,1 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.51,Europe,Values have been provided based on data obtained directly from the study authors
1034,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:06,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1035,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*39:24,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1036,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*40:01,Caucasian (Spanish),,1,1 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.51,Europe,Values have been provided based on data obtained directly from the study authors
1037,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*40:02,Caucasian (Spanish),,1,1 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.54,Europe,Values have been provided based on data obtained directly from the study authors
1038,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*44:02,Caucasian (Spanish),,1,6 / 48,,17 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.98,Europe,Values have been provided based on data obtained directly from the study authors
1039,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*44:03,Caucasian (Spanish),,1,12 / 48,,21 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.8,Europe,Values have been provided based on data obtained directly from the study authors
1040,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*45:01,Caucasian (Spanish),,1,2 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.14,Europe,Values have been provided based on data obtained directly from the study authors
1041,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*47:01,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1042,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*48:01,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1043,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*49:01,Caucasian (Spanish),,1,3 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.6,Europe,Values have been provided based on data obtained directly from the study authors
1044,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*50:01,Caucasian (Spanish),,1,0 / 48,,7 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.16,Europe,Values have been provided based on data obtained directly from the study authors
1045,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*50:02,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1046,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*51:01,Caucasian (Spanish),,1,8 / 48,,20 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.89,Europe,Values have been provided based on data obtained directly from the study authors
1047,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*51:07,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1048,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*51:08,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1049,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*52:01,Caucasian (Spanish),,1,1 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.54,Europe,Values have been provided based on data obtained directly from the study authors
1050,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*53:01,Caucasian (Spanish),,1,4 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,4.83,Europe,Values have been provided based on data obtained directly from the study authors
1051,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*55:01,Caucasian (Spanish),,1,2 / 48,,7 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.82,Europe,Values have been provided based on data obtained directly from the study authors
1052,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*56:01,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1053,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*57:01,Caucasian (Spanish),,1,2 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.4,Europe,Values have been provided based on data obtained directly from the study authors
1054,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*57:03,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1055,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*58:01,Caucasian (Spanish),,1,0 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.18,Europe,Values have been provided based on data obtained directly from the study authors
1056,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-B,MHC class I,HLA-B*78:01,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1057,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Caucasian (Spanish),,1,4 / 48,,14 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.75,Europe,Values have been provided based on data obtained directly from the study authors
1058,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:02,Caucasian (Spanish),,1,3 / 48,,17 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.46,Europe,Values have been provided based on data obtained directly from the study authors
1059,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*01:03,Caucasian (Spanish),,1,1 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.51,Europe,Values have been provided based on data obtained directly from the study authors
1060,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*03:01,Caucasian (Spanish),,1,10 / 48,,29 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1061,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*03:15,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1062,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Caucasian (Spanish),,1,3 / 48,,8 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.03,Europe,Values have been provided based on data obtained directly from the study authors
1063,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:02,Caucasian (Spanish),,1,1 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.56,Europe,Values have been provided based on data obtained directly from the study authors
1064,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:03,Caucasian (Spanish),,1,1 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.82,Europe,Values have been provided based on data obtained directly from the study authors
1065,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:04,Caucasian (Spanish),,1,1 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.67,Europe,Values have been provided based on data obtained directly from the study authors
1066,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:05,Caucasian (Spanish),,1,1 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.67,Europe,Values have been provided based on data obtained directly from the study authors
1067,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:07,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1068,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*04:08,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1069,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Caucasian (Spanish),,1,10 / 48,,38 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.66,Europe,Values have been provided based on data obtained directly from the study authors
1070,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*08:01,Caucasian (Spanish),,1,2 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.96,Europe,Values have been provided based on data obtained directly from the study authors
1071,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*08:06,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1072,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*10:01,Caucasian (Spanish),,1,2 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.82,Europe,Values have been provided based on data obtained directly from the study authors
1073,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*10:10,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1074,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Caucasian (Spanish),,1,3 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.74,Europe,Values have been provided based on data obtained directly from the study authors
1075,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:02,Caucasian (Spanish),,1,0 / 48,,5 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.22,Europe,Values have been provided based on data obtained directly from the study authors
1076,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:03,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1077,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*11:04,Caucasian (Spanish),,1,4 / 48,,8 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.35,Europe,Values have been provided based on data obtained directly from the study authors
1078,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*12:01,Caucasian (Spanish),,1,3 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,3.68,Europe,Values have been provided based on data obtained directly from the study authors
1079,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Caucasian (Spanish),,1,8 / 48,,25 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
1080,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:02,Caucasian (Spanish),,1,8 / 48,,14 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.56,Europe,Values have been provided based on data obtained directly from the study authors
1081,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:03,Caucasian (Spanish),,1,3 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.01,Europe,Values have been provided based on data obtained directly from the study authors
1082,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*13:05,Caucasian (Spanish),,1,1 / 48,,0 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.67,Europe,Values have been provided based on data obtained directly from the study authors
1083,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Caucasian (Spanish),,1,4 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.8,Europe,Values have been provided based on data obtained directly from the study authors
1084,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*14:17,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1085,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Caucasian (Spanish),,0.00174,20 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,5.83,Europe,Values have been provided based on data obtained directly from the study authors
1086,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1087,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*16:01,Caucasian (Spanish),,1,0 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.27,Europe,Values have been provided based on data obtained directly from the study authors
1088,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*16:02,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1089,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*40:30,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1090,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DRB1,MHC class II,HLA-DRB1*40:50,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1091,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:01,Caucasian (Spanish),,1,14 / 48,,45 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.79,Europe,Values have been provided based on data obtained directly from the study authors
1092,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:02,Caucasian (Spanish),,0.00339,29 / 48,,30 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,3.53,Europe,Values have been provided based on data obtained directly from the study authors
1093,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*01:03,Caucasian (Spanish),,1,8 / 48,,28 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.62,Europe,Values have been provided based on data obtained directly from the study authors
1094,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*02:01,Caucasian (Spanish),,1,10 / 48,,38 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.66,Europe,Values have been provided based on data obtained directly from the study authors
1095,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*03:01,Caucasian (Spanish),,1,8 / 48,,32 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.6,Europe,Values have been provided based on data obtained directly from the study authors
1096,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*04:01,Caucasian (Spanish),,1,2 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.96,Europe,Values have been provided based on data obtained directly from the study authors
1097,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQA1,MHC class II,HLA-DQA1*05:01,Caucasian (Spanish),,1,25 / 48,,63 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.98,Europe,Values have been provided based on data obtained directly from the study authors
1098,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*02:01,Caucasian (Spanish),,1,19 / 48,,61 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.64,Europe,Values have been provided based on data obtained directly from the study authors
1099,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:01,Caucasian (Spanish),,1,15 / 48,,41 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.97,Europe,Values have been provided based on data obtained directly from the study authors
1100,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:02,Caucasian (Spanish),,1,7 / 48,,19 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.95,Europe,Values have been provided based on data obtained directly from the study authors
1101,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*03:03,Caucasian (Spanish),,1,2 / 48,,8 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.72,Europe,Values have been provided based on data obtained directly from the study authors
1102,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*04:02,Caucasian (Spanish),,1,2 / 48,,7 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.82,Europe,Values have been provided based on data obtained directly from the study authors
1103,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Caucasian (Spanish),,1,10 / 48,,36 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.69,Europe,Values have been provided based on data obtained directly from the study authors
1104,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:02,Caucasian (Spanish),,1,0 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.18,Europe,Values have been provided based on data obtained directly from the study authors
1105,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*05:03,Caucasian (Spanish),,1,4 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.8,Europe,Values have been provided based on data obtained directly from the study authors
1106,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:01,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1107,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:02,Caucasian (Spanish),,0.0000699,21 / 48,,10 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,7.02,Europe,Values have been provided based on data obtained directly from the study authors
1108,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:03,Caucasian (Spanish),,1,8 / 48,,25 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
1109,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:04,Caucasian (Spanish),,1,6 / 48,,10 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.62,Europe,Values have been provided based on data obtained directly from the study authors
1110,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*06:09,Caucasian (Spanish),,1,2 / 48,,4 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.4,Europe,Values have been provided based on data obtained directly from the study authors
1111,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*30:20,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1112,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-DQB1,MHC class II,HLA-DQB1*50:10,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1113,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,13 / 13,4 / 100,111 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,579 (29.5 - 11362.67),238.4 (14.08 - 4037.8),Asia,
1114,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.471,0.756,2 / 13,9 / 100,137 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,1.84 (0.35 - 9.62),1.27 (0.28 - 5.8),Asia,
1115,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.694,0.945,2 / 13,20 / 100,161 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.73 (0.15 - 3.55),1.05 (0.23 - 4.8),Asia,
1116,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.312,0.953,2 / 13,29 / 100,162 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.45 (0.09 - 2.13),1.05 (0.23 - 4.77),Asia,
1117,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.45,0.638,2 / 13,25 / 100,229 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.55 (0.11 - 2.63),0.7 (0.15 - 3.16),Asia,
1118,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.363,0.709,0 / 13,12 / 100,65 / 1095,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.26 (0.01 - 4.69),0.58 (0.03 - 9.91),Asia,
1119,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,10 / 10,4 / 100,111 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,430.33 (22.64 - 8958.88),185.42 (10.79 - 3185.84),Asia,
1120,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.917,0.812,1 / 10,9 / 100,137 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,1.12 (0.13 - 9.9),0.78 (0.1 - 6.18),Asia,
1121,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.454,0.678,1 / 10,20 / 100,161 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.44 (0.05 - 3.72),0.64 (0.08 - 5.12),Asia,
1122,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.225,0.673,1 / 10,29 / 100,162 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.27 (0.03 - 2.25),0.64 (0.08 - 5.08),Asia,
1123,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.181,0.24,0 / 10,25 / 100,227 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.14 (0.01 - 2.49),0.18 (0.01 - 3.11),Asia,
1124,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.852,0.594,1 / 10,12 / 100,65 / 1095,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.82 (0.09 - 7.01),1.76 (0.22 - 14.11),Asia,
1125,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,6 / 7,4 / 100,111 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,144 (13.85 - 1497.03),53.19 (6.35 - 445.85),Asia,
1126,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.123,0.222,2 / 7,9 / 100,137 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,4.04 (0.68 - 23.91),2.8 (0.54 - 14.56),Asia,
1127,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.366,0.515,0 / 7,20 / 100,161 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.26 (0.01 - 4.77),0.39 (0.02 - 6.79),Asia,
1128,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.445,0.057,3 / 7,29 / 100,162 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,1.84 (0.39 - 8.72),4.32 (0.96 - 19.48),Asia,
1129,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.272,0.349,0 / 7,25 / 100,227 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.2 (0.01 - 3.58),0.25 (0.01 - 4.47),Asia,
1130,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.615,0.974,0 / 7,12 / 100,65 / 1095,maculopapular exanthema (MPE),"Fisher's exact test, chi-squared test",,number of carriers (n),Null,Thailand,gout,,0.47 (0.03 - 8.78),1.05 (0.06 - 18.57),Asia,
1131,http://www.ncbi.nlm.nih.gov/pubmed/26927288,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Malay,0.032,0.00072,8 / 13,7 / 32,47 / 300,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value adjusted from the value reported in the original study to make 0.05 the threshold of significance,number of carriers (n),Bonferroni's correction,Malaysia,,,5.71 (1.41 - 23.1),8.61 (2.7 - 27.47),Asia,
1132,http://www.ncbi.nlm.nih.gov/pubmed/26927288,phenytoin,HLA-B,MHC class I,HLA-B*15:13,Malay,0.006,0.00104,7 / 13,3 / 32,36 / 300,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value adjusted from the value reported in the original study to make 0.05 the threshold of significance,number of carriers (n),Bonferroni's correction,Malaysia,,,11.28 (2.25 - 59.6),8.56 (2.72 - 26.88),Asia,
1133,http://www.ncbi.nlm.nih.gov/pubmed/26927288,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Malay,,,0 / 3,7 / 32,47 / 300,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Malaysia,,,,,Asia,
1134,http://www.ncbi.nlm.nih.gov/pubmed/26927288,phenytoin,HLA-B,MHC class I,HLA-B*15:13,Malay,0.006,0.004,3 / 3,3 / 32,36 / 300,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value adjusted from the value reported in the original study to make 0.05 the threshold of significance,number of carriers (n),Bonferroni's correction,Malaysia,,,59 (2.49 - 1395.74),50.73 (2.57 - 1002.07),Asia,
1135,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-B,MHC class I,HLA-B*40:02,Korean,0.018,0.001,10 / 40,5 / 70,37 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,4.33 (1.36 - 13.79),4.04 (1.83 - 8.9),Asia,
1136,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-DRB1,MHC class II,HLA-DRB1*04:03,Korean,0.003,0.019,7 / 40,1 / 70,31 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,14.64 (1.73 - 123.9),3.11 (1.27 - 7.59),Asia,
1137,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:01,Korean,0.016,0.03,2 / 40,16 / 70,93 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.18 (0.04 - 0.82),0.22 (0.05 - 0.94),Asia,
1646,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,0.023,,45 / 186,44 / 280,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,0.023 (1.08 - 2.73),,Asia,
1139,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-DQB1,MHC class II,HLA-DQB1*05:01,Korean,0.254,0.012,1 / 40,7 / 70,82 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.23 (0.03 - 1.95),0.13 (0.02 - 0.93),Asia,
1140,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-DRB1,MHC class II,HLA-DRB1*04:06,Korean,0.128,0.759,2 / 40,11 / 70,39 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.28 (0.06 - 1.34),0.6 (0.14 - 2.59),Asia,
1141,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-DRB1,MHC class II,HLA-DRB1*14:05,Korean,0.251,0.748,3 / 40,11 / 70,33 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.43 (0.11 - 1.66),1.11 (0.33 - 3.79),Asia,
1142,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-DQB1,MHC class II,HLA-DQB1*05:03,Korean,0.103,1,3 / 40,14 / 70,46 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.32 (0.09 - 1.21),0.77 (0.23 - 2.61),Asia,
1143,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:02,Korean,1,1,0 / 40,1 / 70,2 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
1686,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*24:02,Diverse,,0.253,2 / 39,,18 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1145,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:11,Korean,1,1,1 / 40,1 / 70,19 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,1.77 (0.11 - 29.08),0.63 (0.08 - 4.82),Asia,
1757,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-A,MHC class I,HLA-A*24:02,Korean,0.14,0.0083,11 / 18,11 / 29,188 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,2.57 (0.77 - 8.61),2.48 (0.94 - 6.52),Asia,
1767,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-A,MHC class I,HLA-A*24:02,Korean,0.025,0.005,15 / 21,12 / 29,188 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,4.09 (1.22 - 13.69),3.95 (1.51 - 10.36),Asia,
1791,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,European,,0.46,3 / 28,,1572 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Germany,epilepsy,,,0.6 (0.2 - 1.8),Europe,
1804,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*24:02,European,,0.602,3 / 28,,90 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,0.6 (0.2 - 2),Europe,
1821,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*24:02,Han Chinese,,0.78,4 / 15,/ 118,89 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1161,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:03,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1235,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:03,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1309,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:03,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
504,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*24:05,Japanese,,,0 / 61,1 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
25,http://www.ncbi.nlm.nih.gov/pubmed/19104471,nevirapine,HLA-A,MHC class I,HLA-A*24:07,Thai,,,10 / 128,1 / 144,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,,Bonferroni's correction,Thailand,HIV,patient and control sample sizes represent the number of alleles (not the number of individuals),12.12 (1.96 - 74.24),,Asia,
571,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*24:10,Han Chinese,1,1,0 / 36,1 / 64,1 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.44),5.41 (0.22 - 135.44),Asia,
593,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*24:10,Han Chinese,1,,0 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.32 (0.01 - 8.25),,Asia,
1162,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*24:13,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1236,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:13,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1310,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*24:13,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
505,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*24:20,Japanese,,,0 / 61,4 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
675,http://www.ncbi.nlm.nih.gov/pubmed/23057547,EGF receptor inhibitors,HLA-A,MHC class I,HLA-A*25:01,Unknown,0.6142,,1 / 38,11 / 172,,maculopapular exanthema (MPE),chi-square test,,number of carriers (n),Bonferroni's correction,Germany,cancer,,2.528 (0.316 - 20.196),,Europe,"study looked at several EGF receptor inhibitors (erlotinib, gefitinib, cetuximab panitumumab)."
882,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*25:01,Caucasian (North West),,1,5 / 134,,6 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.66,Europe,Values have been provided based on data obtained directly from the study authors
994,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*25:01,Caucasian (Spanish),,1,1 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.54,Europe,Values have been provided based on data obtained directly from the study authors
1431,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*25:01,Caucasian,0.121,0.395,1 / 2,0 / 28,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),2.331 (0.1 - 20.96),Europe,
158,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,,,3 / 112,7 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.57 (0.1 - 2.3),,Asia,
176,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,,,1 / 23,7 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.94 (0.1 - 8),,Asia,
194,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,,,4 / 51,7 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.76 (0.5 - 6.3),,Asia,
238,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,0.6894,,1 / 26,10 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.4 (0.1 - 3.4),,Asia,
402,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,0.166,0.055,6 / 43,2 / 44,2 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
506,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Japanese,,,2 / 61,65 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
572,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,0.55,1,0 / 36,2 / 64,9 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.38 (0.02 - 8.25),0.84 (0.05 - 14.77),Asia,
594,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Han Chinese,1,,0 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.32 (0.01 - 8.25),,Asia,
883,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*26:01,Caucasian (North West),,1,6 / 134,,5 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.94,Europe,Values have been provided based on data obtained directly from the study authors
995,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*26:01,Caucasian (Spanish),,1,2 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.96,Europe,Values have been provided based on data obtained directly from the study authors
1163,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*26:01,Unknown,,,1 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1237,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*26:01,Unknown,,,1 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1311,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*26:01,Unknown,,0.024,3 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1411,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*26:01,Indian,0.43,,1 / 10,2 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.87 (0.2 - 39.68),,Asia,
1180,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*07:02,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1181,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*07:05,Unknown,,,0 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1182,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*07:11,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1183,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*08:01,Unknown,,,4 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1184,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*13:01,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1185,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*14:02,Unknown,,,2 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1186,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:01,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1187,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Unknown,,,2 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1188,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:03,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1189,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:15,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1190,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*18:01,Unknown,,,1 / 34,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1191,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*27:05,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1192,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*27:07,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1193,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*35:01,Unknown,,,3 / 34,,9 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1194,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*35:02,Unknown,,,1 / 34,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1195,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*35:03,Unknown,,,0 / 34,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1196,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*35:10,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1197,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*35:34,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1198,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*38:01,Unknown,,,1 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1199,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*39:06,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1200,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*40:06,Unknown,,,0 / 34,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1201,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*41:01,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1202,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*44:02,Unknown,,,2 / 34,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1203,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*44:26,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1204,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*45:01,Unknown,,,1 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1205,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*49:01,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1206,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*50:01,Unknown,,,0 / 34,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1207,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*50:02,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1208,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*51:01,Unknown,,0.0006,11 / 34,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1209,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*51:06,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1210,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*51:08,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1211,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*52:01,Unknown,,,0 / 34,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1212,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*55:01,Unknown,,,1 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1213,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*55:02,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1214,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*56:01,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1215,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*57:01,Unknown,,,0 / 34,,4 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1216,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*57:11,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1217,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*58:01,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1218,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*73:01,Unknown,,,0 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1219,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-B,MHC class I,HLA-B*78:06,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1432,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*26:01,Caucasian,0.865,0.323,1 / 2,1 / 28,4 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),7.78 (0.3 - 92.76),Europe,
1464,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*26:01,Caucasian,0.846,0.115,1 / 3,1 / 10,4 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.5 (0.08 - 327.95),31.13 (0.91 - 654.92),Europe,
1524,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,Caucasian,0.789,0.152,1 / 4,2 / 23,4 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.5 (0.09 - 91.59),20.75 (0.68 - 351.67),Europe,
1687,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*26:01,Diverse,,0.619,2 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1792,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,European,,0.313,5 / 28,,530 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,3.5 (1.3 - 9),Europe,
1805,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*26:01,European,,0.5,5 / 28,,30 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,3.6 (1.3 - 10.2),Europe,
507,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*26:02,Japanese,,,2 / 61,15 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
508,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*26:03,Japanese,,,11 / 61,22 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
509,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*26:05,Japanese,,,1 / 61,1 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
884,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*26:08,Caucasian (North West),,1,1 / 134,,0 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,2.42,Europe,Values have been provided based on data obtained directly from the study authors
996,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*26:08,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1164,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*26:09,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1238,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*26:09,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1312,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*26:09,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
510,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*29:01,Japanese,,,0 / 61,1 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
830,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-A,MHC class I,HLA-A*29:01,Han Chinese,0.167,,1 / 10,0 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,10.2 (0.842 - 123.558),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
997,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*29:01,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1165,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*29:01,Unknown,,,1 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1239,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*29:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1313,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*29:01,Unknown,,,1 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
885,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*29:02,Caucasian (North West),,1,8 / 134,,9 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.7,Europe,Values have been provided based on data obtained directly from the study authors
998,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*29:02,Caucasian (Spanish),,1,13 / 48,,18 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,2.27,Europe,Values have been provided based on data obtained directly from the study authors
1166,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*29:02,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1240,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*29:02,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1314,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*29:02,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1433,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*29:02,Caucasian,1,0.922,1 / 2,2 / 28,49 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.63 (0.05 - 28.75),0.52 (0.03 - 4.26),Europe,
1688,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*29:02,Diverse,,0.761,4 / 39,,12 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
159,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*30:01,Han Chinese,,,1 / 112,6 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.23 (0.02 - 1.8),,Asia,
177,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*30:01,Han Chinese,,,1 / 23,6 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.1 (0.13 - 9.6),,Asia,
195,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*30:01,Han Chinese,,,2 / 51,6 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.99 (0.2 - 5),,Asia,
401,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*30:01,Han Chinese,0.013,0.181,6 / 43,0 / 44,4 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
511,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*30:01,Japanese,,,0 / 61,2 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
831,http://www.ncbi.nlm.nih.gov/pubmed/24856347,antiepileptic drugs,HLA-A,MHC class I,HLA-A*30:01,Han Chinese,0.069,,2 / 10,1 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,epilepsy,,12.25 (0.991 - 151.357),,Asia,"Drugs include carbamazepine, lamotrigine, oxcarbazepine, phenytoinm phenobarbital."
999,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:01,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1254,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:02,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1255,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:05,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1256,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:11,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1257,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*08:01,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1258,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*13:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1259,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*14:02,Unknown,,,1 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1260,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1261,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:02,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1262,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:03,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1263,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:15,Unknown,,,1 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1264,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*18:01,Unknown,,,2 / 24,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1265,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*27:05,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1266,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*27:07,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1267,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:01,Unknown,,,4 / 24,,9 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1268,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:02,Unknown,,,1 / 24,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1269,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:03,Unknown,,,0 / 24,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1270,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:10,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1271,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:34,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1272,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*38:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1273,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*39:06,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1274,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*40:06,Unknown,,,0 / 24,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1275,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*41:01,Unknown,,0.011,3 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1276,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*44:02,Unknown,,,2 / 24,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1277,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*44:26,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1278,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*45:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1279,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*49:01,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1280,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*50:01,Unknown,,,1 / 24,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1281,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*50:02,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1282,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:01,Unknown,,0.017,6 / 24,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1283,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:06,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1284,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:08,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1285,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*52:01,Unknown,,,0 / 24,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1286,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*55:01,Unknown,,,2 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1287,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*55:02,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1288,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*56:01,Unknown,,,1 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1289,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*57:01,Unknown,,,0 / 24,,4 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1290,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*57:11,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1291,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*58:01,Unknown,,,0 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1292,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*73:01,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1293,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*78:06,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1167,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*30:01,Unknown,,,1 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1241,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*30:01,Unknown,,,1 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1315,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*30:01,Unknown,,,1 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1689,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*30:01,Diverse,,0.696,3 / 39,,7 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1777,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-A,MHC class I,HLA-A*30:01,Korean,0.503,0.631,0 / 21,2 / 29,31 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
603,http://www.ncbi.nlm.nih.gov/pubmed/23874514,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:02,Caucasian,,0.00005,8 / 28,,50 / 855,drug induced liver injury (DILI) - hepatocellular type of damage,chi-square test,,number of carriers (n),Bonferroni's correction,Spain,bacterial infections,The study reports that amoxicillin-clavulanate is commonly used in Spain and therefore assumed that a large proportion of the population controls were exposed to the drug at some stage of their lives.,,6.7 (2.8 - 15.9),Europe,
886,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:02,Caucasian (North West),,1,3 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,1.12,Europe,Values have been provided based on data obtained directly from the study authors
1000,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:02,Caucasian (Spanish),,1,7 / 48,,6 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,3.21,Europe,Values have been provided based on data obtained directly from the study authors
1434,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*30:02,Caucasian,0.121,0.957,1 / 2,0 / 28,17 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),1.74 (0.08 - 15.25),Europe,
1690,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*30:02,Diverse,,0.619,2 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
887,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:04,Caucasian (North West),,1,1 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.8,Europe,Values have been provided based on data obtained directly from the study authors
1001,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*30:04,Caucasian (Spanish),,1,0 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.49,Europe,Values have been provided based on data obtained directly from the study authors
1168,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*30:04,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1242,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*30:04,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1316,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*30:04,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
9,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Diverse,1,,0 / 9,3 / 91,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,1.33 (0.06 - 27.76),,North America,
10,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Diverse,0.0037,,6 / 26,3 / 91,,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,8.57 (1.67 - 57.5),,North America,
11,http://www.ncbi.nlm.nih.gov/pubmed/23588310,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Diverse,0.0025,,3 / 6,3 / 91,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Canada,epilepsy,,26.36 (2.53 - 307.89),,North America,
114,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,European,,,3 / 20,10 / 257,396 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Null,Taiwan,epilepsy,,,,Asia,
116,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,European,0.001,0.001,7 / 10,10 / 257,396 / 8862,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as < 0.001,number of carriers (n),Null,Taiwan,epilepsy,,57.6 (11 - 341),49.9 (11.6 - 244),Asia,
118,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,1 / 53,3 / 72,26 / 710,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Null,Taiwan,epilepsy,,,,Asia,
120,http://www.ncbi.nlm.nih.gov/pubmed/24322785,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,0.001,0.001,5 / 10,3 / 72,26 / 710,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as < 0.001,number of carriers (n),Null,Taiwan,epilepsy,,23 (4.2 - 125),26.3 (7.2 - 96.5),Asia,
160,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,2 / 112,5 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.53 (0.1 - 2.8),,Asia,
178,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,0.0024,,7 / 23,5 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,12.9 (3.7 - 45.3),,Asia,
196,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,7 / 51,5 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,4.68 (1.4 - 15.5),,Asia,
203,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,1 / 60,4 / 144,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.59 (0.1 - 4.1),,Asia,
212,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,2 / 13,4 / 144,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,6.36 (1.2 - 33.9),,Asia,
221,http://www.ncbi.nlm.nih.gov/pubmed/16538176,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,0.0022,,6 / 18,4 / 144,,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,17.5 (4.6 - 66.5),,Asia,
331,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Korean,,,3 / 7,7 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,4.6 (0.8 - 25.1),,Asia,
344,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Korean,0.011,,10 / 17,7 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,8.8 (2.5 - 30.7),,Asia,
357,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Korean,0.013,,13 / 24,7 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,7.3 (2.3 - 22.5),,Asia,
377,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,1,0.657,1 / 40,1 / 52,4 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
467,http://www.ncbi.nlm.nih.gov/pubmed/21428769,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Caucasian,0.00008,,5 / 12,10 / 257,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",unknown,,number of carriers (n),unknown,England,epilepsy,,25.93 (4.93 - 116.18),,Europe,
512,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Japanese,3.64E-15,,37 / 61,47 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value stated here is the uncorrected value.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
1328,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:02,Unknown,,,1 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1329,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:05,Unknown,,,1 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1330,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*07:11,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1331,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*08:01,Unknown,,,1 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1332,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*13:01,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1333,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*14:02,Unknown,,,1 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1334,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:01,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1335,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:02,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1336,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:03,Unknown,,,1 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1337,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*15:15,Unknown,,,1 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1338,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*18:01,Unknown,,,2 / 20,,6 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1339,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*27:05,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1340,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*27:07,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1341,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:01,Unknown,,,2 / 20,,9 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1342,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:02,Unknown,,,0 / 20,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1343,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:03,Unknown,,,0 / 20,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1344,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:10,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1345,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*35:34,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1346,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*38:01,Unknown,,0.024,3 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1347,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*39:06,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1348,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*40:06,Unknown,,,0 / 20,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1349,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*41:01,Unknown,,,1 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1350,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*44:02,Unknown,,,1 / 20,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1351,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*44:26,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1352,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*45:01,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1353,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*49:01,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1354,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*50:01,Unknown,,,1 / 20,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1355,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*50:02,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1356,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:01,Unknown,,,3 / 20,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1357,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:06,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1358,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*51:08,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1359,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*52:01,Unknown,,,0 / 20,,7 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1360,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*55:01,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1361,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*55:02,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1362,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*56:01,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1363,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*57:01,Unknown,,,0 / 20,,4 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1364,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*57:11,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1365,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*58:01,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1366,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*73:01,Unknown,,,1 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1367,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-B,MHC class I,HLA-B*78:06,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1368,http://www.ncbi.nlm.nih.gov/pubmed/30826555,lamotrigine,HLA-B,MHC class I,HLA-B*13:01,Indian,0.19,,2 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1369,http://www.ncbi.nlm.nih.gov/pubmed/30826555,lamotrigine,HLA-B,MHC class I,HLA-B*13:01,Indian,0.03,,2 / 4,3 / 50,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1370,http://www.ncbi.nlm.nih.gov/pubmed/30826555,lamotrigine,HLA-B,MHC class I,HLA-B*13:01,Indian,0.45,,1 / 8,3 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
573,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,0.33,0.62,1 / 36,0 / 64,15 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6.14 (0.24 - 155.12),1.1 (0.14 - 8.63),Asia,
1372,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Indian,1,,1 / 54,4 / 140,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1373,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Indian,0.44,,8 / 54,10 / 140,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
709,http://www.ncbi.nlm.nih.gov/pubmed/19017052,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Japanese,,0.0004,11 / 22,,53 / 371,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Null,Japan,epilepsy,,,,Asia,
1375,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Indian,0.05,,2 / 12,4 / 140,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1376,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Indian,0.01,,4 / 12,14 / 140,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
888,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*31:01,Caucasian (North West),,1,4 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.79,Europe,Values have been provided based on data obtained directly from the study authors
1378,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,Indian,1,,0 / 4,4 / 140,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1379,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Indian,0.31,,1 / 4,14 / 140,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1002,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*31:01,Caucasian (Spanish),,1,0 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.35,Europe,Values have been provided based on data obtained directly from the study authors
1381,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Indian,0.19,,9 / 62,8 / 200,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1382,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Indian,0.03,,2 / 62,22 / 200,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1144,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-A,MHC class I,HLA-A*31:01,Korean,1,0.419,6 / 40,12 / 70,50 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.85 (0.29 - 2.48),1.54 (0.41 - 3.84),Asia,
1384,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Indian,0.13,,2 / 14,8 / 200,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1385,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Indian,0.21,,3 / 14,22 / 200,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1169,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*31:01,Unknown,,0.007,4 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1387,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Indian,0.0007,,4 / 16,8 / 200,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1388,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Indian,0.4,,3 / 16,22 / 200,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1243,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*31:01,Unknown,,,1 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1390,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Indian,0.07,,2 / 10,8 / 200,,fixed drug eruption,Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1391,http://www.ncbi.nlm.nih.gov/pubmed/30826555,phenytoin,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Indian,0.6,,0 / 10,22 / 200,,fixed drug eruption,Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1317,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*31:01,Unknown,,,1 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1393,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Malay,0.00000004,,14 / 16,8 / 64,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,49 (9.35 - 256.81),,Asia,
1371,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Indian,0.01,,6 / 54,3 / 140,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1395,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.0094,,4 / 6,13 / 106,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,14.3 (2.38 - 86.03),,Asia,
1374,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Indian,1,,0 / 12,3 / 140,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1397,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Indian,0.084,,2 / 6,2 / 57,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,13.8 (1.51 - 124.99),,Asia,
1398,http://www.ncbi.nlm.nih.gov/pubmed/26996548,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,3.1E-15,,28 / 32,51 / 285,,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Holm-Bonferroni correction,Taiwan,gout,,32.1 (10.8 - 95.6),,Asia,
1399,http://www.ncbi.nlm.nih.gov/pubmed/26996548,allopurinol,HLA-B,MHC class I,HLA-B*58:02,Han Chinese,0.0000000082,,13 / 14,51 / 285,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Holm-Bonferroni correction,Taiwan,gout,,59.6 (7.6 - 466.3),,Asia,23 of the cases were reported previously by 15743917 (Also in this database).
1400,http://www.ncbi.nlm.nih.gov/pubmed/26996548,allopurinol,HLA-B,MHC class I,HLA-B*58:03,Han Chinese,1E-26,,52 / 57,51 / 285,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Holm-Bonferroni correction,Taiwan,gout,,47.7 (18.2 - 125.4),,Asia,18 of the cases were reported previously by 15743917 (Also in this database).
1401,http://www.ncbi.nlm.nih.gov/pubmed/26996548,allopurinol,HLA-B,MHC class I,HLA-B*58:04,Han Chinese,0.01,,3 / 3,51 / 285,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Holm-Bonferroni correction,Taiwan,gout,,31.9 (1.62 - 626.6),,Asia,
1402,http://www.ncbi.nlm.nih.gov/pubmed/26996548,allopurinol,HLA-B,MHC class I,HLA-B*58:05,Han Chinese,0.0000000023,,26 / 40,51 / 285,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Holm-Bonferroni correction,Taiwan,gout,,8.5 (4.2 - 17.5),,Asia,
1403,http://www.ncbi.nlm.nih.gov/pubmed/26632391,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Korean,0.001,,8 / 9,116 / 949,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",p-values reported as <0.001,number of carriers (n),Null,South Korea,gout,,57.5 (7.12 - 463.5),,Asia,
1404,http://www.ncbi.nlm.nih.gov/pubmed/26632391,lamotrigine,HLA-B,MHC class I,HLA-B*44:03,Korean,0.053,,3 / 7,1 / 18,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)","Fisher's exact test, chi-squared test",,number of carriers (n),Null,South Korea,epilepsy,,12.75 (1.03 - 157.14),,Asia,
1377,http://www.ncbi.nlm.nih.gov/pubmed/30826555,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Indian,1,,0 / 4,3 / 140,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Asia,
1392,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Malay,,,0 / 16,4 / 64,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,0.4 (0.02 - 7.96),,Asia,
1394,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,,0 / 6,3 / 106,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,2.3 (0.11 - 48.9),,Asia,
1396,http://www.ncbi.nlm.nih.gov/pubmed/28570299,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Indian,0.046,,3 / 6,5 / 57,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Malaysia,epilepsy,,10.4 (1.6 - 65.8),,Asia,
1525,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Caucasian,0.047,0.006,2 / 4,1 / 23,7 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,22 (1.03 - 1190.36),35.14 (2.95 - 434.59),Europe,
1617,http://www.ncbi.nlm.nih.gov/pubmed/29242946,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Han Chinese,,0.033,2 / 5,,16 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",,number of carriers (n),Null,China,epilepsy,,,11.1 (1.7 - 71.4),Asia,
1651,http://www.ncbi.nlm.nih.gov/pubmed/29125944,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,Arab,0.004,,4 / 7,1 / 25,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Tunisia,epilepsy,,32 (2.6 - 289.2),,Africa,
1691,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*31:01,Diverse,,1,4 / 39,,13 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1758,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-A,MHC class I,HLA-A*31:01,Korean,0.237,0.021,8 / 18,2 / 29,50 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,11.43 (1.95 - 59.77),7.27 (2.63 - 18.45),Asia,
1414,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*07:02,Indian,0.1,,3 / 10,5 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6 (0.78 - 46.14),,Asia,
1415,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*15:01,Indian,1,,0 / 10,4 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.43 (0.02 - 9.34),,Asia,
1416,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*44:02,Indian,0.1,,3 / 10,5 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6 (0.78 - 46.14),,Asia,
1417,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*35:01,Indian,0.53,,1 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.83 (0.15 - 22.36),,Asia,
1418,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*40:01,Indian,0.53,,1 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.83 (0.15 - 22.36),,Asia,
1419,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*40:02,Indian,0.55,,0 / 10,5 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.33 (0.01 - 7.11),,Asia,
1420,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*40:06,Indian,1,,0 / 10,2 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.85 (0.03 - 20.45),,Asia,
1421,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-B,MHC class I,HLA-B*50:01,Indian,1,,0 / 10,4 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.43 (0.02 - 9.34),,Asia,
1422,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*15:01,Indian,0.62,,1 / 10,11 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.27 (0.02 - 2.77),,Asia,
1423,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*15:02,Indian,1,,0 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.58 (0.02 - 13.05),,Asia,
1424,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Indian,0.36,,3 / 10,10 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.66 (0.37 - 19.06),,Asia,
1425,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Indian,0.56,,2 / 10,5 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.66 (0.34 - 20.5),,Asia,
1426,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*10:01,Indian,1,,1 / 10,4 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.31 (0.11 - 15.03),,Asia,
1427,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*14:01,Indian,1,,0 / 10,2 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.85 (0.03 - 20.45),,Asia,
1428,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-DRB1,MHC class II,HLA-DRB1*04:01,Indian,0.43,,1 / 10,2 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),2.87 (0.2 - 39.68),,Asia,
1775,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-A,MHC class I,HLA-A*31:01,Korean,1,0.711,1 / 21,2 / 29,50 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.68 (0.06 - 7.97),0.44 (0.06 - 3.31),Asia,
1793,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,European,,0.455,4 / 28,,396 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,3.5 (1.2 - 10.2),Europe,
1806,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,European,,1.131,4 / 28,,26 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,3.2 (1 - 10),Europe,
1816,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-A,MHC class I,HLA-A*31:01,European,,0.00000004,7 / 10,,369 / 8862,drug-induced hypersensitivity syndrome (DIHS),Null,,number of carriers (n),Null,Germany,epilepsy,,,49.9 (12.9 - 193.6),Europe,
161,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*32:01,Han Chinese,,,2 / 112,2 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,1.36 (0.18 - 9.8),,Asia,
179,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*32:01,Han Chinese,,,1 / 23,2 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,3.4 (0.3 - 39.1),,Asia,
197,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*32:01,Han Chinese,,,2 / 51,2 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,3.06 (0.2 - 22.3),,Asia,
576,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*32:01,Han Chinese,1,1,0 / 36,1 / 64,5 / 1138,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.65 (0.03 - 16.44),3.17 (0.17 - 58.55),Asia,
889,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*32:01,Caucasian (North West),,1,5 / 134,,12 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.36,Europe,Values have been provided based on data obtained directly from the study authors
1438,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*07:02,Caucasian,1,1,1 / 2,3 / 28,42 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.04 (0.04 - 14.68),0.63 (0.03 - 5.17),Europe,
1439,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*08:01,Caucasian,1,1,1 / 2,2 / 28,34 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.63 (0.05 - 28.75),0.81 (0.04 - 6.7),Europe,
1440,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*14.01,Caucasian,0.865,0.599,1 / 2,1 / 28,9 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),3.39 (0.14 - 32.69),Europe,
1441,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*14.02,Caucasian,0.865,0.995,1 / 2,1 / 28,18 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),1.63 (0.07 - 14.25),Europe,
1442,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*15:01,Caucasian,0.865,0.395,1 / 2,1 / 28,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),2.331 (0.1 - 20.96),Europe,
1443,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*18:01,Caucasian,0.09,1,2 / 2,0 / 28,46 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,19 (0.79 - 13030000),1.29 (0.18 - 7.08),Europe,
1444,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*35:01,Caucasian,0.865,1,1 / 2,1 / 28,35 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),0.78 (0.04 - 6.47),Europe,
1445,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*38:01,Caucasian,0.487,0.175,2 / 2,2 / 28,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.71 (0.3 - 48.08),6.28 (0.68 - 32.52),Europe,
1446,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*44:02,Caucasian,1,1,1 / 2,3 / 28,22 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.04 (0.04 - 14.68),1.319 (0.06 - 11.25),Europe,
1447,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*44:03,Caucasian,0.487,1,2 / 2,2 / 28,67 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.71 (0.3 - 48.08),0.79 (0.11 - 4.31),Europe,
1448,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*49:01,Caucasian,0.704,0.175,2 / 2,3 / 28,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.38 (0.22 - 24.02),6.28 (0.68 - 32.52),Europe,
1449,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Caucasian,0.908,0.902,2 / 2,9 / 28,41 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.603 (0.07 - 4.34),1.48 (0.2 - ),Europe,
1450,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*53:01,Caucasian,0.121,0.599,1 / 2,0 / 28,9 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),3.39 (0.14 - 32.69),Europe,
1451,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*03:03,Caucasian,0.121,0.834,1 / 2,0 / 28,14 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),2.13 (0.09 - 19.19),Europe,
1452,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*04:01,Caucasian,0.925,0.961,2 / 2,7 / 28,70 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.5 (0.22 - 9.89),1.31 (0.25 - 46.09),Europe,
1453,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*05:01,Caucasian,1,1,1 / 2,4 / 28,45 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.75 (0.03 - 9.49),0.58 (0.03 - 4.74),Europe,
1454,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*07:01,Caucasian,0.754,1,3 / 2,6 / 28,72 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.83 (0.26 - 12.6),1.26 (0.24 - 5.86),Europe,
1455,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*08:02,Caucasian,0.487,0.496,1 / 2,2 / 28,26 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.71 (0.3 - 48.08),2.5 (0.34 - 14.21),Europe,
1456,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*12:03,Caucasian,0.281,0.238,3 / 2,3 / 28,34 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.17 (0.49 - 37.45),3.22 (0.6 - 15.48),Europe,
1457,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*15:02,Caucasian,0.281,0.021,3 / 2,3 / 28,12 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.17 (0.49 - 37.45),10.04 (1.73 - 54.19),Europe,
1458,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*15:05,Caucasian,0.281,0.494,1 / 2,0 / 28,7 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),4.39 (0.18 - 44.62),Europe,
1459,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*16:01,Caucasian,1,0.762,1 / 2,3 / 28,56 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.04 (0.04 - 14.68),0.44 (0.02 - 3.57),Europe,
1003,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*32:01,Caucasian (Spanish),,1,2 / 48,,14 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.4,Europe,Values have been provided based on data obtained directly from the study authors
1138,http://www.ncbi.nlm.nih.gov/pubmed/27666425,oxcarbazepine,HLA-A,MHC class I,HLA-A*32:01,Korean,0.299,0.049,2 / 40,1 / 70,3 / 485,maculopapular exanthema (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,3.63 (0.32 - 41.37),8.46 (1.37 - 52.16),Asia,
1170,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*32:01,Unknown,,,3 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1244,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*32:01,Unknown,,,1 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1318,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*32:01,Unknown,,,2 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1435,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*32:01,Caucasian,0.15,0.108,3 / 2,2 / 28,24 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,6.5 (0.65 - 75.71),4.77 (0.88 - 23.54),Europe,
1466,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*35:08,Caucasian,0.395,0.034,1 / 3,0 / 10,3 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.5 (0.12 - 11530000),41.67 (1.15 - 1032.92),Europe,
1467,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*38:01,Caucasian,0.001,0.001,3 / 3,0 / 10,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,147 (1.88 - 483),124.7 (6.78 - 77760000),Europe,
1468,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*44:02,Caucasian,0.846,0.494,1 / 3,1 / 10,22 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.5 (0.08 - 327.95),5.25 (0.18 - 78.61),Europe,
1469,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*49:01,Caucasian,0.846,0.312,1 / 3,1 / 10,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.5 (0.08 - 327.95),9.23 (0.31 - 144.81),Europe,
1470,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*04:01,Caucasian,1,1,1 / 3,2 / 10,70 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2 (0.04 - 78.77),1.31 (0.05 - 18.75),Europe,
1471,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*07:01,Caucasian,0.846,1,1 / 3,1 / 10,72 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.5 (0.08 - 327.95),1.26 (0.04 - 18.02),Europe,
1472,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*12:03,Caucasian,0.217,0.105,2 / 3,1 / 10,34 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,18 (0.47 - 3602.53),12.88 (0.88 - 369.75),Europe,
1473,http://www.ncbi.nlm.nih.gov/pubmed/27888155,antiepileptic drugs,HLA-B,MHC class I,HLA-B*38:01,Caucasian,0.012,0.001,5 / 12,2 / 38,13 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,12.86 (1.66 - 123.82),14.35 (3.34 - 61.53),Europe,“antiepileptic drugs” referrs to patients that were prescribed phenytoin and lamotrigine
1526,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*32:01,Caucasian,0.558,0.675,1 / 4,1 / 23,24 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,7.33 (0.15 - 397.99),3.18 (0.12 - 36.65),Europe,
1619,http://www.ncbi.nlm.nih.gov/pubmed/30599396,oxcarbazepine,HLA-A,MHC class I,HLA-A*32:01,Han Chinese,,0.05,4 / 60,0 / 180,,drug-induced skin reaction (DISI),"Fisher's exact test, chi-square test",p-value reported as <0.05,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),15.877 (1.817 - 138.72),,Asia,
1476,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*07:02,Caucasian,1,0.619,1 / 2,7 / 23,42 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.83 (0.06 - 128.13),5.02 (0.13 - 188.12),Europe,
1477,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Caucasian,0.017,0.001,1 / 2,0 / 23,0 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,47 (1.08 - 50330000),507 (9.88 - 53680000),Europe,
1478,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*27:05,Caucasian,0.303,0.184,1 / 2,1 / 23,11 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,22 (0.3 - 543.73),22 (0.56 - 887.79),Europe,
1479,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*44:02,Caucasian,0.017,0.345,1 / 2,0 / 23,22 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,47 (1.08 - 50330000),10.5 (0.28 - 301.04),Europe,
1480,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*03:03,Caucasian,0.017,0.229,1 / 2,0 / 23,14 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,47 (1.08 - 50330000),17.07 (0.44 - 668.64),Europe,
1481,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*05:01,Caucasian,0.303,0.658,1 / 2,1 / 23,45 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,22 (0.3 - 543.73),4.62 (0.12 - 172.84),Europe,
1482,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*07:02,Caucasian,0.98,1,1 / 2,6 / 23,49 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.83 (0.06 - 128.11),2.12 (0.06 - 79.58),Europe,
1483,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*08:01,Caucasian,0.017,0.031,1 / 2,0 / 23,1 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,47 (1.08 - 50330000),252 (3.62 - 6025.57),Europe,
1692,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*32:01,Diverse,,1,1 / 39,,5 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1842,http://www.ncbi.nlm.nih.gov/pubmed/30776417,vancomycin,HLA-A,MHC class I,HLA-A*32:01,European,0.00000001,2E-16,19 / 23,0 / 46,3418 / 54249,drug-induced hypersensitivity syndrome (DIHS),logistic regression,,number of carriers (n),Bonferroni's correction,Worldwide,bacterial infections,patient and controls were recruited from multiple countries (USA and Australia),,,,
1171,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*32:04,Unknown,,,0 / 34,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1245,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*32:04,Unknown,,,2 / 24,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1319,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*32:04,Unknown,,,0 / 20,,2 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1489,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*14:02,Caucasian,0.661,0.64,1 / 5,1 / 28,18 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,5.5 (0.12 - 269.64),3.26 (0.13 - 34.16),Europe,
1490,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*15:01,Caucasian,0.661,0.49,1 / 5,1 / 28,13 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,5.5 (0.12 - 269.64),4.62 (0.18 - 50.26),Europe,
1491,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*35:03,Caucasian,0.069,0.224,1 / 5,0 / 28,5 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,15.67 (0.41 - 12580000),12.4 (0.45 - 169.87),Europe,
1492,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*39:06,Caucasian,0.919,0.114,1 / 5,2 / 28,2 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.63 (0.07 - 58.39),31.38 (0.92 - 660.15),Europe,
1493,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*41:01,Caucasian,0.661,0.151,1 / 5,1 / 28,3 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,5.5 (0.12 - 269.64),20.83 (0.68 - 353.08),Europe,
1494,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*44:03,Caucasian,0.919,1,1 / 5,2 / 28,67 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.63 (0.07 - 58.39),0.69 (0.03 - 6.76),Europe,
1495,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*49:01,Caucasian,1,0.49,1 / 5,3 / 28,13 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.66 (0.05 - 30.19),4.62 (0.18 - 50.26),Europe,
1496,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*50:01,Caucasian,0.661,0.188,1 / 5,1 / 28,4 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,5.5 (0.12 - 269.64),15.56 (0.54 - 232.41),Europe,
1497,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Caucasian,0.797,1,1 / 5,9 / 28,41 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.39 (0.01 - 5.02),1.29 (0.06 - 12.76),Europe,
1498,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-B,MHC class I,HLA-B*53:01,Caucasian,0.069,0.361,1 / 5,0 / 28,9 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,15.67 (0.41 - 12580000),6.78 (0.26 - 78.72),Europe,
1499,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*03:03,Caucasian,0.069,0.521,1 / 5,0 / 28,14 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,15.67 (0.41 - 12580000),4.27 (0.17 - 46),Europe,
1500,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*03:04,Caucasian,0.919,0.49,1 / 5,2 / 28,13 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.63 (0.07 - 58.39),4.62 (0.18 - 50.26),Europe,
1501,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*04:01,Caucasian,1,1,1 / 5,7 / 28,70 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.57 (0.02 - 7.71),0.65 (0.03 - 6.36),Europe,
1502,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*06:02,Caucasian,1,0.829,1 / 5,5 / 28,25 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.19 (0.04 - 19.03),2.28 (0.09 - 23.19),Europe,
1503,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*07:01,Caucasian,1,1,1 / 5,7 / 28,72 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.57 (0.02 - 7.71),0.63 (0.03 - 6.11),Europe,
1504,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*07:02,Caucasian,1,1,1 / 5,6 / 28,49 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.57 (0.02 - 7.71),1.04 (0.04 - 10.22),Europe,
1505,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*08:02,Caucasian,0.919,0.854,1 / 5,2 / 28,26 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.63 (0.07 - 58.39),2.18 (0.09 - 22.14),Europe,
1506,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*14:02,Caucasian,1,0.291,1 / 5,3 / 28,7 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.66 (0.05 - 30.19),8.86 (0.33 - 109.21),Europe,
1507,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*16:01,Caucasian,1,1,1 / 5,4 / 28,56 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.66 (0.05 - 30.19),0.88 (0.04 - 8.6),Europe,
1508,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-C,MHC class I,HLA-C*17:01,Caucasian,1,0.038,1 / 5,3 / 28,1 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.66 (0.05 - 30.19),63.25 (1.41 - 2989.6),Europe,
1833,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*33,Han Chinese,,0.75,4 / 15,/ 118,64 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1004,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*33:01,Caucasian (Spanish),,1,1 / 48,,11 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.3,Europe,Values have been provided based on data obtained directly from the study authors
1172,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*33:01,Unknown,,,2 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1512,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*08:01,Caucasian,0.114,0.716,1 / 3,0 / 10,34 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,12.6 (0.27 - 11530000),3.22 (0.11 - 47.14),Europe,
1513,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*15:01,Caucasian,0.112,0.312,1 / 3,0 / 10,13 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,12.6 (0.27 - 11530000),9.23 (0.31 - 44.81),Europe,
1514,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*18:01,Caucasian,0.08,0.182,2 / 3,0 / 10,46 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,35 (0.81 - 34600000),9 (0.62 - 256.55),Europe,
1515,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*27:05,Caucasian,0.112,0.269,1 / 3,0 / 10,11 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,12.6 (0.27 - 11530000),11 (0.36 - 176.29),Europe,
1516,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-B,MHC class I,HLA-B*39:05,Caucasian,0.112,0.001,1 / 3,0 / 10,0 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,12.6 (0.27 - 11530000),304.2 (7.18 - 266300000),Europe,
1517,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*03:03,Caucasian,0.112,0.33,1 / 3,0 / 10,14 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,12.6 (0.27 - 11530000),8.54 (0.29 - 132.8),Europe,
1518,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*07:01,Caucasian,0.217,0.403,2 / 3,1 / 10,72 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,18 (0.47 - 3603.25),5.03 (0.35 - 142.38),Europe,
1519,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*07:02,Caucasian,1,0.961,1 / 3,3 / 10,49 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.17 (0.03 - 34.03),2.08 (0.07 - 30.09),Europe,
1520,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-C,MHC class I,HLA-C*15:02,Caucasian,0.217,0.291,1 / 3,1 / 10,12 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,18 (0.47 - 3603.25),10.04 (0.33 - 159.07),Europe,
1246,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*33:01,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1320,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*33:01,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1406,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*33:01,Indian,0.31,,2 / 10,1 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),6 (0.3 - 116.6),,Asia,
1749,http://www.ncbi.nlm.nih.gov/pubmed/28043905,ticlopidine,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.00002,4 / 5,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,blood clot,,,163.1 (16.2 - 1642),,
1750,http://www.ncbi.nlm.nih.gov/pubmed/28043905,methyldopa,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.00001,2 / 4,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,blood pressure,,,97.8 (12.8 - 743.8),,
1751,http://www.ncbi.nlm.nih.gov/pubmed/28043905,fenofibrate,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.00000032,3 / 7,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,cholesterol,,,58.7 (12.3 - 279.8),,
1752,http://www.ncbi.nlm.nih.gov/pubmed/28043905,terbinafine,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.00000000067,6 / 14,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,fungal infections,,,40.5 (12.5 - 131.4),,
1753,http://www.ncbi.nlm.nih.gov/pubmed/28043905,enalapril,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.001,2 / 4,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,blood pressure,,,34.8 (3.9 - 302.9),,
1529,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*07:02,Caucasian,1,1,2 / 4,7 / 23,42 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,0.76 (0.03 - 11.47),1.68 (0.07 - 18.73),Europe,
1530,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*35:01,Caucasian,1,0.698,1 / 4,4 / 23,35 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.58 (0.05 - 28.72),3.04 (0.12 - 34.93),Europe,
1531,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*35:02,Caucasian,0.111,0.233,1 / 4,0 / 23,7 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),12.05 (0.43 - 166.49),Europe,
1532,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*40:01,Caucasian,0.111,0.377,1 / 4,0 / 23,12 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),6.69 (0.25 - 82.96),Europe,
1533,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*44:02,Caucasian,0.111,0.629,1 / 4,0 / 23,22 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),3.5 (0.13 - 40.59),Europe,
1534,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*51:01,Caucasian,1,1,1 / 4,5 / 23,41 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,1.2 (0.04 - 19.9),1.72 (0.07 - 19.3),Europe,
1535,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-B,MHC class I,HLA-B*58:01,Caucasian,0.111,0.115,1 / 4,0 / 23,7 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),11.74 (0.42 - 161.91),Europe,
1536,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*03:02,Caucasian,0.111,0.152,1 / 4,0 / 23,4 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),20.75 (0.68 - 351.67),Europe,
1537,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*03:04,Caucasian,0.991,0.404,1 / 4,3 / 23,13 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.22 (0.07 - 46.47),6.15 (0.23 - 75.39),Europe,
1538,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*04:01,Caucasian,0.409,0.626,2 / 4,4 / 23,70 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,4.75 (0.33 - 75.86),2.61 (0.26 - 26.56),Europe,
1539,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*05:01,Caucasian,0.558,1,1 / 4,1 / 23,45 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,7.33 (0.15 - 397.99),1.54 (0.06 - 17.19),Europe,
1540,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*07:02,Caucasian,0.675,0.354,2 / 4,6 / 23,49 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.83 (0.21 - 39.19),4.16 (0.41 - 42.63),Europe,
1541,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-C,MHC class I,HLA-C*14:02,Caucasian,0.558,0.115,1 / 4,1 / 23,7 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,7.33 (0.15 - 397.99),11.74 (0.42 - 161.91),Europe,
1542,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Diverse,0.004,,31 / 128,24 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,2.76 (1.64 - 4.66),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1543,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.000112,,28 / 128,19 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,4.11 (2.28 - 7.39),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1544,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Diverse,,,21 / 128,105 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.59 (0.39 - 0.9),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1545,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Diverse,,,23 / 128,70 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.37 (0.23 - 0.6),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1546,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Diverse,,,21 / 128,161 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.69 (1.91 - 7.11),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1547,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Diverse,,,24 / 128,39 / 376,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.97 (0.58 - 1.63),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1548,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Diverse,,,13 / 65,24 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,2.16 (1.08 - 4.32),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1549,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.00000381,,20 / 65,19 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,6.52 (3.34 - 12.73),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1550,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Diverse,,,21 / 65,105 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.62 (0.35 - 1.08),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1551,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Diverse,,,11 / 65,70 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.52 (0.26 - 1.03),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1552,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Diverse,,,12 / 65,161 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,4.25 (1.95 - 9.26),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1553,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Diverse,,,12 / 65,39 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.96 (0.49 - 1.89),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1554,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Diverse,0.007,,18 / 63,24 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.46 (1.82 - 6.55),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1555,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Diverse,,,8 / 63,19 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,2.13 (0.91 - 4.98),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1556,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Diverse,,,19 / 63,105 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.56 (0.31 - 1),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1557,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Diverse,,,12 / 63,70 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.6 (0.31 - 1.17),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1558,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Diverse,,,9 / 63,161 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.13 (1.35 - 7.28),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1559,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Diverse,,,12 / 63,39 / 376,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.99 (0.5 - 1.96),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1560,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Diverse,0.012,,49 / 235,24 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,2.28 (1.44 - 3.59),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1561,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.001,,40 / 235,19 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.01 (1.76 - 5.14),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1562,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Diverse,,,76 / 235,105 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.68 (0.45 - 0.9),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1563,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Diverse,,,53 / 235,70 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.75 (0.51 - 1.1),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1564,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Diverse,0.014,,38 / 235,161 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.62 (2.03 - 6.46),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1565,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Diverse,,,39 / 235,39 / 376,,"drug-induced skin reaction (DISI),maculopapular eruption (MPE)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.87 (0.57 - 1.34),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1566,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Diverse,,,18 / 107,24 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,1.75 (0.95 - 3.2),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1567,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Diverse,,,12 / 107,19 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,1.7 (0.69 - 4.2),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1568,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*40:01,Diverse,,,36 / 107,105 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.64 (0.43 - 1.1),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1569,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Diverse,,,30 / 107,70 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,1.01 (0.62 - 1.62),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1570,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Diverse,,,17 / 107,161 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,3.55 (1.77 - 7.1),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1571,http://www.ncbi.nlm.nih.gov/pubmed/30270535,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Diverse,,,15 / 107,39 / 376,,maculopapular eruption (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Worldwide,epilepsy,,0.71 (0.39 - 1.3),,,"Patients and controls are of East Asian ancestry; including Taiwan, Thailand and Japan"
1572,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,13 / 13,4 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,579 (29.5 - 11362.67),238.4 (14.08 - 4037.8),Asia,
1573,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.471,0.756,2 / 13,9 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,1.84 (0.35 - 9.62),1.27 (0.28 - 5.8),Asia,
1574,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.694,0.945,2 / 13,20 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.73 (0.15 - 3.55),1.05 (0.23 - 4.8),Asia,
1575,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.312,0.953,2 / 13,29 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.45 (0.09 - 2.13),1.05 (0.23 - 4.77),Asia,
1576,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.45,0.638,2 / 13,25 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.55 (0.11 - 2.63),0.7 (0.15 - 3.16),Asia,
1577,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.363,0.709,0 / 13,12 / 100,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.26 (0.01 - 4.69),0.58 (0.03 - 9.91),Asia,
1578,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,10 / 10,4 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,430.33 (22.64 - 8958.88),185.42 (10.79 - 3185.84),Asia,
1579,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.917,0.812,1 / 10,9 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,1.12 (0.13 - 9.9),0.78 (0.1 - 6.18),Asia,
1580,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.454,0.678,1 / 10,20 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.44 (0.05 - 3.72),0.64 (0.08 - 5.12),Asia,
1581,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.225,0.673,1 / 10,29 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.27 (0.03 - 2.25),0.64 (0.08 - 5.08),Asia,
1582,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.181,0.24,0 / 10,25 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.14 (0.01 - 2.49),0.18 (0.01 - 3.11),Asia,
1583,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.852,0.594,1 / 10,12 / 100,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.82 (0.09 - 7.01),1.76 (0.22 - 14.11),Asia,
1584,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Thai,0.001,0.001,6 / 7,4 / 100,,maculopapular eruption (MPE),Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Thailand,gout,,144 (13.85 - 1497.03),53.19 (6.35 - 445.85),Asia,
1585,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*13:01,Thai,0.123,0.222,2 / 7,9 / 100,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,4.04 (0.68 - 23.91),2.8 (0.54 - 14.56),Asia,
1586,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*15:02,Thai,0.366,0.515,0 / 7,20 / 100,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.26 (0.01 - 4.77),0.39 (0.02 - 6.79),Asia,
1587,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*40:01,Thai,0.445,0.057,3 / 7,29 / 100,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,1.84 (0.39 - 8.72),4.32 (0.96 - 19.48),Asia,
1588,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*46:01,Thai,0.272,0.349,0 / 7,25 / 100,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.2 (0.01 - 3.58),0.25 (0.01 - 4.47),Asia,
1589,http://www.ncbi.nlm.nih.gov/pubmed/27486401,allopurinol,HLA-B,MHC class I,HLA-B*51:01,Thai,0.615,0.974,0 / 7,12 / 100,,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,Thailand,gout,,0.47 (0.03 - 8.78),1.05 (0.06 - 18.57),Asia,
1754,http://www.ncbi.nlm.nih.gov/pubmed/28043905,sertraline,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.0008,2 / 5,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,depression,,,29 (4 - 207.2),,
1755,http://www.ncbi.nlm.nih.gov/pubmed/28043905,erythromycin,HLA-A,MHC class I,HLA-A*33:01,Caucasian,,0.005,2 / 10,,106 / 10588,drug induced liver injury (DILI),logistic regression,"Number of carriers not reported here, only carrier frequency (0.01) thereore this is the rounded value of carriers",number of carriers (n),Null,Worldwide,bacterial infections,,,10.2 (2 - 51.7),,
1592,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Thai,,,2 / 39,18 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.22 (0.05 - 1.01),,Asia,
1593,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,,,5 / 39,13 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.89 (0.3 - 2.7),,Asia,
1594,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*38:02,Thai,,,8 / 39,6 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,3.7 (1.19 - 11.51),,Asia,
1595,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Thai,,,8 / 39,36 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.4 (0.17 - 0.97),,Asia,
1596,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Thai,,,7 / 39,4 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,4.1 (1.32 - 17.54),,Asia,
1597,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*56:02,Thai,,,4 / 39,1 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,10.4 (1.12 - 96.31),,Asia,
1598,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Thai,,,9 / 39,8 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,3.15 (1.11 - 8.91),,Asia,
1599,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-C,MHC class I,HLA-C*14:02,Thai,,,7 / 39,3 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,6.49 (1.59 - 26.62),,Asia,
53,http://www.ncbi.nlm.nih.gov/pubmed/21545408,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Caucasian,,0.0011,2 / 7,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,gout,,,,Europe,
230,http://www.ncbi.nlm.nih.gov/pubmed/15743917,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.00022,0.047,34 / 51,24 / 135,20 / 93,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Taiwan,gout,,9.3,7.3,Asia,
1602,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Thai,,,7 / 21,18 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,2.06 (0.72 - 5.84),,Asia,
1603,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,,,2 / 21,13 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.64 (0.13 - 3.08),,Asia,
1604,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*38:02,Thai,,,3 / 21,6 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,2.39 (0.55 - 10.45),,Asia,
1605,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*46:01,Thai,,,5 / 21,36 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.49 (0.16 - 1.44),,Asia,
1606,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*51:01,Thai,,,4 / 21,4 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,5.18 (1.18 - 22.74),,Asia,
1607,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*56:02,Thai,,,1 / 21,1 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,4.55 (0.27 - 75.86),,Asia,
1608,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-B,MHC class I,HLA-B*58:01,Thai,,,2 / 21,8 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,1.11 (0.22 - 5.63),,Asia,
1609,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-C,MHC class I,HLA-C*14:02,Thai,,,3 / 21,3 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,4.94 (0.92 - 26.49),,Asia,
286,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Korean,0.00000331,0.0000000688,22 / 25,15 / 57,140 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,20.5 (5.4 - 78.6),18.1 (5.3 - 61.3),Asia,
1611,http://www.ncbi.nlm.nih.gov/pubmed/29242946,allopurinol,HLA-B,MHC class I,HLA-B*13:02,Han Chinese,0.001,0.035,3 / 18,0 / 64,10 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",p-values reported as <0.001,number of carriers (n),Null,China,gout,,24.4 (1.2 - 494.5),5.5 (1.36 - 22),Asia,
1612,http://www.ncbi.nlm.nih.gov/pubmed/29242946,allopurinol,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,,0.001,18 / 18,7 / 64,49 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",p-values reported as <0.001,number of carriers (n),Null,China,gout,,283.7 (15.4 - 5212),175.3 (10.4 - 2960),Asia,
1613,http://www.ncbi.nlm.nih.gov/pubmed/29242946,allopurinol,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,,0.001,18 / 18,/ 64,48 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",p-values reported as <0.001,number of carriers (n),Null,China,gout,,,180 (10.6 - 3034),Asia,
289,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Korean,0.0000117,0.000000783,18 / 20,15 / 57,140 / 485,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,25.2 (5.2 - 121.8),22.2 (5.1 - 97.1),Asia,
1615,http://www.ncbi.nlm.nih.gov/pubmed/29242946,sulfasalazine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,,0.001,7 / 11,,43 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",p-values reported as <0.001,number of carriers (n),Null,China,,,,9.8 (2.7 - 34.8),Asia,
1616,http://www.ncbi.nlm.nih.gov/pubmed/29242946,sulfasalazine,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,,0.027,6 / 11,,65 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",,number of carriers (n),Null,China,,,,4 (1.2 - 13.6),Asia,
292,http://www.ncbi.nlm.nih.gov/pubmed/21301380,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Korean,0.084,0.084,4 / 5,15 / 57,140 / 485,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Hochberg's correction,South Korea,gout,,11.2 (1.16 - 108.3),9.9 (1.1 - 89.2),Asia,
1618,http://www.ncbi.nlm.nih.gov/pubmed/29242946,carbamazepine,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,,0.03,3 / 5,,43 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",,number of carriers (n),Null,China,epilepsy,,,8.4 (1.4 - 51.6),Asia,
1610,http://www.ncbi.nlm.nih.gov/pubmed/29242946,allopurinol,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,,0.001,14 / 18,/ 64,64 / 283,drug-induced hypersensitivity syndrome (DIHS),"Fisher's exact test, chi-square test",p-values reported as <0.001,number of carriers (n),Null,China,gout,,,12 (3.8 - 37.7),Asia,
1620,http://www.ncbi.nlm.nih.gov/pubmed/30599396,oxcarbazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,,0.193,0 / 60,11 / 180,,drug-induced skin reaction (DISI),"Fisher's exact test, chi-square test",,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.232 (0.03 - 1.824),,Asia,
1621,http://www.ncbi.nlm.nih.gov/pubmed/28391407,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Thai,0.4637,0.443,3 / 15,14 / 100,102 / 758,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Null,Thailand,epilepsy,,1.54 (0.38 - 6.14),1.61 (0.45 - 5.8),Asia,
1622,http://www.ncbi.nlm.nih.gov/pubmed/28391407,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,0.1767,0.0544,5 / 15,18 / 100,108 / 758,Stevens-Johnson syndrome (SJS),Fisher's exact test,,number of carriers (n),Null,Thailand,epilepsy,,2.28 (0.69 - 7.48),3.01 (1.01 - 8.97),Asia,
1623,http://www.ncbi.nlm.nih.gov/pubmed/28391407,phenytoin,HLA-B,MHC class I,HLA-B*13:01,Thai,0.0003,0.0001,11 / 21,14 / 100,102 / 758,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),adjusted significance threshold (Bonferroni),Thailand,epilepsy,,6.76 (2.42 - 18.85),7.07 (2.93 - 17.08),Asia,
1624,http://www.ncbi.nlm.nih.gov/pubmed/28391407,phenytoin,HLA-B,MHC class I,HLA-B*15:02,Thai,0.0402,0.0995,0 / 21,18 / 100,108 / 758,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),adjusted significance threshold (Bonferroni),Thailand,epilepsy,,0.1 (0.01 - 1.79),0.14 (0.01 - 2.32),Asia,
1625,http://www.ncbi.nlm.nih.gov/pubmed/25918017,methazolamide,HLA-B,MHC class I,HLA-B*59:01,Han Chinese,0.000000000002,,7 / 8,0 / 30,1 / 283,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,,,1974 (111.8 - 34868.4),,Asia,
1626,http://www.ncbi.nlm.nih.gov/pubmed/25918017,methazolamide,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,0.002,,7 / 8,11 / 30,88 / 283,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,China,,,15.5 (1.9 - 128),,Asia,
1627,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.000000000000135,,39 / 56,28 / 179,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,China,epilepsy,,12.37 (6.16 - 24.86),,Asia,
1628,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,7.36E-14,,42 / 55,38 / 177,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,11.82 (5.76 - 24.23),,Asia,
1629,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*12:02,Han Chinese,0.000109,,29 / 54,45 / 176,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,3.38 (1.79 - 6.36),,Asia,
1005,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*33:03,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1631,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,0.003,,4 / 56,0 / 179,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,30.77 (1.63 - 580.87),,Asia,
1632,http://www.ncbi.nlm.nih.gov/pubmed/28476759,carbamazepine,HLA-DRB1,MHC class II,HLA-DRB1*01:01,Han Chinese,0.013,,4 / 54,1 / 176,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,14 (1.53 - 128.1),,Asia,
1247,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*33:03,Unknown,,,0 / 24,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1321,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*33:03,Unknown,,,0 / 20,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1173,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*33:03,Unknown,,,0 / 34,,5 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1636,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.0000000000193,,50 / 91,56 / 321,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Bonferroni's correction,China,epilepsy,,5.77 (3.49 - 9.55),,Asia,
1637,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,0.0000000000197,,53 / 88,73 / 319,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,5.1 (3.09 - 8.42),,Asia,
1638,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-DRB1,MHC class II,HLA-DRB1*012:02,Han Chinese,0.001,,38 / 87,81 / 317,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,0.26 (1.38 - 3.7),,Asia,
162,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,,,15 / 112,30 / 152,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.63 (0.32 - 1.2),,Asia,
1640,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:11,Han Chinese,0.031,,4 / 31,2 / 321,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,7.33 (1.32 - 40.7),,Asia,
1641,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:01,Han Chinese,0.025,,8 / 91,9 / 321,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,China,epilepsy,,3.34 (1.25 - 8.93),,Asia,
180,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,,,4 / 23,30 / 152,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.86 (0.27 - 2.7),,Asia,
1643,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.761,,19 / 132,28 / 179,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,0.761 (0.48 - 1.71),,Asia,
198,http://www.ncbi.nlm.nih.gov/pubmed/24268988,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,,,8 / 51,30 / 152,,maculopapular exanthema (MPE),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Taiwan,epilepsy,,0.76 (0.32 - 1.7),,Asia,
1645,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.619,,9 / 58,19 / 102,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,0.619 (0.34 - 1.91),,Asia,
332,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Korean,,,1 / 7,12 / 50,,Stevens-Johnson syndrome (SJS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,0.5 (0.6 - 4.8),,Asia,
1647,http://www.ncbi.nlm.nih.gov/pubmed/28476759,antiepileptic drugs,HLA-B,MHC class I,HLA-B*15:02,Han Chinese,0.563,,28 / 190,47 / 281,,maculopapular eruption (MPE),chi-square test,,number of carriers (n),Null,China,epilepsy,,0.563 (0.52 - 1.43),,Asia,
1648,http://www.ncbi.nlm.nih.gov/pubmed/28596278,asparaginase,HLA-DRB1,MHC class II,HLA-DRB1*07:01,European,0.0000456,,52 / 140,40 / 219,,drug-induced hypersensitivity syndrome (DIHS),Multivariate logistic regression,,number of carriers (n),Bonferroni's correction,Hungary,cancer,,2.86 (1.73 - 4.75),,Europe,
1649,http://www.ncbi.nlm.nih.gov/pubmed/28596278,asparaginase,HLA-DQB1,MHC class II,HLA-DQB1*02:02,European,0.000185,,39 / 140,26 / 219,,drug-induced hypersensitivity syndrome (DIHS),Multivariate logistic regression,,number of carriers (n),Bonferroni's correction,Hungary,cancer,,2.99 (1.68 - 5.31),,Europe,
1650,http://www.ncbi.nlm.nih.gov/pubmed/26265500,benznidazole,HLA-B,MHC class I,HLA-B*35:05,Unknown,0.033,,5 / 11,6 / 39,,drug-induced skin reaction (DISI),chi-square test / Fisher exact,,number of carriers (n),Null,Spain,chagas disease,,,,Europe,
345,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Korean,,,5 / 17,12 / 50,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.3 (0.4 - 4.5),,Asia,
1652,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,Diverse,0.029,0.0021,8 / 12,4 / 17,54 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),6.5 (1.2 - 33.57),6.78 (1.96 - 23.38),Asia,
1653,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*15:21,Diverse,0.55,1,2 / 12,1 / 17,33 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),3.2 (0.26 - 40.05),1.24 (0.26 - 5.89),Asia,
1654,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*18:01,Diverse,0.12,0.06,4 / 12,1 / 17,29 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),8 (0.76 - 83.88),3.59 (1.02 - 12.66),Asia,
1655,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*35:05,Diverse,0.37,0.49,1 / 12,4 / 17,39 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),0.29 (0.02 - 3.04),0.42 (0.053 - 3.36),Asia,
1656,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*44:03,Diverse,1,0.7,3 / 12,5 / 17,42 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),0.8 (0.15 - 4.26),0.46 (0.58 - 3.68),Asia,
1657,http://www.ncbi.nlm.nih.gov/pubmed/29053440,carbamazepine,HLA-B,MHC class I,HLA-B*57,Diverse,0.0078,0.0018,10 / 12,5 / 17,87 / 236,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Null,Indonesia,epilepsy,patient and control ethnicities are diverse (Javanese and Sundanese),12 (1.9 - 75.72),8.56 (1.83 - 40),Asia,
358,http://www.ncbi.nlm.nih.gov/pubmed/21917426,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Korean,,,6 / 24,12 / 50,,drug-induced skin reaction (DISI),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,South Korea,epilepsy,,1.1 (0.3 - 3.3),,Asia,
376,http://www.ncbi.nlm.nih.gov/pubmed/23830818,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.119,0.213,4 / 40,12 / 52,14 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
513,http://www.ncbi.nlm.nih.gov/pubmed/21149285,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Japanese,,,5 / 61,59 / 376,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,"Study reports the use of Bonferroni's correction but the corrected values were not reported, The p-value was reported as not significant after correction.",number of carriers (n),unknown,Japan,epilepsy,,,,Asia,
574,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.37,0.08,0 / 36,4 / 64,62 / 528,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.21 (0.01 - 3.96),0.11 (0.01 - 1.9),Asia,
1662,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-B,MHC class I,HLA-B*13:01,Han Chinese,3.86,14,2 / 12,2 / 34,44 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,3.2 (0.4 - 25.73),1.09 (0.23 - 5.13),Asia,
1663,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-B,MHC class I,HLA-B*40:01,Han Chinese,5.77,14,3 / 12,5 / 34,80 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,1.93 (0.39 - 9.72),0.85 (0.22 - 3.21),Asia,
1664,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.03,0.36,6 / 12,2 / 34,63 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,16 (2.59 - 98.99),3.49 (1.09 - 11.2),Asia,
1665,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,14,0.66,2 / 12,7 / 34,7 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,0.77 (0.14 - 4.36),7.89 (1.45 - 42.88),Asia,
1666,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,2.27,14,2 / 12,1 / 34,49 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,6.6 (0.54 - 80.61),0.96 (0.2 - 4.5),Asia,
1667,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,0.21,0.73,7 / 12,7 / 34,89 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,5.4 (1.31 - 22.28),3.05 (0.94 - 9.88),Asia,
1668,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,2.27,14,2 / 12,1 / 34,48 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,6.6 (0.54 - 80.61),0.98 (0.21 - 4.61),Asia,
1669,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-C,MHC class I,HLA-C*03:03,Han Chinese,9.02,3.78,2 / 12,4 / 34,23 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,1.5 (0.24 - 9.47),2.26 (0.47 - 10.94),Asia,
1670,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,2.49,6.79,4 / 12,4 / 34,65 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,3.75 (0.77 - 18.39),1.68 (0.49 - 5.75),Asia,
1671,http://www.ncbi.nlm.nih.gov/pubmed/29575644,clarithromycin,HLA-C,MHC class I,HLA-C*07:02,Han Chinese,9.88,7.63,3 / 12,7 / 34,108 / 283,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,1.29 (0.27 - 6.05),0.54 (0.14 - 2.04),Asia,
1672,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-B,MHC class I,HLA-B*15:27,Han Chinese,,,2 / 12,,1 / 279,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,,55.6 (4.647 - 665.24),Asia,
1673,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,,,6 / 12,,26 / 279,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,,9.731 (2.927 - 32.353),Asia,
1674,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-C,MHC class I,HLA-C*14:02,Han Chinese,,,4 / 12,,20 / 279,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,,6.475 (1.794 - 23.371),Asia,
1675,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-C,MHC class I,HLA-C*15:02,Han Chinese,,,4 / 12,,21 / 279,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,,6.143 (1.708 - 22.093),Asia,
1676,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,0.005,,6 / 9,2 / 26,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,24 (3.247 - 177.405),,Asia,
1677,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-C,MHC class I,HLA-C*14:02,Han Chinese,0.1526,,4 / 9,2 / 25,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,9.2 (1.304 - 64.895),,Asia,
1678,http://www.ncbi.nlm.nih.gov/pubmed/27527109,clindamycin,HLA-C,MHC class I,HLA-C*15:02,Han Chinese,0.0589,,4 / 9,1 / 25,,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,bacterial infections,,19.2 (1.753 - 210.332),,Asia,
595,http://www.ncbi.nlm.nih.gov/pubmed/22348435,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,1,,0 / 24,1 / 24,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,patients and tolerant controls who are positive for HLA-B*15:02,,Null,China,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),0.32 (0.01 - 8.25),,Asia,
699,http://www.ncbi.nlm.nih.gov/pubmed/24399721,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.001,,7 / 20,5 / 125,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as 0.000. This is likley a rounding issue.,number of carriers (n),Null,China,epilepsy,,12.923 (3.584 - 46.592),,Asia,
1527,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*33:03,Caucasian,0.111,0.046,1 / 4,0 / 23,2 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),41.83 (1.15 - 1037.03),Europe,
404,http://www.ncbi.nlm.nih.gov/pubmed/23830818,lamotrigine,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.048,0.08,3 / 43,10 / 44,14 / 72,maculopapular exanthema (MPE),"Fisher's exact test, Chi-squared test",,number of carriers (n),Corrected for chi-square,China,epilepsy,,,,Asia,
1770,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-A,MHC class I,HLA-A*33:03,Korean,0.061,0.012,1 / 21,8 / 29,140 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.13 (0.02 - 1.15),0.12 (0.02 - 0.93),Asia,
1407,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*33:03,Indian,0.53,,2 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.83 (0.15 - 22.36),,Asia,
1693,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*33:03,Diverse,,1,1 / 39,,5 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
43,http://www.ncbi.nlm.nih.gov/pubmed/21545408,paracetamol,HLA-A,MHC class I,HLA-A*33:03,Caucasian,,,0 / 10,,0 / 115,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",chi-square test,,number of carriers (n),Yates' continuity correction,Italy,,,,,Europe,
239,http://www.ncbi.nlm.nih.gov/pubmed/20235791,phenytoin,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,0.5271,,2 / 26,17 / 113,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Taiwan,epilepsy,,0.5 (0.1 - 2.2),,Asia,
1591,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-A,MHC class I,HLA-A*33:03,Thai,,,12 / 39,13 / 92,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,2.7 (1.1 - 6.63),,Asia,
1601,http://www.ncbi.nlm.nih.gov/pubmed/26928377,phenytoin,HLA-A,MHC class I,HLA-A*33:03,Thai,,,2 / 21,13 / 92,,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,p-value was reported as not significant,number of carriers (n),Bonferroni's correction,Thailand,epilepsy,,0.64 (0.13 - 3.08),,Asia,
1822,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-A,MHC class I,HLA-A*33:03,Han Chinese,,0.75,4 / 15,/ 118,64 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
140,http://www.ncbi.nlm.nih.gov/pubmed/17339877,ticlopidine,HLA-A,MHC class I,HLA-A*33:03,Japanese,0.000000732,,12 / 14,12 / 85,,drug induced liver injury (DILI) - cholestatic,Fisher's exact test,,number of carriers (n),Bonferroni's correction,Japan,,,36.5 (7.25 - 183.82),,Asia,
890,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*34:02,Caucasian (North West),,1,0 / 134,,2 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.16,Europe,Values have been provided based on data obtained directly from the study authors
1006,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*34:02,Caucasian (Spanish),,1,1 / 48,,2 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.51,Europe,Values have been provided based on data obtained directly from the study authors
1694,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*34:02,Diverse,,0.318,2 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1174,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*36:01,Unknown,,,2 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1248,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*36:01,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1322,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*36:01,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1695,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*36:01,Diverse,,1,2 / 39,,7 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1175,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*36:02,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1700,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*07:02,Diverse,,0.0779,1 / 39,,17 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,0.149 (0.0193 - 1.15),South America,
1701,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*08:01,Diverse,,0.0483,1 / 39,,20 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1702,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*13:02,Diverse,,1,1 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1703,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*14:01,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1704,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*15:01,Diverse,,1,1 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1705,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*15:10,Diverse,,1,1 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1706,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*18:01,Diverse,,0.696,3 / 39,,7 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1707,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*27:05,Diverse,,0.318,2 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1708,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*35:01,Diverse,,0.787,4 / 39,,18 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1709,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*35:02,Diverse,,0.318,2 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1710,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*35:03,Diverse,,0.619,2 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1711,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*35:08,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1712,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*38:01,Diverse,,0.0775,3 / 39,,2 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1713,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*39:03,Diverse,,1,1 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1714,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*40:01,Diverse,,1,1 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1715,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*40:02,Diverse,,0.318,2 / 39,,3 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1716,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*41:01,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1717,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*42:01,Diverse,,1,2 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1718,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:02,Diverse,,0.248,6 / 39,,12 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1719,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*44:03,Diverse,,0.0371,10 / 39,,15 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,2.71 (1.11 - 6.65),South America,
1720,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*45:01,Diverse,,1,1 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1721,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*49:01,Diverse,,0.735,3 / 39,,9 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1722,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*50:01,Diverse,,0.222,2 / 39,,2 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1723,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*51:01,Diverse,,0.0448,2 / 39,,25 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,0.234 (0.0527 - 1.03),South America,
1724,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*52:01,Diverse,,0.339,0 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1725,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*53:01,Diverse,,0.761,4 / 39,,12 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1726,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*55:01,Diverse,,1,1 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1727,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*56:01,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1728,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*57:01,Diverse,,1,2 / 39,,8 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1729,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*57:03,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1730,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*58:01,Diverse,,0.146,5 / 39,,7 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1731,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-B,MHC class I,HLA-B*58:02,Diverse,,0.426,3 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1732,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*01:02,Diverse,,0.686,1 / 39,,8 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1733,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*02:02,Diverse,,0.524,4 / 39,,10 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1734,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*03:02,Diverse,,1,1 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1735,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*03:03,Diverse,,0.735,2 / 39,,11 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1736,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*03:04,Diverse,,0.735,2 / 39,,11 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1737,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*04:01,Diverse,,0.438,15 / 39,,41 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1738,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*05:01,Diverse,,0.0687,7 / 39,,10 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1739,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*06:02,Diverse,,0.0702,9 / 39,,15 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1740,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*07:01,Diverse,,0.555,10 / 39,,43 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1741,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*07:02,Diverse,,0.477,5 / 39,,25 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1742,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*07:04,Diverse,,0.575,0 / 39,,4 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1743,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*08:02,Diverse,,0.353,0 / 39,,7 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1744,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*12:03,Diverse,,0.00613,7 / 39,,5 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,5.6 (1.67 - 18.8),South America,
1745,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*14:02,Diverse,,0.339,0 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1746,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*15:02,Diverse,,0.525,2 / 39,,13 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1747,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*16:01,Diverse,,0.767,3 / 39,,15 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1748,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-C,MHC class I,HLA-C*17:01,Diverse,,1,2 / 39,,10 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1249,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*36:02,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1323,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*36:02,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1176,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*43:01,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1250,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*43:01,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1324,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*43:01,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
891,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*66:01,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
1436,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*66:01,Caucasian,0.865,0.135,1 / 2,1 / 28,1 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,3.38 (0.08 - 1143.42),31.5 (0.77 - 1299.99),Europe,
1756,http://www.ncbi.nlm.nih.gov/pubmed/26959717,flupirtine,HLA-DRB1,MHC class II,HLA-DRB1*16:01,European,,0.000067,5 / 10,,275 / 10588,drug induced liver injury (DILI),Fisher's exact test,,number of carriers (n),Null,Germany,pain,,,18.74 (4.31 - 81.42),Europe,
1528,http://www.ncbi.nlm.nih.gov/pubmed/27888155,carbamazepine,HLA-A,MHC class I,HLA-A*66:01,Caucasian,0.111,0.031,1 / 4,0 / 23,1 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,20.14 (0.5 - 16770000),84 (1.76 - 4395.32),Europe,
1696,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*66:01,Diverse,,0.000575,6 / 39,,1 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,24 (2.79 - 206),South America,
1759,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-B,MHC class I,HLA-B*13:02,Korean,0.089,0.0069,5 / 18,2 / 29,32 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,5.19 (0.89 - 30.43),5.44 (1.82 - 16.23),Asia,
1760,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-B,MHC class I,HLA-B*35:03,Korean,0.14,0.16,2 / 18,0 / 29,4 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,15.03 (2.56 - 88.16),Asia,
1761,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-B,MHC class I,HLA-B*52:01,Korean,0.063,0.02,4 / 18,1 / 29,27 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,8 (0.81 - 78.47),4.84 (1.49 - 15.73),Asia,
1762,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-B,MHC class I,HLA-B*57:01,Korean,0.14,0.0069,2 / 18,0 / 29,2 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,30.19 (3.99 - 228.05),Asia,
1763,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-C,MHC class I,HLA-C*03:04,Korean,0.017,0.49,1 / 18,11 / 29,62 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.09 (0.01 - 0.83),0.4 (0.05 - 3.07),Asia,
1764,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-C,MHC class I,HLA-C*04:01,Korean,0.068,0.024,6 / 18,3 / 29,62 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,4.33 (0.92 - 20.32),3.41 (1.24 - 9.42),Asia,
1765,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-C,MHC class I,HLA-C*12:02,Korean,0.063,0.014,4 / 18,1 / 29,24 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,8 (0.82 - 78.47),5.49 (1.68 - 17.94),Asia,
1766,http://www.ncbi.nlm.nih.gov/pubmed/28351624,lamotrigine,HLA-C,MHC class I,HLA-C*12:03,Korean,0.14,0.23,2 / 18,0 / 29,5 / 485,drug-induced skin reaction (DISI),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,12 (2.16 - 66.6),Asia,
294,http://www.ncbi.nlm.nih.gov/pubmed/19668019,lamotrigine,HLA-A,MHC class I,HLA-A*68:01,Caucasian (predominantly),,,4 / 44,0 / 86,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS)",Fisher's exact test,p-value was reported as not significant (after correction for multiple comparisons),,Bonferroni's correction,United States,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),19.22 (1.01 - 365),,North America,
1768,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-C,MHC class I,HLA-C*01:02,Korean,0.086,0.033,12 / 21,9 / 29,161 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,2.96 (0.92 - 9.53),2.68 (1.11 - 6.5),Asia,
1769,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-C,MHC class I,HLA-C*07:02,Korean,0.166,0.034,7 / 21,4 / 29,73 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,3.13 (0.78 - 12.57),2.82 (1.1 - 7.23),Asia,
514,http://www.ncbi.nlm.nih.gov/pubmed/23328091,nevirapine,HLA-A,MHC class I,HLA-A*68:01,Diverse,0.017,,0 / 53,8 / 103,,drug-induced hypersensitivity syndrome (DIHS),unknown,,number of carriers (n),Null,South Africa,HIV,,,,Africa,
1771,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-C,MHC class I,HLA-C*07:01,Korean,0.254,1,0 / 21,3 / 29,3 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
1772,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-C,MHC class I,HLA-C*03:04,Korean,0.11,0.743,3 / 21,11 / 29,62 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.27 (0.07 - 1.14),1.14 (0.33 - 3.97),Asia,
1773,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*11:01,Korean,1,0.12,4 / 21,6 / 29,43 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.9 (0.22 - 3.7),2.42 (0.78 - 7.51),Asia,
1774,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-B,MHC class I,HLA-B*15:02,Korean,1,1,0 / 21,1 / 29,2 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
892,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*68:01,Caucasian (North West),,1,6 / 134,,8 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.68,Europe,Values have been provided based on data obtained directly from the study authors
1776,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-B,MHC class I,HLA-B*15:11,Korean,0.171,0.0215,2 / 21,0 / 29,19 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,2.58 (0.56 - 11.89),Asia,
1007,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*68:01,Caucasian (Spanish),,1,3 / 48,,7 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.17,Europe,Values have been provided based on data obtained directly from the study authors
1778,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-B,MHC class I,HLA-B*13:02,Korean,0.503,0.387,0 / 21,2 / 29,32 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
1779,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-B,MHC class I,HLA-B*58:01,Korean,1,1,2 / 21,4 / 29,59 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.66 (0.11 - 3.98),0.76 (0.17 - 3.35),Asia,
1780,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-DRB1,MHC class II,HLA-DRB1*13:01,Korean,1,1,0 / 21,1 / 29,9 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,,,Asia,
1781,http://www.ncbi.nlm.nih.gov/pubmed/26282450,lamotrigine,HLA-DQB1,MHC class II,HLA-DQB1*06:09,Korean,1,1,1 / 21,2 / 29,36 / 485,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,South Korea,epilepsy,,0.68 (0.06 - 7.97),0.62 (0.08 - 4.78),Asia,
1782,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,16 / 25,164 / 833,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,9.3 (3.8 - 23),,,Drug treatment recorded in study as “lapatinib and trastuzumab”
1783,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,20 / 28,166 / 790,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,9.4 (4.1 - 2.7),,,
1784,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,13 / 20,155 / 822,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,8 (3.1 - 20.4),,,Drug treatment recorded in study as “lapatinib then trastuzumab”
1785,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,10 / 26,145 / 677,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,2.3 (1 - 5.2),,,Drug treatment recorded in study as “lapatinib and trastuzumab”
1786,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,26 / 41,142 / 641,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,6.1 (3.1 - 11.8),,,
1787,http://www.ncbi.nlm.nih.gov/pubmed/28786423,lapatinib,HLA-DRB1,MHC class II,HLA-DRB1*07:01,Diverse,,,11 / 16,164 / 701,,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,cancer,,7.2 (2.5 - 21),,,Drug treatment recorded in study as “lapatinib then trastuzumab”
1788,http://www.ncbi.nlm.nih.gov/pubmed/28323125,minocycline,HLA-B,MHC class I,HLA-B*35:02,Caucasian,,0.0000000257,4 / 25,,41 / 6835,drug induced liver injury (DILI),logistic regression,,number of carriers (n),Null,Worldwide,bacterial infections,,,29.6 (7.8 - 89.8),,
1177,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*68:01,Unknown,,,2 / 34,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1251,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:01,Unknown,,,0 / 24,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1325,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:01,Unknown,,,0 / 20,,3 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1410,http://www.ncbi.nlm.nih.gov/pubmed/28101480,levetiracetam,HLA-A,MHC class I,HLA-A*68:01,Indian,0.53,,1 / 10,3 / 50,,maculopapular eruption (MPE),Fisher's exact test,,,Null,India,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),1.83 (0.15 - 22.36),,Asia,
1697,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*68:01,Diverse,,0.735,3 / 39,,9 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1794,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*08:01,European,,0.348,8 / 28,,1835 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.5 (0.7 - 3.5),Europe,
1795,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*13:02,European,,0.251,3 / 28,,549 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.8 (0.5 - 6),Europe,
1796,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,European,,1,0 / 28,,3 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,44.4 (2.2 - 879.5),Europe,
1797,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*18:01,European,,0.744,3 / 28,,838 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.1 (0.3 - 3.8),Europe,
1798,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*38:01,European,,0.392,4 / 28,,330 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,4.3 (1.5 - 12.5),Europe,
1799,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*44:02,European,,0.074,1 / 28,,1428 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,0.2 (0 - 1.4),Europe,
1800,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*44:03,European,,0.284,4 / 28,,726 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.9 (0.6 - 5.4),Europe,
1801,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,European,,0.0000183,11 / 28,,593 / 8862,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,9 (4.2 - 19.4),Europe,
893,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*68:02,Caucasian (North West),,1,2 / 134,,4 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.43,Europe,Values have been provided based on data obtained directly from the study authors
1008,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*68:02,Caucasian (Spanish),,1,1 / 48,,3 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,1.07,Europe,Values have been provided based on data obtained directly from the study authors
1178,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*68:02,Unknown,,,0 / 34,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1252,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:02,Unknown,,,0 / 24,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1326,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:02,Unknown,,,0 / 20,,1 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1807,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*08:01,European,,0.113,8 / 28,,85 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,2.1 (0.9 - 4.9),Europe,
1808,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*13:02,European,,0.213,3 / 28,,29 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,2.1 (0.6 - 7.3),Europe,
1809,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*15:02,European,,1,0 / 28,,0 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,18.6 (0.4 - 953.5),Europe,
1810,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*18:01,European,,0.478,3 / 28,,41 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.4 (0.4 - 4.9),Europe,
1811,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*38:01,European,,0.541,4 / 28,,20 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,4.2 (1.3 - 13.4),Europe,
1812,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*44:02,European,,0.105,1 / 28,,87 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,0.2 (0 - 1.4),Europe,
1813,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*44:03,European,,0.762,4 / 28,,62 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Null,Germany,epilepsy,,,1.3 (0.4 - 3.7),Europe,
1814,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,European,,0.000458,11 / 28,,45 / 529,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Null,,number of carriers (n),Bonferroni's correction,Germany,epilepsy,,,7 (3.1 - 15.8),Europe,
1815,http://www.ncbi.nlm.nih.gov/pubmed/30972788,carbamazepine,HLA-B,MHC class I,HLA-B*57:01,European,,1,0 / 10,,593 / 8862,drug-induced hypersensitivity syndrome (DIHS),Null,,number of carriers (n),Null,Germany,epilepsy,,,0.7 (0 - 11.3),Europe,
1488,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*68:02,Caucasian,0.919,0.188,1 / 5,2 / 28,4 / 253,drug-induced hypersensitivity syndrome (DIHS),Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,2.63 (0.07 - 58.39),15.56 (0.54 - 232.41),Europe,
1817,http://www.ncbi.nlm.nih.gov/pubmed/28062682,nevirapine,HLA-C,MHC class I,HLA-C*04:01,Black,0.00000413,,18 / 51,25 / 182,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",logistic regression,,number of carriers (n),Bonferroni's correction,Malawi,HIV,,0.75 (2.45 - 9.22),,Africa,
1698,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*68:02,Diverse,,1,2 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1179,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antiepileptic drugs,HLA-A,MHC class I,HLA-A*68:03,Unknown,,,1 / 34,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,epilepsy,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several antiepileptic drugs (carbamazepin, lamotrigine, phenobarbital, phenytoin, sodium valproate and topiramate)"
1253,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:03,Unknown,,,0 / 24,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several beta-lactam drugs (amoxicillin, cefixime, cefixime, ceftriaxon, ceftriaxon , cephalexin, co-amoxiclave and penicillin)"
1327,http://www.ncbi.nlm.nih.gov/pubmed/31089385,antibacterial drugs,HLA-A,MHC class I,HLA-A*68:03,Unknown,,,0 / 20,,0 / 80,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),drug-induced hypersensitivity syndrome (DIHS),acute generalized exanthematous pustulosis (AGEP)","Fisher's exact test, chi-squared test",p-value was reported as not significant,,Null,Iran,bacterial infections,patient and control sample sizes represent the number of alleles (not the number of individuals),,,Europe,"study looked at several non beta-lactam drugs (actinomycin, azithromycin, ciprofloxacin, cotrimoxazole, erythromycin and vincristine)"
1009,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*69:01,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1465,http://www.ncbi.nlm.nih.gov/pubmed/27888155,lamotrigine,HLA-A,MHC class I,HLA-A*69:01,Caucasian,0.395,0.001,1 / 3,0 / 10,0 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,p-values reported as <0.001,number of carriers (n),Null,Spain,epilepsy,,10.5 (0.12 - 11530000),304.2 (7.18 - 26640000),Europe,
1824,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*38:02,Han Chinese,,1,2 / 15,/ 118,40 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1825,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*51:01,Han Chinese,,0.64,2 / 15,/ 118,26 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1826,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*46:01,Han Chinese,0.02,0.05,7 / 15,22 / 118,60 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,3.82 (1.25 - 11.65),,Asia,
1827,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*58:01,Han Chinese,,0.73,3 / 15,/ 118,49 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1828,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*44:03,Han Chinese,,0.1,2 / 15,/ 118,9 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1829,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*39:01,Han Chinese,,0.048,2 / 15,/ 118,1 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Bonferroni's correction,China,tetanus,,,43.38 (3.69 - 509.85),Asia,
1830,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-B,MHC class I,HLA-B*35:01,Han Chinese,,0.12,2 / 15,/ 118,10 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1010,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*74:01,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1699,http://www.ncbi.nlm.nih.gov/pubmed/28278336,NSAID and 'multi-ingredient cold medication',HLA-A,MHC class I,HLA-A*74:01,Diverse,,1,2 / 39,,6 / 133,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),severe occular complicatoins",Fisher's exact test,,number of carriers (n),Bonferroni's correction,Brazil,common cold,,,,South America,
1011,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*80:01,Caucasian (Spanish),,1,0 / 48,,1 / 121,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,Spain,bacterial infections,,,0.83,Europe,Values have been provided based on data obtained directly from the study authors
1437,http://www.ncbi.nlm.nih.gov/pubmed/27888155,phenytoin,HLA-A,MHC class I,HLA-A*80:01,Caucasian,0.121,0.003,1 / 2,0 / 28,0 / 253,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN)",Fisher's exact test,,number of carriers (n),Null,Spain,epilepsy,,10.06 (0.3 - 76020000),89.47 (2.72 - 66580000),Europe,
1835,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*03:04,Han Chinese,,1,3 / 15,/ 118,65 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1836,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*03:03,Han Chinese,,0.36,2 / 15,/ 118,23 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1837,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*07:02,Han Chinese,,0.43,4 / 15,/ 118,108 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1838,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*01:02,Han Chinese,,0.09,8 / 15,/ 118,88 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1839,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*03:02,Han Chinese,,0.31,4 / 15,/ 118,48 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1840,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*08:01,Han Chinese,,0.53,2 / 15,/ 118,69 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
1841,http://www.ncbi.nlm.nih.gov/pubmed/27749688,tetanus antitoxin,HLA-C,MHC class I,HLA-C*04:01,Han Chinese,,0.36,2 / 15,/ 118,23 / 283,maculopapular eruption (MPE),Fisher's exact test,,number of carriers (n),Null,China,tetanus,,,,Asia,
894,http://www.ncbi.nlm.nih.gov/pubmed/21570397,amoxicillin-clavulanate,HLA-A,MHC class I,HLA-A*92:19,Caucasian (North West),,1,0 / 134,,1 / 107,drug induced liver injury (DILI),Fisher's exact test,,,Bonferroni's correction,United Kingdom,bacterial infections,,,0.26,Europe,Values have been provided based on data obtained directly from the study authors
1843,http://www.ncbi.nlm.nih.gov/pubmed/30758654,trichloroethylene,HLA-B,MHC class I,HLA-B*13:01,Unknown,0.001,,25 / 30,10 / 40,,"Stevens-Johnson syndrome (SJS),toxic epidermal necrolysis (TEN),maculopapular exanthema (MPE)",chi-square test,p-values reported as <0.001,number of carriers (n),Null,China,,,,,Asia,